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ABSTRACT	
Background:	When	the	technique	to	use	ERCP	was	introduced	almost	fifty	years	ago,	the	morbidity	in	treatment	of	hepato-biliary	diseases	decreased	due	to	the	introduction	of	this	mini-invasive	modality,	reducing	the	need	for	open	surgical	procedures.	However,	ERCP	procedures	are	still	marred	with	complications	such	as	pancreatitis,	cholangitis,	hemorrhage	and	perforation	and	every	measure	must	be	undertaken	to	reduce	these	adverse	events.		
Objectives:	The	hypotheses	of	this	thesis	were:	1)	Prophylactic	antibiotics	in	ERCP	do	not	reduce	the	complication	rates	enough	to	recommend	it	generally.	2)	Prophylactic	pancreatic	stents	reduce	the	PEP	risk	more	the	larger	they	are.	3)	A	grading	scale	for	the	complexity	of	the	ERCP	procedure	(HOUSE)	was	validated	in	relation	to	success-rates,	complications	and	duration	of	the	procedure.	4)	Preoperative	SEMS	in	periampullary	tumors	show	less	bacterial	contamination	in	intraoperatively	collected	bile	than	plastic	stents,	thereby	reducing	perioperative	complications.		
Methods:	In	the	first	study	all	ERCPs,	included	in	GallRiks	between	May	2005	and	June	2013,	were	studied	regarding	complication	rates	in	relation	to	prophylactic	antibiotics.	Further,	in	the	second	paper,	all	ERCPs	between	2006	and	2014	where	an	accidental	pancreatic	cannulation	occurred	and	a	prophylactic	pancreatic	stent	was	used	were	investigated,	determinating	how	the	diameter	and	length	of	the	stent	affected	the	adverse	events.	In	the	third	study,	an	ERCP	complexity	classification,	(HOUSE),	was	validated	in	relation	to	success-rates,	complications	and	duration	of	the	procedure.	The	final	study,	an	RCT	compared	preoperative	SEMS	to	plastic	stents	in	resectable	periampullary	tumors	regarding	intraoperative	bacterial,	histopathological	and	surgical	technical	findings	as	well	as	perioperative	complications.		
Results:	In	the	first	study	complications	were	studied	in	relation	to	prophylactic	antibiotics.	We	found	a	reduction	of	26	%	of	OR	in	overall	complications	if	prophylactic	antibiotics	were	given,	but	in	absolute	figures	reduction	of	the	risk	was	a	modest	2.6%	and	the	NNT	38	patients	to	avoid	one	complication.	In	our	second	study	an	almost	fourfold	OR	elevation	(OR	3.58)	in	complication	rates	was	seen	if	prophylactic	pancreatic	stents	with	a	diameter	≤5	Fr	were	used	compared	to	stents	>5	Fr,	the	complication	rates	were	further	lowered	(1.4	%)	if	the	stents	were	>5	cm.	The	third	paper	validated	a	new	three-graded	ERCP	complexity	grading	scale	(HOUSE)	in	relation	to	success	and	complication	rates,	demonstrating	a	doubled	PEP	rate	in	HOUSE	2	and	3	(7.0	%	and	6.8	%)	compared	to	class	1	(3.4%)	and	longer	procedure	times,	the	higher	the	HOUSE	class	(HOUSE	1,	40	min;	2,	65	min;	and	3,	106	min).	In	the	final	study,	comparing	preoperative	SEMS	to	plastic	stents	in	resectable	periampullary	tumors,	higher	preoperative	stent	dysfunction	rates	were	found	among	the	plastic	stents	(19	%	vs	0	%,	p=0.03).	Intraoperatively,	no	differences	were	seen	in	bacterial	occurrence	in	collected	bile	or	in	operative	technical	difficulties,	but	a	higher	histopathological	foreign	body	reaction	(sinus	histiocytos)	in	lymph	nodes	in	the	hepato-duodenal	ligament	in	the	plastic	stent	group.	Also,	the	overall	postoperative	complication	rates	were	increased	in	the	group	where	plastic	stents	were	used	(72	%	vs	52	%),	as	were	the	frequency	of	anastomotic	leakages	(12	%	vs	3.7	%),	but	none	of	these	postoperative	complications	reached	statistical	significance.		
Conclusion:	Prophylactic	antibiotics	in	ERCP	lower	the	overall	complication	rates	but	not	sufficiently	to	recommend	this	as	prophylaxis	in	every	ERCP	procedure.	On	the	contrary,	prophylactic	pancreatic	stents	could	be	used	more	frequently	in	ERCP	and	larger	diameters	and	longer	stents	demonstrated	lower	complications	rates.	We	also	launched	an	ERCP	complexity	grading	scale	(HOUSE)	and	validated	it	in	relation	to	complication	rates	and	procedure	duration.	Finally,	we	demonstrated	that	SEMS	could	be	used	in	resectable	periampullary	tumors	and	found	no	differences	in	bacterial	growth	in	intraoperatively	collected	bile	but	a	lower	preoperative	stent	dysfunction	rate	if	SEMS	were	used.	Neither	did	we	find	any	intraoperative	technical	downsides	when	using	SEMS,	or	any	disadvantages	in	postoperative	complication	rates.	
Keywords:	ERCP,	postoperative	complications,	post-ERCP	pancreatitis,	antibiotic	prophylaxis,	pancreatic	stent,	ERCP	complexity	grading,	preoperative	stents,	pancreatic	cancer,	periampullary	tumors	
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1.	ERCP,	endoscopic	stents	and	ERCP	complications	and	prevention	
1.1	History	of	biliary	and	pancreatic	surgery	and	the	development	of	ERCP	
and	endoscopic	biliary	stents	
	
1.1.1	Surgery	for	gallstone	disease		When	anesthesiology	was	developed	in	the	mid-19th	century—for	instance,	with	the	introduction	of	ether	anesthesia	by	Thomas	Green	Morton	in	1846—the	necessary	prerequisites	for	biliary	surgery	were	fulfilled.	Another	important	finding	in	the	mid-	19th	century	was	the	increasing	knowledge	of	the	aseptics	gained	by	Semmelweiss	in	Vienna	in	1847,	which	was	another	basis	for	starting	to	perform	biliary	operations.		The	first	operations	for	gallstones	were	performed	as	two-step	procedures	where	a	cholecystostomy/fistulae	was	created	through	which	the	stones	could	then	be	removed	
(Thudicum	J.	L.	W.,	et	al.,	1859).	It	then	took	several	years	until	the	first	one-step	gallstone	operation	was	performed	(Bobbs,	J.	S.,	1868)	remarkably	during	an	attempt	to	operate	on	an	ovarian	cyst.	In	this	case,	the	gallbladder	was	opened	and	only	the	stones	were	removed,	leaving	the	gallbladder	in	situ.	The	first	cholecystectomy	was	performed	in	Berlin	in	1882	(Langenbuch,	C.	J.	A.,	1882),	and	a	few	years	after	that,	the	first	cholecystectomy	was	performed	in	Sweden	by	von	Unge	(Bolling	G.,	et	al.,	1891).	At	the	time,	the	operations	for	gallstone	disease	were	experimental,	and	several	years	passed	before	they	became	part	of	routine	surgery.	Initially,	only	patients	with	severe	complications	with	respect	to	gallstone	disease	underwent	surgery,	but	gradually	cholecystectomy	developed	into	a	common	surgical	procedure.	Finally,	almost	one	hundred	years	later,	the	development	of	the	laparoscopic	technique	made	it	possible	to	perform	minimally	invasive	cholecystectomies	(Mühe,	E.,	
et	al.,	1986);	this	method	rapidly	became	(and	remains)	the	gold	standard	for	treatment	
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of	gallstone	disease.	The	first	laparoscopic	cholecystectomy	in	Sweden	was	performed	by	Arvidsson	in	1992	(Arvidsson,	D.	et	al.,	1992).	The	year	before	that,	in	1991,	Petelin	described	the	first	transcystic	and	common	bile	duct	exploration,	which	was	performed	laparoscopically	(Petelin,	J.	B.,	1991)	.		
1.1.2	Pancreatic	surgery		Similar	to	surgery	for	gallstone	disease,	pancreatic	surgery	was	dependent	on	the	development	of	anesthesiology	and	the	invention	of	aseptics.	In	1882,	Trendelenburg,	performed	the	first	distal	pancreatectomy	and	was	followed	by	Codivilla,	who	described	the	first	pancreatico-duodenectomy	in	1898;	but,	unfortunately,	none	of	these	patients	survived	their	postoperative	courses.		Another	pioneer	in	the	field	of	pancreatic	surgery	was	Mayo,	who	was	more	successful	by	choosing	smaller	and	less	aggressive	endocrine	pancreatic	tumors	on	which	to	operate.	Pancreatic	surgery	was	still	risky	and	hazardous	but	was	slowly	gaining	its	place	in	surgery,	but	it	was	not	until	the	1930s	when	Whipple	performed	his	first	procedures	that	the	field	opened	for	further	development	(Whipple,	A.	O.,	et	al.,	1935).	At	first,	the	Whipple	procedure	was	described	as	a	two-step	operation,	starting	with	a	gastro-enterostomy	and	a	cholecysto-gastrostomy	and	followed	by	a	duodenectomy	and	pancreatic	head	resection	three	to	four	weeks	later.	Since	the	K-vitamin	was	not	discovered	until	1939,	the	bleeding	tendency	was	still	a	problem,	and	it	was	not	until	1940	that	Whipple´s	team	managed	to	perform	the	first	one-step	procedure	including	resection	of	the	bile	duct,	gallbladder,	duodenum,	pancreatic	head	and	part	of	the	stomach,	which	was	the	foundation	of	the	pancreatico-duodenectomy	still	used	today.	The	development	of	better	perioperative	supportive	care,	better	radiological	imaging	and	better	surgical	techniques	through	the	referral	of	pancreatic	surgery	to	tertiary	
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referral	centers	have	lowered	the	perioperative	morbidity	and	mortality	from	the	1980s	until	today,	but	the	long-term	survival	of	pancreatic	cancer	remains	disappointingly	low	with	an	overall	five-year	survival	remaining	under	five	percent.	As	many	of	the	pancreatic	tumors	are	already	irresectable	at	clinical	presentation,	these	were	historically	treated	with	bilio-digestive	shunts,	which	are	now	mostly	performed	as	Roux-en-Y-reconstructions,	anastomosing	the	jejunum	to	the	hepatic	duct.	This	anastomosis	was	named	after	the	surgeon	Cesar	Roux,	who	in	1892	performed	the	first	anastomosis	from	the	jejunum	to	another	organ—but,	in	his	case,	not	to	the	bile	duct	but	to	the	stomach.	The	number	of	surgical	bilio-digestive	shunts	has	gradually	decreased	since	the	introduction	of	endoscopic	techniques	(ERCP)	in	the	1970s,	making	it	possible	to	insert	endoscopic	stents	in	the	bile	duct	without	performing	a	conventional	surgical	bypass.			
1.2	Endoscopic	retrograde	cholangio-pancreaticography	(ERCP)	
	
1.2.1	The	Development	of	Endoscopic	Retrograde	Cholangio-Pancreaticography	
		The	development	of	flexible	endoscopes	in	the	1960s	made	it	possible	with	a	side-viewing	fiber	instrument	to	insert	a	catheter	through	the	papilla	and	inject	contrast	to	image	the	bile	ducts.	This	was	first	performed	by	McCune	in	1968	(McCune,	W.	S.,	et	al,	
1968)	in	the	USA,	but	it	took	several	years	until	the	technique	was	introduced	by	Lennart	Wehlin	in	Sweden	in	1972	(Cronstedt,	J.,	et	al.,	1985).	Still,	ERCP	was	only	a	diagnostic	tool	until	1974	when	Classen	and	Demling	in	Germany	
(Classen,	M.	et	al.,	1974)	and	Kawai	in	Japan	(Kawai,	K.,	et	al.,	1974)	–	independently	of	each	other	–	performed	the	first	sphincterotomies	that	enabled	endoscopic	common	bile	
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duct	stone	(CBDS)	extraction.	In	Sweden,	it	took	another	five	years	until	Nordgren	
(Nordgren,	C.,	1979)	and	Liedberg	(Liedberg,	G.,	1979)	performed	the	first	Swedish	endoscopic	sphincterotomies.	ERCP	rapidly	developed	into	the	first	hand	treatment	of	CBDS	due	to	its	advantages	in	reducing	postoperative	morbidity	through	its	minimally	invasiveness,	especially	in	combination	with	the	later	development	of	the	laparoscopic	cholecystectomy.	Simultaneously,	the	need	for	diagnostic	ERCP	vanished	as	MRCP	was	introduced	in	the	1990s,	and	today	almost	all	ERCPs	are	therapeutic.		On	the	other	hand,	the	diagnostic	ERCPs	were	refined	when	the	single-operator	peroral	cholangioscopy	was	introduced	in	2006	(The	SpyGlass	Direct	Visualization	SystemTM,	
Boston	Scientific,	Marlborough,	Massachusetts,	USA),	making	it	possible	to	visualize	both	the	bile	and	pancreatic	ducts	(Arnelo	U.,	et	al.,	2007)–this	technique	had	been	described	already	in	1972	but	required	two	endoscopists	and	a	mother-baby-	endoscope	with	poor	visual	quality	(Classen,	M.,	et	al.,	1972).	
	
1.2.2	The	cannulation	procedure	of	ERCP		The	cannulation	is	the	start	of	an	ERCP	when	the	endoscopist	gains	access	to	the	desired	duct,	which	is	most	often	the	bile	duct	and	more	occasionally	the	pancreatic	duct.	This	can	be	an	easy	procedure,	but	it	can,	on	the	other	hand,	be	both	challenging	and	time-consuming.	Traditionally,	an	ERCP	catheter	was	used	for	the	cannulation,	and	contrast	was	injected	when	the	endoscopist	thought	he	had	entered	the	bile	duct.	However,	the	technique	to	obtain	access	has	changed	over	the	years,	and	nowadays	the	most	preferred	method	is	to	use	a	sphincterotome	preloaded	with	a	guidewire.	The	benefit	of	the	guidewire	would	be	to	avoid	contrast	injections	to	the	pancreatic	duct,	thereby	reducing	the	risk	of	PEP	(Freeman,	M.	L.,	et	al.,	2005,	Lella	F.,	et	al.,	2004,	Zorron	Pu,	L.,	et	
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al.,	2015).	Additionally,	there	are	reports	that	indicate	that	the	guidewire	technique	might	even	increase	the	cannulation	success	rates	(Cennamo,	V.,	et	al.,	2009).		In	The	Swedish	National	Registry	for	Gallstone	Surgery	and	ERCP	(GallRiks),	an	overall	cannulation	success-rate	of	92	%	was	seen	(Enochsson,	L.	et	al.,	2010),	which	reflects	the	results	of	success	in	everyday	ERCP	in	Sweden.	The	cannulation	success	rate	is	also	dependent	on	the	number	of	ERCPs	performed	by	each	individual	endoscopist,	as	shown	by	Freeman	(Freeman,	M.	L.,	et	al.,	2001)	where	those	endoscopists	performing	more	than	two	ERCPs	per	week	reached	a	cannulation	success	rate	of	96.5	%	compared	to	those	performing	fewer	(91.5	%).			
1.2.3	The	guidewire	technique		A	guidewire	is	used	inside	the	ERCP	catheter	or	spincterotome	to	gain	access	to	the	biliary	tract	–	this	technique	has	been	shown	to	minimize	the	risk	of	developing	PEP	compared	to	the	traditional	contrast-assisted	cannulation	technique	(Cennamo,	V.,	et	al.,	
2009,	Cheung,	J.,	et	al.	2009,	Lella,	F.,	et	al.,	2004).		
1.2.4	Difficult	cannulation		When	a	cannulation	should	be	considered	difficult	has	gained	much	interest	since	it	is	correlated	to	the	post-operative	complication	rates	after	ERCP	(Freeman,	M.	L.,	et	al.,	
1996).	Different	attempts	have	been	made	to	define	a	difficult	cannulation—for	instance,	by	measuring	how	many	cannulation	attempts	that	have	been	made	before	a	successful	cannulation	is	reached	(Lee,	T.	H.,	et	al.,	2009),	how	long	it	took	before	a	successful	cannulation	was	achieved	(Kaffes,	A.	J.,	et	al.,	2005,	Katsinelos	P.	et	al.,	2008,	Laasch,	H.	U.,	
et	al.,	2003,	Lee,	T.	H.,	et	al.,	2009,	Li,	J.	et	al.,	2016,	Maeda,	S.,	et	al.,	2003,	Zhou,	P.	H.	et	al.,	
2006)	or	how	many	guidewire	passes	and	contrast	injections	to	the	pancreatic	duct	that	
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had	occurred	before	cannulation	was	attained	(Kaffes,	A.	J.,	et	al.,	2005,	Zhou,	P.	H.	et	al.,	
2006).	Halttunen	and	co-workers,	(Halttunen,	J.	et	al.,	2014)	recently	presented	a	proposal	for	defining	a	difficult	cannulation,	where	one	of	the	following	criteria	should	be	met	for	it	to	be	considered	difficult:	five	attempts	of	cannulation,	five	minutes	of	cannulation	or	two	passages	of	the	guidewire	into	the	pancreatic	duct.	This	definition	was	based	on	a	significantly	increased	PEP	rate	if	either	of	these	criteria	were	fulfilled	before	cannulation	was	achieved.	If	the	cannulation	took	more	than	five	minutes,	the	PEP	rate	rose	from	2.6	%	to	11.8	%,	and	if	the	guidewire	was	inserted	to	the	pancreatic	duct	once,	the	PEP	rate	was	3.7	%,	whereas	the	PEP	rate	rose	to	13.1	%	when	the	guidewire	was	inserted	twice.	This	definition	was	adapted	by	the	ESGE	in	2016	(Testoni,	P.	A.,	et	al.,	
2016)	to	define	a	difficult	cannulation.		
1.2.5	Pancreatic	guidewire-assisted	technique			For	a	difficult	cannulation	of	the	bile	duct	where	the	guidewire	enters	the	pancreatic	duct,	it	has	been	advocated	to	use	the	pancreatic	guidewire-assisted	cannulation,	where	the	pancreatic	guidewire	is	kept	in	place	in	the	pancreatic	duct	and	a	second	guidewire	is	inserted	through	the	papilla,	thereby	hopefully	achieving	access	to	the	bile	duct	through	this	second	guidewire.	However,	the	evidence	for	such	a	method	is	rather	conflicting	with	different	cannulation	success	and	PEP	rates	in	different	studies	
(Angsuwatcharakon,	P.,	et	al.,	2012,	Belverde,	B.,	et	al.,	2012,	Draganov,	P.	et	al.,	2005,	
Gronroos,	J.	M.	et	al.,	2011,	Herreros	de	Tejada,	A.,	et	al.,	2009,	Ito,	K.	et	al.,	2008,	Tanaka,	
R.,	et	al.,	2013,	Xinopoulus,	D.,	et	al.,	2011,	Yoo,	Y.	W.,	et	al.,	2013).	In	a	recent	Cochrane	analysis,	Tse	concluded	that	there	was	an	increased	risk	of	PEP	following	pancreatic	guidewire-assisted	cannulation,	which	could	be	reduced	with	the	use	of	pancreatic	
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stents,	but	that	pancreatic	guidewire-assisted	cannulation	did	not	elevate	the	cannulation	rates	compared	to	repeat	conventional	cannulation	or	precut	sphincterotomy	(Tse,	F.,	et	al.,	2016).	Still,	the	pancreatic	guidewire	technique	is	recommended	by	the	ESGE	(Testoni,	P.	A,	et	al.,	2016)	in	combination	with	a	PEP-protective	prophylactic	pancreatic	stent	(see	Table	1).			
Table	1.	
Pancreatic	guidewire-assisted	cannulation:	Tse,	F.,	et	al.	meta-analysis,	Cochrane	
Database	Syst	Rev	2016;	(5):	CD010571.	PGW=pancreatic	guidewire.	The	table	demonstrates	the	studies	included	in	the	Cochrane	analysis,	when	primary	cannulation	failed	(and	how	this	was	defined)	and	then	the	success	rates	of	the	PGW	cannulation	and	the	success	rates	of	this	secondary	cannulation	method.		 Studies	 Year	 n	 Primary	cannulation	 When	failure?	 When	failure?(PGW)	 PGW	failure	Angsuwatcharakon	 2012	 44	 92	%	 10	min	 10	min	 13	%	Coté	 2012	 87	 81	%	 6	min	 6	min	 19	%	Herreros	de	Tejada	 2009	 188	 73	%	 5	tries	 10	tries	 25	%	Ito	 2010	 70	 93	%	 5	tries	 No	limit	 8	%	Maeda	 2003	 53	 50	%	 10	min	 No	limit	 7	%	Yoo	 2013	 71	 93	%	 10min/tries		 10	tries	 31	%	Zheng	 2010	 64	 NA	 5	tries	 No	limit	 8	%	
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1.2.6	Endoscopic	sphincterotomy	(EST)		The	EST,	where	the	papilla	and	the	sphincter	of	Oddi	are	divided,	is	performed	in	the	vast	majority	of	ERCP	procedures	and	represents	a	way	of	obtaining	access	to	the	bile	duct	and	to	receive	a	working	channel	through	which	it	is	possible	to	intervene	through	the	orifice—for	instance,	making	it	possible	to	insert	a	stent	or	to	extract	bile	duct	stones.	ERCP	with	EST	also	represents	a	good	alternative	to	surgery	in	the	elderly	with	concomitant	diseases,	and	it	has	a	lower	risk	of	morbidity	compared	to	traditional	open	surgery.		For	a	long	time,	there	was	hesitation	to	perform	ESTs	in	younger	patients,	because	of	the	assumed	elevated	risk	of	long-lasting	adverse	events	(Bergman,	J.	J.,	et	al.,	1996,	
Costamagna,	G.	et	al.,	2002)	caused	by	the	enteric	biliary	reflux	of	bacteria	from	the	gut	into	the	bile	ducts,	increasing	the	risk	of	developing	cholangiocarcinoma.	Those	risks	have,	in	later	studies,	not	been	verified	(Stromberg,	C.	et	al.,	2008),	and	EST	is	nowadays	used	in	most	ERCPs	independently	of	the	patient’s	age	as	a	natural	complement	to	the	ERCP	facilitating	interventions	and	for	gaining	access	to	the	bile	duct.		Although	ERCP	is	a	minimally	invasive	procedure,	there	are	still	complications	that	occur	after	sphincterotomy	in	4-15	%	(Cheng,	C.	L.,	et	al.,	2006,	Christensen,	M.,	et	al.,	
2004,	Cotton,	P.	B.,	et	al.,	2009,	Cotton,	P.	B.,	et	al.,	1991,	Freeman,	M.	L.,	et	al.,	1996),	depending	on	the	indications,	patients	and	operators,	where	pancreatitis,	cholangitis,	duodenal	perforation	and	post-sphincterotomy	bleeding	represent	the	most	common	complications.	
1.2.7	Precut	sphincterotomy	with	needle-knife		Basically,	there	are	two	different	ways	to	approach	a	difficult	cannulation	when	a	needle-knife	spincterotome	is	used:	either	through	a	conventional	needle-knife	
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papillotomy	starting	at	the	natural	orifice	or	performed	as	a	separate	incision	above	the	natural	orifice	(i.e.,	a	so-called	suprapapillary	fistulotomy),	for	instance,	in	cases	where	there	is	a	protruding	papilla	with	an	impacted	stone.	Both	methods	report	similar	cannulation	success	and	complication	rates	(Abu-Hamda,	E.	M.,	et	al.,	2005,	Gullichsen,	R.,	
et	al.,	2005),	but	ESGE	recommends	a	suprapapillary	fistulotomy	(Testoni,	P.	A.,	et	al,	
2016).	There	are	studies	that	show	that	precut	sphincterotomy	is	associated	with	an	increased	risk	of	PEP	(Ding,	X.	et	al.,	2015),	but	the	elevated	risk	is	most	probably	related	to	the	timing	when	the	precut	sphincterotomy	is	undertaken.	If	the	precut	sphincterotomy	is	performed	as	an	emergency	action	after	attempting	conventional	cannulation	for	a	long	period	of	time,	then	the	risk	will	increase	for	adverse	events,	perhaps	not	as	an	effect	of	the	precut	sphincterotomy	itself	but	rather	as	a	confounding	effect	of	the	long	duration	of	repeat	cannulation	attempts.		If	the	precut	sphincterotomy	instead	is	performed	early	during	the	ERCP,	no	increase	in	PEP	rates	have	been	detected	compared	to	conventional	sphincterotomy	(Sundaralingam,	P.,	et	al.,	2015).	However,	one	must	remember	that	a	precut	spincterotomy	is	a	high-risk	procedure	
(Testoni,	P.	A.,	et	al.,	2010)	that	requires	an	experienced	endoscopist	to	be	performed	safely	and	should	only	be	performed	in	cases	where	the	indication	for	the	biliary	access	is	strong.	Whether	early	precut	sphincterotomy	should	be	preferred	to	continued	conventional	cannulation	attempts	is	highlighted	in	two	meta-analyses	from	2010	(Cennamo,	V.,	et	al.,	
2010,	Gong,	B.,	et	al.,	2010),	which	concluded	that	there	might	be	a	lower	PEP	risk	if	an	early	precut	sphincterotomy	was	chosen	(2.5	%	vs	5.3	%),	but	the	overall	complication-	and	cannulation	success	rates	did	not	differ.	
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The	ESGE	recommendation	(Testoni,	P.	A.,	et	al.,	2016)	is	therefore	an	early	precut	needle	knife	fistulotomy	because	of	the	lower	risk	for	PEP,	performed	by	an	experienced	endoscopists	(cannulation	rate	over	80	%).	Additionally,	they	also	recommend	a	pancreatic	stent	to	be	used	if	the	pancreatic	duct	is	easily	accessed.	.	
1.2.8	Pancreatic	sphincterotomy	
		In	a	situation	where	the	guidewire	only	achieves	access	to	the	pancreatic	duct,	there	is	the	opportunity	for	bile	duct	access	via	performing	a	pancreatic	sphincterotomy,	which	was	first	described	by	Goff	in	1995	(Goff,	J.	S.,	et	al.,	1995).	The	pancreatic	sphincterotomy	could	be	completed	with	an	additional	needle-knife	sphincterotomy	on	the	bile	duct,	giving	a	bile	duct	access	in	95	%	of	the	cases	(Halttunen,	J.	et	al.,	2009).	The	complication	rates	were	reported	to	be	similar	to	a	precut	sphincterotomy	(Halttunen,	J.	
et	al.,	2009)	or	even	lower	(Miao,	L.,	et	al.	2015).	As	an	alternative	to	the	pancreatic	guidewire,	a	pancreatic	stent	could	be	used	as	an	aid	for	the	pancreatic	sphincterotomy	when	trying	to	gain	biliary	access	(Goldberg,	E.,	et	al.,		
2005),	demonstrating		good	cannulation	rates	(97	%)	with	acceptable	complications.			
1.2.9	Rendezvous-assisted	cannulation	and	sphincterotomy		An	elegant	way	to	improve	cannulation	success	rates	and	to	reduce	complication	rates	is	to	use	the	so-called	“rendezvous	approach”	in	ERCP	during	laparoscopic	cholecystectomy	where	common	bile	duct	stones	(CBDS)	are	found	at	the	intraoperative	cholangiography.	The	method	was	initially	described	by	Deslandres	as	a	case	report	and	in	1993	as	a	case	series	(Deslandres,	E.,	et	al.	1993).	A	guidewire	is	inserted	through	the	cholangiography	catheter	into	the	duodenum,	where	it	is	picked	up	by	a	snare	through	
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the	working	channel	of	the	duodenoscope	and	a	sphincterotome	is	then	inserted	over	the	guidewire	to	secure	biliary	access	and	thus	reduce	the	risk	for	PEP	(Swahn,	F.,	et	al.,	
2013,	Noel	R.,	et	al.,	2013)			
1.2.10	PTC-assisted	cannulation	in	ERCP		Percutaneous	transhepatic	cholangiography	(PTC)	was	previously	a	method	for	treatment	and	performing	diagnostics	of	diseases	in	the	biliary	tree,	but	it	has	been	abandoned	as	a	first-hand	method	since	the	introduction	of	ERCP,	since	PTC	has	higher	complication	rates	and	is	more	inconvenient	for	patients.	PTC	is	still	used	if	cannulation	fails	during	ERCP	and	could	later	be	used	as	an	aid	to	cannulation	to	achieve	biliary	access.						
1.2.11	EUS-assisted	cannulation	in	ERCP		With	the	introduction	of	linear	echo-endoscopes,	new	possibilities	have	developed	to	achieve	biliary	access	when	conventional	cannulation	fails.	Methods	have	been	described	where	the	biliary	tree	is	punctured,	either	through	the	stomach	to	the	left	hepatic	duct	or	through	duodenum	to	the	common	bile	duct,	introducing	a	guidewire	into	the	bile-duct	and	out	through	the	papilla	for	a	rendezvous	cannulation	or	deploying	a	stent	directly	through	the	puncture	site.		
1.3	Endoscopic	biliary	stents	
1.3.1	The	Development	of	Endoscopic	biliary-pancreatic	stents		The	word	“stent”	originates	from	the	English	dentist	Charles	Stent	(1807-1885),	who	improved	the	dental	impression	procedure	by	adding	gutta	perche	to	the	material	to	
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increase	the	plasticity	of	the	substance,	creating	a	material	suitable	to	use	for	producing	stents	for	biliary	deviation.	The	first	plastic	stent	was	used	in	ERCP	in	1979	and	has	been	in	use	in	endoscopy	procedures	since	then	as	a	rather	cheap	and	easy-to-use	device.	The	fact	that	the	plastic	stents	clog	after	three	to	four	months	increases	morbidity	through	the	need	of	repeat	ERCPs,	which	makes	the	plastic	stent	inferior	for	long-term	use	in	biliary	and	pancreatic	diseases	compared	to	the	later	developed	self-expandable	metal	stents	(SEMS),	which	were	introduced	as	the	“Wallstent”	in	the	1990s	by	Boston	Scientific	(Wallstent	TM,	Boston	Scientific,	Marlborough,	Massachusetts,	USA).	The	Wallstent	was	followed	by	the	nitinol	based	Ultraflex	(UltraflexTM,	Boston	Scientific,	
Marlborough,	Massachusetts,	USA)	stent,	which	has	dominated	the	market.	However,	now	other	SEMS-types	are	available	from	other	companies;	this	has	provided	competition	and	has	led	to	technical	improvements	and	a	balanced	price	development.	Another	important	feature	in	the	development	of	the	SEMS	was	the	invention	of	the	covered	SEMS,	where	a	synthetic	covering	was	applied	around	the	stent	consisting	of	polyurethane,	silicone	or	ePTFE	(polytetrafluoro-ethylene);	this	was	initially	launched	as	a	method	to	prevent	tumor	growth	into	the	stent,	thereby	improving	the	patency	of	the	stent	but	also	to	make	it	more	smooth	to	deploy	and	exchange.	The	question	remains	whether	the	covering	really	affects	the	tumor	ingrowth	and	patency	(Isayama,	H.,	et	al.,	
2004,	Yoon,	W.	J.,	et	al.,	2006)	or	if	the	covering	just	makes	the	SEMS	more	prone	to	dislodge	from	the	bile	duct	(Kullman,	E.,	et	al.,	2010,	Park,	D.	H.,	et	al.,	2006).	
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1.3.2	Bile	duct	stenting	in	periampullary	tumors	with	SEMS		
	1.3.2.1	SEMS	in	periampullary	tumors	under	palliative	conditions		Jaundice	is	a	common	initial	symptom	in	periampullary	tumors,	and	the	majority	of	the	tumors	are	irresectable	at	the	time	of	diagnosis.	Nonetheless,	is	it	important	to	treat	the	jaundice	to	minimize	its	consequences	(e.g.,	the	risk	of	immunosuppression	or	impaired	coagulation).	Traditionally,	those	patients	were	treated	with	a	surgical	bypass	(hepatico-jejunostomy)	or	an	endoscopic	plastic	stent,	but	with	the	development	of	the	SEMS,	the	latter	has	exhibited	a	better	patency,	avoiding	operative	morbidity,	repeat	ERCP	procedures	and	giving	a	lower	total	cost,	despite	the	higher	price	of	each	individual	SEMS	device.		A	recent	meta-analysis	(Zorron	Pu,	L.	et	al.,	2015)	based	on	13	RCTs	with	1,133	patients	demonstrated	a	lower	stent-dysfunction	rate	in	the	SEMS	group	(21.6	%	vs	46.8	%,	p<0.00001)	and	also	a	lower	re-intervention	frequency	in	the	SEMS	group	(21.6	%	vs	56.6	%,	p<0.00001)	but	with	equal	complication	rates.	The	analysis	also	showed	an	increased	mean	survival	rate	if	a	SEMS	was	used	(182	days	vs	150	days,	p<0.0001)	and	a	higher	patency	time	for	the	SEMS	(250	days	vs	124	days,	p<0.0001).	The	total	cost	when	using	a	SEMS	was	also	lower	due	to	fewer	ERCP	procedures,	but	this	difference	was	not	significant.		A	subgroup	where	plastic	stents	could	be	used	is	the	group	of	patients	presenting	with	distant	metastases	or	in	patients	with	a	dysfunctional,	previously	inserted	SEMS;	both	clinical	settings	exhibit	a	short	expected	survival	in	these	groups,	justifying	the	cheaper	plastic	stent	to	be	used	in	these	specific	situations	(Soderlund,	C.	et	
al.,	2006).	In	conclusion,	SEMS	should	almost	always	be	preferred	in	irresectable	periampullary	tumors,	since	it	reduces	the	risk	of	stent	dysfunction	and	thereby	the	risk	of	a	repeat	ERCP	procedure.	This	evidence	has	been	known	since	the	first	RCT	published	on	the	
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subject	in	1992	by	Davids	in	Lancet	(Davids,	P.	H.,	et	al.,	1992),	and	by	following	this	policy	one	will	offer	the	patients	with	irresectable	periampullary	tumors	the	best	palliative	care	with	the	least	added	operative	morbidity.		
Table	2.	Meta-analysis	of	patency	of	plastic	stent	vs	SEMS	in	palliation:	Zorron	Pu	L.,	
et	al.,	2015.	World	J	Gastroenterol	2015;	41	(27):	13374-85.				Studies	Author	&	Year		 Plastic	Stent		Patency	(days)	 SEMS	Patency	(days)	Walter	2014	 172	 293	Moses	2013	 153	 385	Mukai	2013	 112	 359	Sangchan	2012	 35	 103	Isayama	2011	 202	 285	Söderlund	2006	 54	 108	Katsinelos	2006	 124	 255	Prat	1998	 96	 184	
Davids	1992	 126	 273	
Mean	p<0.0001	 124	 250	
		
1.3.2.2	SEMS	in	neo-adjuvantly	treated	periampullary	tumors		An	increasing	proportion	of	patients	diagnosed	with	pancreatic	cancer	are	considered	for	neo-adjuvant	oncological	treatment;	this	proportion	typically	includes	patients	with	
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locally	advanced	tumors	incorporating	the	mesenteric	or	portal	vein.	During	the	down-staging	treatment,	traditionally	the	bile	duct	was	stented	with	a	plastic	stent,	and	this	tradition	has	been	maintained,	since	there	has	been	a	hesitation	among	pancreatic	surgeons	to	use	modern	SEMS,	as	these	have	been	suspected	to	induce	a	more	intense	inflammatory	response	in	the	hepatico-duodenal	ligament,	thereby	jeopardizing	the	later	pancreatic	resection	technically.	On	the	other	hand,	it	is	often	that	the	neo-adjuvant	treatment	period	time	exceeds	a	plastic	stent´s	patency	time,	thereby	risking	a	repeat	ERCP	procedure,	which	costs	the	patient	valuable	time	of	preoperative	oncological	treatment	and	carries	the	risk	of	delaying	the	oncoming	operation.		This	issue	was	highlighted	by	Boulay	and	co-workers	(Boulay,	B.	R.,	et	al.,	2010),	who	studied	49	patients	with	pancreatic	cancer	who	received	plastic	stents	in	a	neo-adjuvant	situation	and	demonstrated	that	more	than	half	of	these	patients	(55	%)	required	a	repeat	ERCP	procedure	due	to	stent	dysfunction,	leading	to	a	hospitalization	for	three	days	for	stent	exchange	and	cholangitis	treatment,	postponing	the	ongoing	neo-adjuvant	treatment	and	delaying	the	operation.	Their	conclusion	was	that	SEMS	should	be	considered	in	the	neo-adjuvant	situation	to	avoid	unnecessary	stent	exchange	procedures	that	delay	the	operation.	SEMS	were	also	investigated	in	the	neo-adjuvant	situation	in	periampullary	tumors	by	Aadam	(Aadam,	A.	A.,	et	al.,	2012),	who	studied	55	patients	with	pancreatic	cancer	of	which	32	were	borderline	resectable.	The	median	time	until	surgery	was	104	days	(range	70-260	days),	and	88	%	of	the	SEMS	remained	patent	until	the	operation.	Of	those	patients	finally	undergoing	surgery,	only	11%	of	the	SEMS	malfunctioned	before	the	operation	took	place.	The	study	was	not	randomized	but	clearly	showed	better	results	compared	to	when	plastic	stents	were	used,	and	no	technical	problems	were	
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seen	during	the	pancreatic	surgery	caused	by	the	SEMS;	this	issue	is	further	discussed	later	in	this	thesis	and	in	Paper	4.	Finally,	Adams	(Adams,	M.	A.,	et	al.,	2012)	demonstrated	several	advantages	for	SEMS	in	the	neo-adjuvant	situation	in	their	retrospective	study	from	2012	that	included	52	patients.	The	complication	rates	were	seven	times	higher	in	the	plastic	stent	group	with	a	threefold-increased	complication	rate	requiring	hospitalization.	The	time	to	a	stent	related	complication	was	almost	five	times	longer	in	the	SEMS	group	(44	days	vs	200	days,	p<0.0001);	together,	this	advocated	for	SEMS	in	patients	undergoing	neo-adjuvant	oncological	treatment	for	periampullary	tumors.		
1.3.2.3	Covered	versus	uncovered	SEMS		Initially,	when	the	SEMS	were	introduced,	they	had	no	covering,	which	would	make	them	more	readily	invaded	by	an	ingrowing	tumor;	therefore,	a	covering	was	added	to	the	SEMS	to	avoid	this	ingrowth.	On	the	other	hand,	there	was	a	concern	that	the	covered	SEMS	were	more	likely	to	dislodge	from	the	bile	duct	or	that	they	would	block	either	the	orifices	of	the	cystic	or	pancreatic	ducts.	The	latter	could	not	be	confirmed	in	Kullman´s	study	from	2010	(Kullman,	E.,	et	al.,	2010),	where	the	only	difference	he	found	between	covered	and	uncovered	stents	was	that	the	covered	ones	dislodged	more	easily	(3	%	vs	0	%,	p=0.03),	but	there	was	no	difference	in	patency	between	the	stent	types.	Several	studies	and	one	meta-analysis	(Almadi,	M.	A.,	et	al.,	2013)	have	shown	similar	results.	The	most	recent	meta-analysis	by	Moole	(Moole,	H.,	et	al.,	2016)	included	2,239	patients	and	demonstrated	an	increased	risk	of	stent	dislodgement	if	covered	stents	were	used	and	an	increased	risk	for	tumor	ingrowth	in	the	uncovered	SEMS;	this	resulted	in	no	differences	in	survival,	patency	or	adverse	events	between	the	stent	types.	Another	meta-analysis	by	Chen,	also	from	2016	(Chen,	M.	Y.,	et	al.,	2016),	showed	
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that	covered	SEMS	had	a	lower	rate	of	adverse	events,	but	again	no	differences	in	survival	or	stent	patency	were	seen.	A	third	meta-analysis	from	2016	by	Li	et	al.	(Li,	J.,	et	
al.,	2016)	could	neither	show	any	differences	in	patency	or	survival,	but	they	preferred	covered	SEMS	since	they	were	easier	to	remove	when	an	exchange	was	needed.	In	conclusion,	there	seems	to	be	no	difference	between	covered	and	uncovered	SEMS	regarding	their	functions;	this	is	probably	because	the	negative	effect	of	the	covered	SEMS’	higher	dislodgement	rates	are	balanced	by	the	non-covered	SEMS’	increased	risk	of	tumor	ingrowth,	which	leads	to	no	differences	between	the	stent	types	regarding	function	and	patency.		
1.3.3	Up-front	surgery	for	periampullary	tumors	vs	preoperative	stenting	before	
pancreatic	surgery		Traditionally,	in	Sweden,	all	jaundiced	patients	with	periampullary	tumors	undergo	a	preoperative	biliary	drainage	procedure,	which	are	most	often	through	an	ERCP	with	an	internal	stent.	This	is	performed	due	to	logistical	reasons	while	waiting	for	their	operations,	most	often	performed	at	a	referral	university	hospital	several	weeks	after	the	onset	of	their	symptoms.	The	theoretical	background	for	such	a	policy	is	to	try	to	reduce	the	negative	effects	of	the	jaundice	(e.g.,	impaired	coagulation,	increased	risk	for	immunosupression	or	cholangitis).	However,	the	evidence	for	such	a	policy	is	not	strong,	as	several	previous	meta-analyses	(Chen,	M	.Y.,	et	al.,	2016,	Fang,	Y.,	et	al,	2013,	Sewnath,	
M.	E.,	et	al.,	2002)	have	shown	negative	effects	from	preoperative	biliary	drainage.	This	policy	adds	morbidity	from	the	ERCPs	(like	PEP)	but	also	from	an	increased	rate	of	postoperative	infectious	complications	after	the	pancreatico-duodenectomy,	since	the	bile	becomes	infected	with	gut	bacteria	from	the	preoperative	biliary	drainage,	inducing	more	postoperative	adverse	events.	
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The	shortcomings	of	these	previous	studies	are	that	many	of	them	are	outdated	and	that	the	preoperative	biliary	drainage	procedures	included	in	these	studies	were	internal	endoscopic	plastic	stents	and	external	PTC	drainages	with	higher	morbidity	rates	than	modern	SEMS.	Actually,	the	last	meta-analysis	(Moole,	H.,	et	al.,	2016)	showed	benefits	from	a	preoperative	biliary	drainage	on	postoperative	results.	However,	this	meta-analysis	contained	many	retrospective	studies,	which	must	be	considered	when	interpreting	the	results.	The	most	cited	article	on	the	subject	is	written	by	van	der	Gaag	(van	der	Gaag,	N.,	et	al.,	
2010)	and	was	published	in	New	England	Journal	of	Medicine	in	2010.	Here,	202	patients	were	randomized	to	either	achieve	a	preoperative	biliary	drainage	through	ERCP	and	a	plastic	stent	or	immediate	surgery	for	pancreatic	cancer.	Complications	related	to	the	biliary	drainage	occurred	in	46	%	of	the	patients,	and	significantly	more	patients	had	a	serious	operative	complication	in	the	biliary	drainage	group	(74	%	vs	39	%,	p<0.01,	RR	0.54,	95	%	CI	0.41-0.71).	In	a	meta-analysis	from	2002	(Sewnath,	M.	E.,	et	al.,	2002)	based	on	5	RCTs	(302	patients)	and	18	cohort	studies	(2,853	patients),	there	were	more	complications	if	a	preoperative	biliary	drainage	was	used	compared	to	up-front	surgery,	but	there	was	no	difference	in	mortality.	However,	if	the	biliary	drainage	was	successful	without	complications,	there	were	fewer	complications	in	this	group	compared	to	the	direct	surgery	group.	Another	meta-analysis	from	2013	(Fang,	Y.,	et	al,	2013)	including	6	RCTs	with	more	than	500	patients	reached	the	same	conclusion	with	an	overall	serious	complication	rate	of	60	%	in	the	preoperative	biliary	drainage	group	compared	to	36	%	in	the	up-front	surgery	group	(RR	1.66,	95	%	CI	1.28-2.16,	p<0.001),	but	there	was	no	difference	in	mortality.	The	main	problem	with	this	meta-analysis	is	that	four	of	the	six	included	RCTs	
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were	based	on	results	from	studies	including	patients	with	PTC-drainages,	which	is	a	method	that	is	no	longer	routinely	used	in	modern	healthcare,	since	it	has	been	replaced	by	endoscopic	internal	drainage.	The	opposite	findings	were	achieved	by	Moole	et	al.	in	the	latest	meta-analysis,	which	was	published	in	2016	(Moole,	H.,	et	al.,	2016).	They	included	26	studies	with	3,552	patients;	however,	not	only	RCTs	but	also	retrospective	studies	were	included.	Their	results	were	opposite	to	Fangs	with	a	lower	odds	ratio	for	major	adverse	events	in	the	biliary	drainage	group	compared	to	the	direct-surgery	group	(OR	0.48,	95	%	CI	0.32-0.74).	An	interesting	future	research	project	would	be	to	compare	up-front	surgery	to	more	modern	preoperative	biliary	drainage	with	SEMS	in	a	prospective,	randomized	fashion,	which	is	discussed	further	in	the	next	chapter.	
	
1.3.4	Preoperative	plastic	stenting	vs	SEMS	in	resectable	periampullary	tumors				The	evidence	is	overwhelming	for	the	superiority	of	SEMS	compared	to	plastic	stents	in	irresectable	tumors	in	the	palliative	setting	(Davids,	P.	H.,	et	al.,	1992,	Soderlund,	C.,	et	al.,	
2006,	Zorron	Pu,	L.,	et	al.,	2015).	In	contrast,	much	less	is	known	about	the	role	of	SEMS	in	the	preoperative	situation	of	resectable	tumors,	and	prospective	RCTs	remain	lacking.	There	has	been	a	debate	among	pancreatic	surgeons	that	SEMS	would	jeopardize	the	surgical	resection,	whether	or	not	a	preoperative	biliary	drainage	is	used,	by	inducing	more	inflammatory	reaction	in	the	hepato-duodenal	ligament,	making	the	resection	more	hazardous,	the	SEMS	more	demanding	to	remove	and	the	pancreatico-biliary	anastomoses	to	the	jejunum	more	difficult	to	create	during	the	Whipple	procedure.	Another	concern	has	been	the	higher	costs	of	the	SEMS.	On	the	other	hand,	the	increasing	number	of	patients	with	long	neo-adjuvant	oncological	treatment	has	led	to	a	
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greater	number	of	patients	that	require	stents	with	longer	patency.	However,	often	the	tumor	status	at	the	time	of	the	ERCP	and	the	stent	deployment	is	unknown,	thereby	leading	the	endoscopist	to	use	a	SEMS	to	avoid	a	repeat	ERCP	for	the	patient	in	case	the	tumor	eventually	is	found	to	be	irresectable.	Despite	that	prospective	RCTs	are	lacking,	a	meta-analysis	was	performed	in	2016	
(Crippa,	S.,	et	al.,	2016),	containing	four	retrospective	studies	and	one	cohort	study	(n=704);	its	conclusions	must	be	interpreted	with	caution,	but	the	analysis	showed	clear	benefits	for	the	SEMS	group.	The	need	for	a	re-intervention	ERCP	was	seen	in	14.8	%	in	the	plastic	stent	group	compared	to	3.4	%	in	the	SEMS	group	(p<0.0001),	and	the	postoperative	pancreatic	fistula	rate	was	also	lower	in	the	SEMS	group	(5.1	%	vs	11.8	%,	p=0.04).	No	other	differences	between	the	groups	were	seen	regarding	postoperative	complications	or	mortality,	but	the	main	conclusion	of	the	study	was	that	more	prospective	RCTs	are	needed	to	finally	solve	the	issue	of	preoperative	stenting	in	resectable	periampullary	tumors.	The	only	study	that	is	not	solely	retrospective	is	the	one	by	Tol	et	al.	from	2016	(Tol,	J.	A.,	
et	al.,	2016),	where	the	patients	from	van	der	Gaags	study	from	2010	(van	der	Gaag,	N.,	
et	al.,	2010)	were	used	as	a	historical	control	group	and	compared	to	49	prospectively	collected	patients	receiving	a	SEMS	prior	to	operation	for	pancreatic	cancer	(53	randomized,	four	excluded).	Those	“new”	49	patients	with	SEMS	then	were	compared	to	the	102	patients	receiving	plastic	stents	preoperatively	and	the	94	patients	with	direct	surgery,	and	both	these	latter	groups	were	enrolled	from	the	van	der	Gaags	study	(van	
der	Gaag,	N.,	et	al.,	2010).	The	biliary	drainage	complications	were	almost	doubled	in	the	plastic	stent	group	compared	to	the	SEMS	(46	%	vs	24	%,	RR	1.9,	95	%	CI	1.1-3.2,	p=0.011),	and	the	specific	stent	related	complications	(stent	dysfunction	and	stent	exchange)	were	much	higher	in	
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the	plastic	stent	group	(30	%	vs	6	%,	p=0.03);	however,	the	surgical	complications	did	not	differ.	The	overall	complications	rates	were	51	%	in	the	SEMS	group,	74	%	in	the	plastic	stent	group	and	39	%	in	the	early	surgery	group.	But	again,	the	stent	groups	were	not	randomized	and	were	performed	during	different	time	periods	with	the	plastic	stent	group	used	as	historical	controls,	which	must	be	considered	when	interpreting	the	results.	This	also	highlights	the	need	for	prospective	RCTs.	In	Decker’s	retrospective	study	from	2011	(Decker,	C.,	et	al.,	2011),	29	patients	undergoing	pancreatico-duodenectomy,	were	preoperatively	biliary	drained	with	18	plastic	stents	and	11	SEMS;	they	showed	no	stent	dysfunctions	in	the	SEMS	group	compared	to	stent	dysfunction	in	39	%	in	the	plastic	stent	group	(p=0.02).	Also,	no	technical	problems	were	seen	during	the	operations.	The	same	conclusion	was	reached	by	Cavell	et	al.	in	2013	(Cavell,	L.	K.,	et	al.,	2013),	who	retrospectively	investigated	71	patients	who	received	SEMS	and	thereafter	underwent	panceatico-duodenectomy,	and	they	found	no	differences	in	serious	postoperative	complications	or	mortality	but	showed	more	wound	infections	and	longer	operational	time	in	the	SEMS	group,	indicating	a	more	challenging	operation	in	the	SEMS	group.	But,	this	did	not	affect	the	resectability	grade	of	the	tumor.	They	concluded	that	SEMS	were	not	contraindicated	in	resectable	tumors.	The	only	study,	also	retrospectively	performed,	that	advocated	for	plastic	stents	preoperatively	was	by	Haapamäki	and	co-workers,	(Haapamaki,	C.,	et	al.,	2015).	As	they	found	no	differences	in	stent	patency,	preoperative	bilirubin	level	decrease,	amount	of	bacteria	in	the	bile	or	in	the	postoperative	complication	rates,	they	therefore	argue	that	one	can	use	cheaper	plastic	stents	if	they	have	the	same	function	as	the	more	expensive	SEMS.	
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Altogether,	the	overall	conclusion	seems	to	be	that	SEMS	are	better	in	the	preoperative	situation	in	resectable	periampullary	tumors,	but	prospective	RCTs	are	still	lacking	and	are	warranted	in	the	future.	However,	this	issue	will	be	further	discussed	in	conjunction	with	Paper	4	later	in	this	thesis.		
	1.4	ERCP	complexity	grading	scales			ERCP	is	the	most	difficult	endoscopic	procedure,	but	the	complexity	between	individual	procedures	varies	considerably.	It	is	therefore	important	to	develop	a	grading	scale	for	the	complexity	of	different	ERCPs	that	could	be	used	as	a	tool	to	predict,	for	instance,	the	postoperative	risk	of	adverse	events	and	thereby	be	able	to	intensify	prophylactic	measures	in	these	particular	procedures.	One	important	character	of	such	a	grading	scale	would	be	to	find	a	system	that,	as	far	as	possible,	could	predict	all	possible	obstacles	associated	with	an	ERCP	procedure.	However,	some	of	the	technical	difficulties	in	ERCP	(e.g.,	a	giant	duodenal	diverticula,	a	difficult	cannulation	due	to	a	small	papilla)	cannot	always	be	foreseen,	but	a	superior	grading	scale	can	anticipate	risks	and	function	as	important	clinical	guidance.		While	complications	are	important	to	predict	in	ERCP,	the	time	and	competence	required	to	perform	a	certain	ERCP	procedure	are	also	important,	as	this	information	could	work	as	an	aid	in	planning	activities	at	different	endoscopy	centers	to	better	use	their	resources.	A	well-balanced	ERCP	complexity	grading	scale	might	also	act	as	a	good	complement	in	training	programs	for	endoscopists	under	training	with	different	skills	to	find	the	right	level	in	an	endoscopic	educational	program.	Finally,	a	well-validated	grading	system	may	be	helpful	in	comparisons	between	different	endoscopic	centers	and	may	also	help	with	billing	processes	between	different	health	care	systems	and	to	
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decide	when	to	refer	more	complex	ERCP	procedures	to	tertiary	referral	centers	with	the	right	competence	for	a	specific	advanced	ERCP	procedure.		There	have	been	previous	attempts	to	establish	ERCP	complexity	grading	scales,	but	the	few	that	have	been	launched	have	either	now	become	outdated	or	have	not	been	validated	in	relation	to	resource	requirements	like	procedure	time	but	instead	only	to	success	and	complication	rates.	ERCP	complexity	grading	systems	are	further	discussed	later	in	this	thesis	in	conjunction	to	Paper	3	(The	HOUSE	classification).		
1.4.1	The	Cotton	and	ASGE	Classification		A	recent	attempt	to	establish	a	complexity	grading	scale	was	performed	by	Cotton	and	co-workers	in	2011	(Cotton,	P.	B.,	et	al.,	2011).	Actually,	this	was	presented	for	all	types	of	endoscopic	procedures	and	not	only	for	ERCPs.	The	aim	of	the	study	was	to	arm	the	endoscopist	with	a	method	to	predict	problems	before	the	start	of	the	procedure	to	be	able	to	improve	the	chance	of	a	technical	success	of	the	endoscopic	procedure.	The	method	used	was	to	send	a	comprehensive	list	of	specific	endoscopic	procedures	to	17	members	of	the	ASGE	(American	Society	for	Gastro	Enterology)	Adverse	Events	Working	Party	with	26	different	ERCP	items	and	ask	them	to	rank	the	procedure	using	a	four-point	scale,	from	which	a	median	value	was	calculated	to	represent	the	complexity	grading	of	that	specific	procedure.	To	make	the	categories	more	adequate,	certain	circumstances	for	the	procedure	could	be	added,	for	example,	if	the	procedure	was	performed	outside	ordinary	working	hours,	if	there	had	been	a	failed	attempt	before,	if	the	procedure	was	performed	on	a	child	under	three	years	or	if	the	patient	had	an	altered	anatomy	of	the	upper	GI-tract	(like	a	Billroth	2-operation).	If	one	of	the	circumstances	mentioned	above	was	present,	then	one	point	was	added	to	the	grading	number	judged	by	the	experts.		
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The	advantage	of	this	scale	is	that	it	is	easy	to	use	and	implement	in	clinical	praxis,	and	the	shortcomings	of	the	system	are	that	it	is	solely	“eminence	based”	and	not	validated	in	relation	to	resource	consumption,	complications	or	success	rates.	Additionally,	it	does	not	completely	cover	all	obstacles	that	could	turn	up	during	an	ERCP	(e.g.,	a	giant	duodenal	diverticula	or	if	a	precut	sphincterotomy	is	required	for	a	difficult	cannulation).		 	
		
33	
	
Table	3.	The	Cotton	classification:	Cotton	P.	B.,	et	al.,	Grading	the	complexity	of	
endoscopic	procedures:	results	of	an	ASGE	working	party.	Gastrointest	Endosc	2011;73(5):	
868-874)		
Cotton		 Type	of	ERCP	Grade	1	 Diagnostic	ERCP,	brush	cytology	Grade	1.5	 Stent	exchange,	stent	extraction	Grade	2	 Biliary	leak,	CBDS	<10mm,	extrahepatic	stent,	prophylactic	pancreatic	stent	Grade	3	 Pancreatic	stone	<5mm,	CBDS>10mm,	migrated	stents,	pancreatitis,	SOD,	papilla	minor,	pancr.strictures,	hilar	strictures,	intrahepatic	stones,	intraductal	imaging	(SPY)	Grade	3.5	 migrated	pancreatic	stents	Grade	4	 pancreatic	stones	>5mm	or	fix,	intraductal	therapy	(EHL),	ampullectomy,	Roux-en-Y,	pseudocysts,	necrosectomy	
+1	point	for	 Billroth	2-op.	anatomy,	child	<3years,	previously	failed	procedure	or	procedure	performed	outside	working	hours	
	
	
1.4.2	The	classification	according	to	Schutz	and	Abbott		This	grading	scale	was	presented	in	2000	(Schutz,	S.	M.,	et	al.,	2000),	and	the	aim	was	to	produce	more	meaningful	outcome	data	to	make	it	possible	for	different	endoscopic	centers	to	compare	their	success	and	complication	rates.	The	study	was	performed	first	
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retrospectively	from	a	database	containing	all	ERCP	procedures	performed	during	1997.	Then,	all	of	the	ERCPs	performed	during	1998	were	added	to	the	study	in	a	prospective	manner	for	a	combined	total	of	more	than	400	patients.	Those	procedures	were	divided	into	a	five-point	scale	according	to	their	technical	difficulty.	To	those	five	levels,	a	“B-grade”	was	added	if	the	patient	had	had	a	previously	failed	endoscopic	procedure	attempt.	They	also	suggested	an	“S”	suffix	for	patients	that	have	had	a	previous	sphincterotomy.	Ultimately,	they	found	more	complications	and	lower	success	rates	in	the	grade-5	procedures	and	that	the	repeat	ERCPs	have	a	very	low	success	rate.		They	also	conclude	that	their	study	was	a	pilot	study,	which	was	underpowered	and	was	a	preliminary	attempt	to	establish	a	complexity	grading	scale.	Another	shortcoming	of	the	study,	now	15	years	later,	is	that	the	classification	contains	special	complexity	grades	for	diagnostic	ERCP	procedures;	something	that	was	abandoned	after	the	introduction	of	the	MRI-technique	(MRCP).		 	
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Table	4.	Grading	ERCP	complexity:	Schutz,	S.	M.	and	R.	M.	Abbott.	Grading	ERCPs	by	
degree	of	difficulty:	a	new	concept	to	produce	more	meaningful	outcome	data.	Gastrointest	
Endosc	2000;	51(5):	535-539.		
Schutz & Abbott Success Complications 
1 Diagnostic ERCP 92-96 % 1.5-3 % 
2 Therapeutic ERCP 
EST, small CBDS, nasobiliary 
drainage 
100 % 10 % 
3 Complex diagnostic  
B2, brush cytology 
80-100 % 17-20 % 
4 Complex therapeutic 
Large CBDS, dilatation, stents 
95-97 % 3 % 
5 Very advanced ERCP  
Precut sphincterotomy, 
lithotripsi, intrahepatic 
stones/strictures, B2-op, 
cholangioscopy, all pancreatic 
interventions 
79-84 % 6-9 % 
	
1.4.3	Morriston	Hospital	Grading	Scale	(Ragunath)		This	classification	was	introduced	in	2003	(Ragunath,	K.,	et	al.,	2003)	to	establish	a	method	to	achieve	a	more	objective	outcome	measurement	system,	and	during	that	year,	all	ERCPs	performed	by	both	experienced	endoscopists	and	trainees	were	
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registered	and	divided	into	a	four-point	complexity	scale,	where	success	and	complication	rates	were	investigated	in	each	class.	They	found	a	linear	relationship	in	success	rates	for	the	trainees	in	relation	to	the	classification,	but	no	relation	was	seen	for	the	experienced	endoscopists,	and	the	latter	was	explained	by	the	low	power	of	the	study	(n=305).	They	also	did	not	reach	any	significant	differences	in	complication	rates,	but	numerically	higher	complication	rates	were	found	in	the	more	complex	procedures	(grade	4,	9	%	compared	to	4	%	in	the	grade	1-3),	which	was	again	explained	by	the	authors	due	to	underpowering	of	the	study.	Other	limitations	of	the	study	were	that	certain	problems	that	evolved	during	the	ERCP	could	not	be	anticipated	like	a	duodenal	diverticula	or	a	need	for	a	precut	sphincterotomy	due	to	a	difficult	cannulation.	A	final	shortcoming	of	the	scale	was	these	specific	levels	of	the	classification	contain	diagnostic	ERCPs,	yet	these	investigations	have	been	abandoned	after	the	introduction	of	the	MRCP;	therefore,	the	classification	is	hard	to	implement	in	modern	endoscopic	therapy.	 	
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Table	5.	Morriston	Hospital	ERCP-Grading	Scale:	Ragunath	K.,	et	al.	Objective	
evaluation	of	ERCP	procedures:	a	simple	grading	scale	for	evaluating	technical	difficulty.	
Postgrad	Med	J	2003;	79(934):	467-470.		
Morriston	Hospital	Grading	Scale	 Successrate	%	 Complications	%	
Grade	1	Diagnostic	ERCP	 87	 4	
Grade	2		EST,	balloon,	CBDS<10mm	 76	 5	
Grade	3	Precut	sphincterotomy,	cytology,	CBDS>10mm,	lithotripsy,	stents,	nasobiliary	drains	
80	 5	
Grade	4	SOD,	papilla	minor,	B2-op,	ampullectomy,	pancreatic	interventions,	cholangioscopy,	EHL,	PTC-rendezvous	
63	 9	
	 			
1.4.4	The	classification	according	to	Madhotra	
		Another	ERCP	complexity	classification	was	the	one	by	Madhotra	(Madhotra,	R.,	et	al.,	
2000),	which	was	presented	as	an	abstract	only,	and	one	of	the	co-authors	was	the	above	mentioned	Cotton	(Cotton,	P.	B.,	et	al.,	2011).	A	database	was	investigated	including	
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8,094	patients	and	divided	into	a	three-point	scale	according	to	the	complexity	of	the	procedure.	The	conclusion	of	the	study	was	simply	that	the	success	rate	was	proportional	to	the	grade	of	the	scale	without	any	further	explanation	expressed	in	the	abstract.	Also,	this	classification	included	diagnostic	ERCPs	that	are	no	longer	used	since	the	introduction	of	MRCP,	making	also	this	classification	difficult	to	implement	in	modern	endoscopic	therapy.		
Table	6.	Classification	according	to	Madhotra:	Madhotra,	R.,	et	al.	Analyzing	ERCP	
practice	by	a	modified	degree	of	difficulty	scale:	a	multicenter	database	analysis.	Am	J	
Gastroenterol	2000;	95:2480–1.		
Classification	according	to	Madhotra	
Grade	1:	Diagnostic	ERCP,	CBDS	<10mm,	extrahepatic	stent,	nasobiliary	drainage	
Grade	2:	Diagnostic	ERCP	in	B2-op,	CBDS	>10mm,	papilla	minor,	intrahepatic	stricture	
Grade	3:	Roux-en-Y/Whipple,	Spyglass,	SOD,	intrahepatic	stones,	therapeutic	ERCP	in	B2-op,	all	pancreatic	ERCPs		
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1.4.5	The	classification	according	to	Torun		Recently,	in	2016,	a	new	complexity	grading	scale	was	introduced	by	Torun	(Torun,	S.,	et	
al.,	2016).	Completely	independently	of	the	introduction	of	the	HOUSE	classification,	this	scale	was	launched	with	similar	parameters	to	our	HOUSE	classification	regarding	complication	rates;	however,	this	had	a	four-point	scale	and	demonstrated	a	relationship	between	the	complications	of	the	groups	from	1.3	%	in	the	group	of	less	complicated	investigations	up	to	10.4	%	in	the	group	of	the	most	complex	ERCPs.		Instead	of	procedure	time,	which	was	measured	in	the	HOUSE	classification,	Torun	focused	on	success	rates	between	the	groups	of	ERCPs	with	different	complexity	and	found	a	linear	relationship	between	the	groups	of	ERCPs	with	different	complexities	(1st	degree	99.3	%,	2nd	degree	97.2	%,	3rd	degree	86.7	%	and	4th	degree	46.7	%	success	rates).	This	new	classification	seems	promising	regarding	measuring	and	comparing	results	from	different	endoscopic	centers	more	fairly,	but	compared	to	the	HOUSE	classification,	it	lacks	the	ability	to	plan	endoscopic	resources	as	it	does	not	include	any	such	parameters—for	example,	procedure	time	for	every	single	ERCP	investigation,	which	was	included	in	the	HOUSE	classification.		 	
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Table	7:	Classification	according	to	Torun:	Torun,	S.,	et	al.,	Turk	J	Gastroenterology,	
2016,	Mar;	27(2):	187-91.	Grade	1	 Grade	2	 Grade	3	 Grade	4	Stent	exchange	 Stone	<10mm	 Stone	>10mm	Minor	papilla	 Migrated	pancreatic	stents	Stent	removal	 Biliary	leakage	 Migrated	biliary	stent	 Pancreatic	stone		>5	mm		 Extra	hepatic	stricture	 Pancreatic-ERCP	Hilar	strictures	 Intrahep	stone	Pseudocyst		 Prophylactic	pancreatic	stent	 Sph.	Oddi	Dysf.		 Necrosectomy	Ampullectomy	Prev	GBY	op		 	 Spyglass	 Prev	Whipple	Spyglass	EHL		
	
	
1.5	Complications	in	ERCP	
	
1.5.1	Post-ERCP	pancreatitis	(PEP)		PEP	is	the	most	common	complication	after	ERCP	and	is	most	often	mild	to	moderate,	but	it	can	occasionally	be	severe	with	subsequent	organ	failure.	The	definitions	of	PEP	used	are	those	defined	by	Cotton	(Cotton,	P.	B.,	et	al.,	1991),		where	a	mild	PEP	was	characterized	by	abdominal	pain,	an	amylase	elevated	three	times	the	normal	value	and	a	need	for	a	hospital	stay	of	two	to	three	days.	A	moderate	PEP	was	defined	as	a	condition	that	required	hospitalization	for	4-10	days.	Finally,	severe	pancreatitis	required	more	than	10	days	in	the	hospital,	showed	signs	of	complications	locally	in	the	pancreas	(e.g.,	necrosis,	pseudocysts)	or	systemically	(e.g.,	
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multiorgan	failure)	or	required	surgical	or	percutaneous	interventions.	Note	that	an	already	existing	pancreatitis	(before	the	ERCP)	can	confuse	the	definition	of	PEP	and	affect	the	PEP	rates	when	this	issue	is	studied.	Also,	an	isolated	amylase	elevation	without	symptoms	can	be	interpreted	as	a	PEP	and	thus	make	postoperative	complications	rates	difficult	to	study	and	even	impossible	to	compare	between	different	series.	The	PEP	rate	was	reported	in	unselected	cases	to	be	around	3.5	%,	where	mild	and	moderate	PEPs	represent	about	90	%	of	all	the	cases	(45	%	each),	and	only	10	%	developed	into	a	severe	PEP	(Andriulli,	A.,	et	al.,	2007).	Similar	findings	were	seen	in	the	Swedish	National	GallRiks	Registry	(Enochsson,	L.	et	al.,	2010),	where	the	overall	PEP	frequency	was	2.7	%	in	this	unselected	database	of	patients,	but	the	PEP	rate	rose	to	5.3%	when	the	pancreatic	duct	had	been	cannulated	compared	to	only	1.8	%	if	only	the	bile	duct	was	cannulated.	There	was	also	a	higher	PEP	frequency	at	the	high-volume	centers	(3.7	%)	compared	to	middle-	and	low-volume	centers	(2.4	%),	indicating	a	case	mix	where	more	complex	procedures	were	performed	at	the	high-volume	centers.	The	exact	mechanism	of	how	PEP	occurs	is	not	known,	but	a	long	list	of	risk	factors	is	known,	where	some	depend	on	the	patient,	some	on	the	endoscopist	and	some	on	the	type	of	intervention.	A	previous	PEP	in	the	patient´s	history	elevated	the	odds	of	a	PEP	by	more	than	five	times,	whereas	women	or	patients	with	a	suspected	sphincter	Oddi	dysfunction	had	two	and	a	half	times	elevated	odds	for	a	PEP.	A	difficult	cannulation,	contrast	injection	to	the	pancreatic	duct	or	a	pancreatic	sphincterotomy	all	increased	the	odds	of	PEP	approximately	three	times	(Andriulli,	A.,	et	al.,	2007,	Freeman,	M.	L,	et	al.,	
2001).	However,	the	type	of	contrast	(high	vs	low	osmolality)	injected	into	the	pancreatic	duct	did	not	affect	the	risk	for	developing	PEP	(George,	S.,	et	al.,	2004).	
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Freeman	also	demonstrated	(Freeman,	M.	L.,	et	al.,	2001)	that	chronic	pancreatitis	had	a	protective	effect	on	the	risk	of	PEP	and	finally	found	no	difference	if	the	procedure	was	performed	on	a	bile	duct	of	a	small	diameter	or	a	dilated	one,	neither	could	he	demonstrate	any	differences	between	high-	and	low-volume	centers	in	PEP	rates	or	whether	or	not	a	biliary	sphincterotomy	was	performed	(Freeman,	M.	L.,	et	al,	2001).		Younger	age	(<60	years)	is	another	risk	factor	associated	with	an	elevated	risk	for	PEP	
(Cheng,	C.	L.,	et	al.,	2006);	this	is	probably	due	to	a	more	atrophic	and	less	reactive	pancreatic	glandulae	in	older	age	compared	to	younger	patients.	 	
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Table	8.	Riskfactors	for	PEP:	Dumonceau,	J.	M.,	et	al.,	Prophylaxis	of	post-ERCP	
pancreatitis:	European	Society	of	Gastrointestinal	Endoscopy	(ESGE)	Guideline	-	updated	
June	2014.	Endoscopy	2014;	46	(9):	799-815.	
	
a)Patient-related	risk	factors	
	 OR	(95	%CI)	 Relative	risk	SOD	 1.9 (1.4 – 2.6)	 8.6 % vs. 2.5 %	Female	 3.5 (1.1 – 10.6)	 4.0 % vs. 2.1 %	Previous	pancreatitis	 2.5 (1.9 – 3.1)	 6.7 % vs. 3.8 %	Younger	age	 1.1 – 2.9	 6.2 % vs. 2.6 %	Previous	PEP	 8.7 (3.2 – 23.9)	 30 % vs. 3.5 %	No	chronic	pancreatitis	 1.9 (1.0 – 3.5)	 4.0 % vs. 3.1 %	Normal	bilirubin	level	 1.9 (1.2 – 2.9)	 4.2 % vs. 1.4 %	Non-dilated	bile	duct	 - 3.8 % vs. 2.3 %		
b) Procedure-related	risk	factors	Cannulation>10	minutes	 1.8 (1.1 – 2.7)	 3.8 % vs. 10.8 %	Pancreatic	guidewire	passage	 2.8 (1.8 – 4.3)	 2.9 % vs. 9.5 %	Pancreatic	contrast	injection	 2.2 (1.6 – 3.0)	 3.3 % vs. 1.7 %	Precut	sphincterotomy	 2.3 (1.4 – 3.7)	 5.3 % vs. 3.1 %	Pancreatic	sphincterotomy	 3.1 (1.6 – 5.8)	 2.6 % vs. 2.3 %	Biliary	balloon-sphincter	dil.	 4.5 (1.5 – 13.5)	 9.3 % vs. 2.6 %	Failure	of	CBDS	clearance	 3.4 (1.3 – 9.1)	 1.7 % vs. 1.6 %	Intraductal	Ultrasound	 2.4 (1.3 – 4.4)	 8.4 % vs. 2.8 %		
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1.5.2	Infectious	complications	to	ERCP	(cholangitis,	abscess,	sepsis)		Very	often	stasis	of	the	bile	duct	is	the	problem	when	an	ERCP	is	undertaken,	resulting	in	infected	bile	as	part	of	the	disease	and	not	always	as	a	direct	complication	to	the	ERCP.	On	the	other	hand,	an	infectious	complication	can	be	a	direct	consequence	of	an	incomplete	drainage	of	a	bile	duct	segment	but	where	the	ERCP	procedure	per	se	contaminates	the	bile	with	gut	bacteria.	Finally,	cholangitis	can	occur	due	to	a	failed	cannulation	that	does	not	allow	the	bile	ducts	to	be	drained,	resulting	in	a	manifest	sepsis	or	abscess	formation.	Altogether,	these	different	situations	make	the	figures	of	infectious	complications	in	ERCP	difficult	to	interpret	and	can	vary	between	different	series	in	relation	to	the	inclusion	criteria	for	post-ERCP	infection	complication	rates.	However,	has	there	been	an	attempt	by	Cotton	(Cotton,	P.	B.,	et	al.,	1991)	to	define	cholangitis,	where	a	mild	cholangitis	was	defined	as	a	temperature	over	38	°C	for	24-48	hours.	A	moderate	cholangitis	was	defined	as	lasting	for	at	least	three	days	of	in-hospital	care	or	requiring	a	repeat	ERCP	or	PTC	for	drainage	of	the	bile	ducts.	Finally,	a	severe	cholangitis	corresponded	to	a	septic	shock	or	a	cholangitis	requiring	a	surgical	intervention.	Cholangitis	is	reported	to	occur	in	about	0.5	%-5	%	after	ERCP	(Christensen,	M.,	et	al.,	
2004,	Masci,	E.,	et	al.,	2001),	depending	on	the	patient	groups	and	whether	or	not	failure	of	complete	drainage	has	been	recorded	as	a	complication.	The	cholangitis	may	proceed	into	abscesses	of	the	liver	or	to	manifest	sepsis.	Hilar	tumors	and	patients	with	primary	sclerosing	cholangitis	(PSC)	are	considered	to	be	more	prone	to	develop	infectious	complications	because	the	risk	of	leaving	undrained	areas	of	the	bile	tree	is	greater	since	these	diseases	are	multilocular	(PSC)	or	affect	multiple	bile	ducts	(hilar	tumors).	
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The	treatment	of	cholangitis	is	otherwise	quite	straightforward:	antibiotics	are	administered	intravenously,	and	additional	drainage	is	performed	via	ERCP	or	PTC	to	localize	and	treat	undrained	areas	of	the	bile	tree,	if	needed.	Prophylactic	antibiotics	to	prevent	complications	after	ERCP	are	still	used	at	many	endoscopic	centers.	Two	recent	meta-analyses	studying	prophylactic	antibiotics	in	ERCP	
(Bai,	Y.,	et	al.,	2009,	Brand,	M.,	et	al.,	2010)	reached	different	conclusions.	The	first,	which	was	performed	by	Brand	(Brand,	M.,	et	al.,	2010),	stated	that	prophylactic	antibiotics	have	a	role	in	complicated	ERCPs,	especially	when	drainage	is	not	reached,	whereas	Bai	
(Bai,	Y.,	et	al.,	2009),	who	performed	the	other	meta-analysis,	reached	the	conclusion	that	prophylactic	antibiotics	cannot	prevent	cholangitis	at	all.		
	
1.5.3	Duodenal	perforations		Duodenal	perforation	occurs	in	less	than	one	percent	of	the	ERCPs	(Christensen,	M.,	et	al.,	
2004,	Freeman,	M.	L.,	et	al.,	1996,	Vandervoort,	J.,	et	al.,	2002,	Wang,	P.,	et	al.,	2009,	
Williams,	E.	J.,	et	al.,	2007)	and	is	usually	retroperitoneally	located	and	most	often	does	not	require	any	operation	but	can	be	treated	with	antibiotics.	However,	some	of	the	perforations	are	intra-abdominal	and	more	often	require	an	operation,	and	the	clinical	challenge	is	to	provide	an	early	identification	of	these	patients	who	would	otherwise	deteriorate	rapidly	if	not	for	the	operation.	A	CT	scan	is	often	of	great	help,	but	the	free	air	outside	the	gut	lumen	frequently	seen	after	ERCP	does	not	always	require	operation,	so	the	assessment	will	ultimately	be	clinically	based.	Stapfer	presented	a	four-point	classification	(Stapfer,	M.,	et	al.,	2000)	according	to	the	management	required	to	manage	these	complications,	where	the	first	class	needs	operation,	and	the	class	with	the	highest	number	almost	always	could	be	treated	conservatively.	
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Lately,	the	therapy	arsenal	for	duodenal	perforations	has	been	extended	with	the	possibility	to	temporarily	deploy	a	covered	SEMS	in	the	bile	duct	as	an	alternative	to	surgical	exploration,	hereby	minimizing	the	leakage	(Artifon,	E.	L.	et	al.,	2015).	A	classification	of	the	perforation´s	severity	is	also	established,	where	a	mild	perforation	was	defined	as	a	possible	or	very	slight	leak	that	could	be	treated	conservatively	and	requiring	less	than	three	days	in	the	hospital	and	a	moderate	perforation	requiring	4-10	days	in	the	hospital,	whereas	a	severe	perforation	was	defined	as	requiring	more	than	10	days	in	the	hospital	or	a	need	for	a	percutaneous	drainage	or	a	surgical	intervention	
(Cotton,	P.	B.,	et	al.,	1991).		
1.5.4	Post-sphincterotomy	hemorrhage		Bleeding	of	clinical	significance	occurs	in	about	1-3	percent	of	ERCPs	(Cotton,	P	.B.,	et	al.,	
2009,	Freeman,	M.	L.,	et	al.,	1996,	Masci,	E.,	et	al.,	2001),	depending	on	the	definition	of	bleeding,	and	is	more	frequent	for	a	precut	sphincterotomy	or	if	an	obstruction	of	the	papilla	of	Vateri	is	present	(Masci,	E.,	et	al.,	2001).	Other	risk	factors	for	bleeding	include	coagulopathy	or	anticoagulation	therapy,	on-going	cholangitis,	low	case-volume	of	the	endoscopist	or	detectable	bleeding	during	the	EST	(Freeman,	M.	L.,	et	al.,	1996).	Also,	regarding	this	specific	complication,	a	definition	of	the	different	stages	of	the	severity	of	the	bleeding	has	been	made	by	Cotton	et	al.	(Cotton,	P.	B.,	et	al.,	1991),	where	mild	bleeding	was	defined	where	the	patient	did	not	require	blood	transfusions	compared	to	a	moderate	bleeding,	where	the	patient	needed	up	to	four	units	of	blood,	or	severe	bleeding,	where	the	patient	required	five	units	of	blood	or	more	or	an	angiographic	or	surgical	intervention.	The	treatment	modalities	in	a	postoperative	sphincterotomy	bleeding	are	similar	to	the	ones	used	in	any	upper	gastrointestinal	bleeding,	like	endoscopic	injection	therapy	with	
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adrenalin	or	applying	endoscopic	clips.	As	an	initial	measure	to	stop	the	bleeding,	often	a	balloon	is	inflated	at	the	sphincterotomy	site	to	gain	initial	hemostasis	so	further	interventions	can	be	undertaken	if	necessary.	An	increased	use	of	SEMS	inserted	in	the	distal	bile	duct	has	been	used	as	a	temporary	method	to	compress	the	bleeding	site	to	achieve	hemostasis.		If	endoscopic	and	pharmacological	methods	fail,	more	invasive	measures	can	be	used	like	angiographic	coiling	of	the	gastro-duodenal	artery	or	open	surgery	to	gain	hemostasis	through	a	duodenotomy.		
1.5.5	Other	complications			Additional	different	but	more	seldom	occurring	complications	have	been	described	after	ERCP,	both	systemic	and	of	more	local	types	related	to	the	procedure	in	the	duodenum.	Endoscopic	perforations	of	the	instrument	could	occur	and	must	be	treated	depending	on	their	localization	and	seriousness.	Perforations	caused	by	endoscopic	stents	have	also	been	described	(Christensen,	M.,	et	al.,	2004).	The	SEMS	may	also	cause	an	obstruction	of	the	cystic	duct	leading	to	cholecystitis,	which	can	be	treated	like	any	cholecystitis	with	operation	or	cholecystostomy.	A	special	complication	for	ERCP	is	the	so-called	“Winnie-the-Pooh	syndrome”	referring	to	when	a	stone	is	grasped	in	a	stone	catcher	basket	and	stuck	inside	it,	and	there	is	no	possibility	to	remove	neither	the	stone	nor	the	basket	out	of	the	bile	duct.	Sometimes,	the	patient	needed	to	have	surgery	to	remove	both	the	stone	and	basket	with	the	ERCP	instrument	in	place	during	the	operation.	However,	this	issue	has	now	been	solved,	since	modern	stone	catcher	baskets	can	be	taken	apart	at	the	distal	end,	distal	to	the	stone,	giving	the	operator	the	opportunity	to	get	the	basket	out	but	leaving	the	stone	in	situ	to	be	handled	later.	
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General	complications	(e.g.,	cardiac	or	pulmonary)	could	occur	like	in	any	operation	and	is	described	in	less	than	one	percent	of	the	ERCPs	(Christensen,	M.,	et	al.,	2004).	Also,	respiratory	complications	are	described	due	to	the	stress	to	the	cardiopulmonary	system	from	the	intervention	or	as	an	effect	of	pulmonary	aspiration	during	the	procedure	and	happens	in	about	one	and	a	half	percent	of	the	ERCPs	(Christensen,	M.,	et	
al.,	2004).	Finally,	thromboembolic	events	must	be	mentioned	and	are	reported	in	0.7	%	of	the	patients	undergoing	ERCP,	such	as	cerebrovascular	events	and	pulmonary	embolism.		
1.6	Prophylactic	measures	to	ERCP	to	avoid	postoperative	complications	
	
1.6.1	Pancreatic	stents		Pancreatic	stents	are	thought	to	improve	the	drainage	of	the	pancreatic	juice	after	the	ERCP	and	hereby	reduce	the	risk	of	PEP.	In	the	guidelines	from	the	European	Society	of	Gastrointestinal	Endoscopy	(ESGE)	from	2014,	the	recommendations	are	to	use	a	prophylactic	pancreatic	stent	in	all	high-risk	and	mixed-case	groups	of	ERCPs,	since	it	diminishes	the	risk	of	PEP	and	almost	eliminates	the	risk	of	severe	PEP	(Dumonceau,	J.	
M.,	et	al.,	2014).	This	statement	was	based	on	previous	meta-analyses,	for	instance,	the	one	from	Singh	from	2004,	where	five	trials	with	481	patients	showed	an	increased	OR	of	3.2	if	no	pancreatic	stent	was	used	with	a	risk	of	PEP	of	15.5	%	compared	to	5.8	%	if	a	stent	was	deployed	in	the	pancreatic	duct	(Singh,	P.,	et	al.,	2004).	Similar	results	were	found	in	a	meta-analysis	by	Choudhary	and	co-workers	(Choudhary,	A.,	et	al.,	2011),	where	a	reduction	in	PEP	from	17.8	%	to	8.8	%	(OR	0.22,	95	%	CI	0.12-0.38)	was	demonstrated	if	
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a	pancreatic	stent	was	used	prophylactically,	corresponding	to	a	NNT	of	8	stents	to	avoid	one	PEP.	In	another	meta-analysis	by	Mazaki	and	co-workers	based	upon	14	studies	and	more	than	1,500	patients	(Mazaki,	T.	et	al.,	2014),	an	overall	RR	of	0.39	(95	%	CI	0.29-0.53)	for	PEP	was	shown	if	prophylactic	pancreatic	stents	were	used,	and	an	even	lower	RR	for	severe	PEP	was	seen	(RR	0.26,	95	%	CI	0.09-0.76).	Similar	findings	were	noted	by	Fan	and	co-workers	in	2015	(Fan,	J.	H.,	et	al.,	2015)	in	a	further	meta-analysis	with	over	1,600	patients	that	demonstrated	a	reduction	in	PEP	rates	from	10.4	%	to	4	%	if	pancreatic	stents	were	deployed	prophylactically	in	high-risk	ERCPs,	corresponding	to	an	OR	of	0.35.	Yet	another	meta-analysis	(Vadala	di	Prampero,	S.	F.,	et	al.,	2016)	studied	the	effect	of	prophylactic	pancreatic	stents	in	12	RCTs	including	1,269	patients	and	found	an	OR	of	0.28	(95	%	CI	0.8-0.42).	Altogether,	one	can	conclude	that	this	issue	is	well	studied	with	overwhelming	results	that	advocate	the	use	of	prophylactic	pancreatic	stents,	especially	in	difficult	ERCPs.	The	largest	separate	study	often	included	in	the	meta-analyses	is	by	Sofuni	and	co-workers.	(Sofuni,	A.,	et	al.,	2011),	where	426	patients	were	randomized	to	either	achieve	a	prophylactic	pancreatic	stent	or	not,	demonstrating	a	reduction	in	the	PEP	rates	if	pancreatic	stents	were	used	(15.2	%	vs	7.9	%,	p=0.021);	in	the	ITT	analysis,	however,	the	significant	difference	disappeared.	In	the	recommendations	from	the	ESGE	from	2014,	where	prophylactic	pancreatic	stents	are	advocated	(Dumonceau,	J.	M.,	et	al.,	2014),	the	guidelines	suggest	a	5-Fr	pancreatic	stent	to	be	used.	This	finding	was	supported	by	the	meta-analysis	of	Afghani	from	2014	(Afghani,	E.,	et	al.,	2014),	where	the	5-Fr	stent	was	described	as	superior	to	the	3-Fr	stent,	whereas	the	type	of	stent	seemed	to	be	of	less	importance	(e.g.,	straight,	
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pigtail,	flanged).	However,	only	two	studies	were	included	in	the	meta-analysis,	that	actually	directly	compared	5-Fr	to	3-Fr	stents	(Chahal,	P.,	et	al.,	2009,	Zolotarevsky,	E.,	et	
al.,	2011)	and	these	studies	did	not	demonstrate	any	differences	in	adverse	events	rates,	and	the	conclusion	that	5-Fr	stents	are	better	was	based	only	on	indirect	evidence	where	the	complication	rates	of	5-Fr	and	3-Fr	stents	have	been	compared	to	no	stent	at	all.	The	absolute	complication	rate	figures	have	then	been	compared,	and	from	these	figures	the	conclusion	has	been	drawn	that	5	Fr	stents	are	better	in	reducing	complications	after	ERCP.	Consequently,	more	studies	are	required	with	direct	comparisons	of	different	stent	sizes	in	prospective,	randomized	trials.	Another	advantage	of	the	5-Fr	stent	that	is	often	mentioned	is	its	easier	placement,	since	it	does	not	require	a	special	guidewire	for	deployment	(Cha,	S.	W.,	et	al.,	2013).		Regarding	the	length	of	the	prophylactic	pancreatic	stents,	Chahal	and	co-workers	
(Chahal,	P.,	et	al.,	2009)	recommended	shorter	stents	since	these	reduced	the	need	for	a	repeat	endoscopy	to	remove	the	stent	(98	%	vs	88	%	spontaneous	dislodgement).	This	study	also	demonstrated	a	lower	PEP	rate	in	the	5-Fr	group	compared	to	the	3-Fr	stents,	although	this	difference	was	not	significant.	Further	aspects	of	the	effect	of	prophylactic	pancreatic	stents	are	discussed	more	thoroughly	later	in	this	thesis	and	in	Paper	2.		
1.6.2	Pharmacological	treatment	with	NSAID	as	PEP	prophylaxis	in	ERCP			Rectally	administered	NSAID	reduces	the	risk	of	PEP	in	both	high-	and	low-risk	procedures,	and	this	has	been	demonstrated	in	several	meta-analyses	(Dai,	H.	F.,	et	al.,	
2009,	Ding,	X.,	et	al.,	2012,	Sethi,	S.,	et	al.,	2014,	Sun,	H.	L.,	et	al.,	2014,	Yaghoobi,	M.,	et	al.,	
2013,	Yuhara,	H.,	et	al.,	2014).	The	guidelines	from	ESGE	(Dumonceau,	J.	M.,	et	al.,	2014)	therefore	recommend	100-mg	indomethacin	or	diclofenac	given	rectally	before	or	after	
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the	ERCP	and	has	been	reported	to	be	used	in	an	increasing	part	of	the	ERCP	procedures	over	time.	In	a	randomized	controlled	trial	from	2012	by	Elmunzer	and	co-workers,	published	in	New	England	Journal	of	Medicine	(Elmunzer,	B.	J.,	et	al.,	2012),	the	PEP	rate	was	not	only	diminished	from	16.9	%	to	9.2	%	(p<0.005)	when	using	indomethacin	compared	to	placebo,	but	it	was	also	reducing	the	part	of	severe	PEPs	from	8.8	%	to	4.4	%	(p=0.03).	NSAIDs	administered	through	other	routes	than	rectally	seem	to	have	no	effect	in	preventing	PEP	nor	does	a	lower	dose	seem	to	have	a	PEP-protective	effect.		Seven	meta-analyses	have	been	published	on	the	subject	of	NSAID-prophylaxis	in	ERCP	since	2009	(Dai,	H.	F.,	et	al.,	2009,	Ding,	X.,	et	al.,	2012,	Kubiliun,	N.	M.,	et	al.,	2015,	Sethi,	S.,	
et	al.,	2014,	Sun,	H.	L.,	et	al.,	2014,	Yaghoobi,	M.,	et	al.,	2013,	Yuhara,	H.,	et	al.,	2014)	and	they	all	demonstrate	significant	beneficial	effects	on	PEP	rates	with	reductions	of	ORs		between	0.44	and	0.57,	where	the	absolute	PEP	rates	were	lowered	from	between	10.3	%	and	16.8	%	to	5.1	%	and	8.9	%.	These	studies	also	report	a	NNT	with	rectally	administered	NSAID	to	avoid	one	PEP	between	approximately	11	and	34	patients	(for	details,	see	Table	9).	 	
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Table	9:	Prophylactic	NSAID	meta-analyses	since	2009.	Dumonceau,	J.M.,	et	al.,	
Prophylaxis	of	post-ERCP	pancreatitis:	European	Society	of	Gastrointestinal	Endoscopy	
(ESGE)	Guideline.	Endoscopy,	2014;	46(9):	799-815.				 Author	 Year	 n	 PEP	NSAID		
PEP	placebo	 OR	(95	%	CI)	 NNT	
Dai	 2009	 1300	 8.9	%	 16.8	%	 0.46 (0.32 – 0.65) NA	Ding	 2012	 2269	 8.0	%	 13.9	%	 0.57 (0.38 – 0.86) 17	Yaghoobi	 2013	 1470	 5.1	%	 10.3	%	 0.49 (0.34 – 0.71) 20	Sun	 2013	 1846	 6.4	%	 16.0	%	 0.45 (0.34 – 0.61) NA	Yuhara	 2014	 1981	 7.8	%	 16.0	%	 0.55	(0.43	-	0.72)	 NA	Sethi	 2014	 2133	 6.6	%	 15.1	%	 0.44	(0.34	-	0.57)	 11			
1.6.3	Other	pharmacological	treatment	in	avoiding	PEP		
	
1.6.3.1	The	use	of	octreotide	and	somatostatin	as	prophylaxis	against	PEP	has	not	been	generally	recommended	in	ERCP	but	only	in	selected	cases	due	to	lack	of	evidence,	discordant	data	and	a	high	NNT	to	avoid	complications.	A	meta-analysis	of	18	RCTs	and	over	3,000	patients	(Zhang,	Y.,	et	al.,	2009)	could	not	demonstrate	any	benefits	in	reducing	PEP	rates.	A	subgroup	analysis	of	higher	doses	of	octreotide	(>0.5	mg),	however,	showed	a	significant	odds	ratio	drop	(OR	0.45)	in	PEP	rates.	Another	meta-
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analysis	by	Omata	and	co-workers	(Omata,	F.,	et	al.,	2010)	could	not	show	any	benefits	in	using	octreotid	in	conjunction	with	ERCP,	whereas	somatostatin	reduced	the	risk	of	PEP	(OR	0.52,	95	%	CI	0.30-0.90),	especially	when	given	in	high	doses	or	as	a	bolus	injection	in	high-risk	ERCPs.	In	summary,	octreotide	and	somatostatin	cannot	be	generally	recommended	as	a	PEP	prophylaxis	in	ERCP	due	to	the	heterogeneous	documentation	and	high	NNT	to	avoid	one	PEP.		
1.6.3.2	Protease	inhibitors	(gabexate,	ulinastatin)	cannot	not	be	recommended	as	PEP	prophylaxis	in	ERCP	as	none	of	them	showed	any	significant	benefits	from	published	meta-analyses	(Dumonceau,	J.	M.,	et	al.,	2014).		
1.6.3.3	Glyceryl	trinitrate	(GTN)	has	been	used	as	an	agent	in	trying	to	reduce	PEP	rates	but	has	been	proven	useless	if	administered	transdermally;	however,	it	may	have	an	effect	if	given	sublingually	but	is	not	generally	recommended	in	ERCP	by	the	ESGE	
(Dumonceau,	J.	M.,	et	al.,	2014).	A	meta-analysis	from	2013	(Ding,	J.,	et	al.,	2013)	including	2,649	patients	in	12	RCTs	found	that	it	lowered	the	overall	PEP	risk	(RR	0.67)	after	ERCP,	but	unfortunately	it	did	not	exhibit	an	effect	for	moderate	and	severe	PEP.	A	further	subgroup	analysis	showed	that	the	most	effective	administration	form	was	sublingually	as	compared	to	transdermal	and	topical	applications.		
1.6.3.4	Drugs	not	shown	to	prevent	from	PEP	and	therefore	not	recommended	Botulinum	toxin,	lidocaine,	nifedipine,	epinephrine	(perhaps	in	diagnostic	ERCPs),	antioxidants	(like	allopurinol,	acetylcysteine,	beta-carotene),	heparin,	interleukin-10,	anti-inflammatory	drugs	(other	than	indomethacin	and	diclofenac)	like	pentoxyfelline,	
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semapimod,	acetylhydrolase	and	finally	glucocorticoids	are	all	substances	without	sufficient	evidence	to	be	recommended	as	prophylaxis	in	ERCP-therapy.	
	
1.6.4	Prophylactic	antibiotics	in	ERCP		Prophylactic	antibiotics	are	still	commonly	used	adjacenct	to	ERCP	as	prophylaxis	against	infectious	complications,	although	the	evidence	for	such	a	strategy	is	quite	weak.		In	1999,	Subhani	and	co-workers	published	a	review	article	(Subhani,	J.M.,	et	al.,	1999),	where	they	proposed	that	antibiotics	should	be	administered	in	these	ERCPs	where	biliary	drainage	could	not	be	achieved,	which	they	calculated	to	be	about	10	%	of	the	ERCPs	(90	%	cannulation	rate).	But,	they	estimated	that	in	this	subgroup	of	ERCPs,	about	80	%	would	benefit	from	prophylaxis,	justifying	a	general	recommendation	for	prophylaxis	in	this	group.	After	that,	only	three	meta-analyses	have	been	reported	on	the	subject	of	prophylactic	antibiotics	in	ERCP;	they	each	reached	different	conclusions	regarding	the	effect	of	prophylaxis	against	complications.		The	first	was	by	Harris	in	1999	(Harris,	A.,	et	al.,	1999)	and	the	second	was	from	Bai	in	2009	(Bai,	Y.,	et	al.,	2009),	where	the	latter	reported	no	benefit	from	prophylactic	antibiotics	on	the	frequency	of	postoperative	cholangitis	in	uncomplicated	ERCPs,	and	therefore	they	did	not	recommend	general	prophylaxis	with	antibiotics	in	ERCP.		The	third	meta-analysis	was	a	Cochrane	analysis	from	2010	by	Brand	(Brand,	M.,	et	al.,	
2010),	where	the	authors	concluded	that	prophylactic	antibiotics	reduce	the	RR	of	cholangitis	(RR=0.5,	95	%	CI	0.33-0-91)	and	that	of	bacteremia	(RR=0.5,	95	%	CI	0.33-0.78),	but	in	the	random	effects	meta-analysis	only	the	effects	on	bacteremia	remained	significant.	Also,	no	effect	on	the	postoperative	mortality	was	seen	nor	was	there	any	effect	on	the	adverse	postoperative	events.	Their	conclusion	from	these	risk	reductions	is	that	antibiotics	might	be	beneficial	in	reducing	complications	but	not	obviously	in	
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uncomplicated	ERCPs;	they	also	recommend	further	research	for	these	patients	where	biliary	access	cannot	be	achieved	and	propose	that	antibiotics	then	perhaps	could	be	given	during	or	after	these	ERCP	procedures	when	cannulation	fails.	One	problem	with	the	included	studies	was	that	many	of	them	were	performed	without	placebo	control	and	were	hence	not	blinded.	Most	of	the	studies	included	were	also	small	and	performed	with	different	antibiotics,	and	the	latest	included	study	was	from	2006	(Llach,	J.,	et	al.,	
2006),	whereas	most	of	the	studies	were	from	the	1990s.	For	example,	the	study	from	Niederau	(Niederau,	C.,	et	al.,	1994),	who	randomized	50	patients	to	receive	either	cefotaxim	or	no	antibiotics	at	all,	found	differences	only	in	the	bacteremia	rates	between	the	groups	and	recommended	prophylactic	antibiotics	only	to	patients	with	biliary	stasis,	where	all	the	adverse	events	occurred.		Another	study	included	in	the	meta-analyses	is	the	one	by	Räty	(Raty,	S.,	et	al.,	2001),	who	prospectively	randomized	321	patients	to	receive	cephtazidime	or	nothing	and	demonstrated	significant	beneficial	effects	on	both	cholangitis	rates	(4.4	%	vs	0	%)	and	PEP	rates	(9.4	%	vs	2.6	%),	recommending	antibiotics	in	all	ERCPs.	A	final	study	worth	mentioning,	because	of	its	larger	size	(n=551),	is	the	one	from	van	den	Hazel	(van	den	
Hazel,	S.	J.,	et	al.,	1996),	which	was	also	from	the	1990s	and	placebo	controlled.	This	group	reached	the	opposite	conclusion	and	did	not	recommend	prophylactic	antibiotics	(piperacillin),	since	the	cholangitis	rates	were	similar	in	the	groups	whether	or	not	they	had	been	randomized	to	achieve	piperacillin	(4.4	%	vs	6.0	%).	A	large	study	by	Cotton	et	al.	(Cotton,	P.	B.,	et	al.,	2008)	that	was	not	included	in	the	above	mentioned	meta-analyses	also	demonstrated	an	unchanged	frequency	of	infectious	complications,	as	antibiotics	successively	were	phased	out	during	the	study	period.	They	compared	the	later	ERCP	procedures	where	no	prophylactic	antibiotics	were	administered	to	the	historical	control	ERCPs	where	prophylactic	antibiotics	were	
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used	and	showed	no	differences	in	postoperative	complications;	they	thus	advocated	for	a	limited	use	of	prophylactic	antibiotics	in	ERCP.		Although	prophylactic	antibiotics	are	widely	used	in	ERCP,	one	must	conclude	that	the	evidence	for	their	efficacy	is	quite	limited,	since	the	studies	included	in	the	meta-analyses	are	quite	old,	and	the	results	of	the	meta-analyses	are	contradictory.	On	the	other	hand,	the	guidelines	from	ESGE	from	1998	(Rey,	J.	R.,	et	al.,	1998)	were	liberate	and	advocated	prophylactic	antibiotics	in	all	ERCPs,	but	are	not	recommend	as	PEP-prophylaxis	in	the	ESGEs	Guidelines	from	2014	(Dumonceau,	J.	M.,	et	al.,	2014).	The	lack	of	conformity	in	using	prophylactic	antibiotics	has	led	to	a	practice	where	many	centers	use	prophylactic	antibiotics	in	cases,	where	bile	duct	drainage	cannot	be	achieved,	something	which	cannot	always	can	be	predicted.	Subsequently,	antibiotics	are	given	in	difficult	ERCPs	with	an	elevated	assumed	risk	for	non-drainage	(e.g.,	hilar	tumors,	PSC,	or	other	intrahepatic	diseases).	This	strategy	was	presented	by	Kager	(Kager,	L.	M.,	et	al.,	
2012)	as	a	practical	way	to	deal	with	how	to	use	prophylactic	antibiotics	in	ERCP.	This	is,	in	a	way,	an	implementation	of	Brand´s	meta-analysis	(Brand,	M.,	et	al.,	2010)	in	clinical	praxis	and	a	way	to	establish	a	policy	for	how	to	use	prophylactic	antibiotics	in	everyday	ERCPs	when	scientific	evidence	is	insufficient.	A	retrospective	series	by	Ishigaki	and	co-workers	from	2015	(Ishigaki,	T.,	et	al.,	2015)	compared	605	patients	in	two	groups	with	and	without	antibiotics	regarding	cholangitis	and	PEP	rates.	In	the	group	given	prophylactic	antibiotics,	the	PEP	rate	was	4.3	%	versus	4.9	%	in	the	group	where	no	antibiotics	were	administered	(p=0.72);	there	were	also	no	differences	in	the	risk	of	developing	cholangitis	(prophylactic	antibiotics	1.7	%	vs	no	antibiotics	2.0	%,	p=0.99).	Finally,	Hauser	and	co-workers	(Hauser,	G.,	et	al.,	2017)	prospectively	randomized	272	patients	to	achieve	either	rectally	administered	sodium	diclofenac	plus	placebo	
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intravenously	(mimicking	antibiotics)	or	intravenous	antibiotics	plus	placebo	rectally	administered	(mimicking	sodium	diclofenac)	and	compared	the	PEP	rates	between	these	groups.	They	found	that	the	PEP	rates	were	lower	in	the	group	receiving	rectally	administered	sodium	diclofenac	(8.5	%)	compared	to	the	group	who	received	antibiotics	(14.7	%);	however,	the	difference	was	not	significant	(p=0.17),	but	the	results	indicate	that	prophylactic	antibiotics	could	be	questioned	as	a	general	routine	in	ERCP.	In	conclusion,	the	evidence	for	using	prophylactic	antibiotics	in	every	ERCP	is	limited,	and	the	recommendation	should	be	to	use	prophylactic	antibiotics	in	the	cases	where	the	risk	of	incomplete	drainage	of	the	bile	ducts	is	high	or	not	achieved	at	all.	The	subject	of	prophylactic	antibiotics	is	further	discussed	adjacent	to	Paper	1	later	in	this	thesis,	but	in	summary	more	randomized	studies	including	modern	antibiotics	and	updated	endoscopic	settings	are	required	to	settle	the	issue	of	how	to	use	prophylactic	antibiotics	in	ERCP.	
1.6.5	Electrosurgical	current			Blended	diathermy	should	be	preferred	to	pure-cut	diathermy,	especially	in	patients	with	an	increased	risk	of	bleeding.	However,	the	type	of	diathermia	does	not	affect	the	risk	of	developing	PEP	(Verma,	D.,	et	al.,	2007).	
1.6.6	Double	guidewire	cannulation	
		When	access	is	only	achieved	to	the	pancreatic	duct	during	an	ERCP	cannulation,	it	has	been	suggested	that	this	guidewire	should	be	left	in	place	in	the	pancreatic	duct	and	a	second	guidewire	introduced	to	obtain	access	to	the	biliary	tract.	This	issue	has	been	subject	to	a	recent	Cochrane	analysis	by	Tse	and	co-workers	(Tse,	F.,	et	al.,	2016),	who	concluded	that	this	technique	increases	the	risk	of	PEP,	but	this	could	perhaps	be	managed	by	deployment	of	a	pancreatic	stent.	However,	the	doublewire	technique	in	
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this	meta-analysis	was	not	shown	to	be	superior	to	continued	conventional	cannulation	or	precut	sphincterotomy,	and	its	place	among	cannulation	techniques	is	hereby	questioned,	but	despite	this,	is	still	recommended	in	the	ESGE-recommendations	from	2016	(Testoni,	P.	A.,	et	al.,	2016)	in	combination	with	a	prophylactic	pancreatic	stent.		
1.6.7	Carbon	dioxide	(CO2)		Carbon	dioxide	is	recommended	by	the	ESGE	(Dumonceau,	J.	M.,	et	al	2014),	since	it	reduces	post-ERCP	procedural	abdominal	pain,	but	otherwise	it	does	not	affect	the	complication	rates	after	ERCP.		
1.6.8	Balloon	dilatation			The	ESGE	(Dumonceau,	J.	M.,	et	al	2014)	does	not	recommend	sphincter	Oddi	dilatation	as	a	routine	procedure	instead	of	sphincterotomy,	since	it	has	a	higher	risk	of	developing	PEP	but	could	be	used	as	an	alternative	in	selected	cases,	for	instance,	when	the	risk	of	bleeding	is	increased.	Large	balloon	dilatation	(<20	mm)	after	sphincterotomy	should	be	reserved	for	selected	difficult	common	bile	duct	stones	and	seems	to	be	associated	with	fewer	bleedings	but	similar	PEP	rates	as	conventional	stone	extraction	methods	(Feng,	Y.,	et	al.,	2012).	However,	much	of	the	evidence	in	this	issue	seems	to	be	collected	from	retrospective	studies.	
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2.	AIMS	
2.1	Paper	1	(The	role	of	antibiotic	prophylaxis	in	routine	ERCP)	
	
Primary	aims:	To	evaluate	the	effect	of	prophylactic	antibiotics	in	routine	ERCPs	on	overall	complication	rates.	
Secondary	aims:	To	study	the	effects	of	prophylactic	antibiotics	in	routine	ERCPs	on	different	subgroups	of	complications	with	special	regard	to	infectious	and	septic	ones;	also,	to	investigate	the	complication	rates	in	relation	to	prophylactic	antibiotics	of	the	most	common	indications	of	ERCP.		
2.2	Paper	2	(The	impact	of	prophylactic	pancreatic	stenting	on	PEP	rates)	
	
Primary	aims:	To	study	if	prophylactic	pancreatic	stents	reduce	complications	(especially	PEP	rates),	when	the	pancreatic	duct	is	inadvertently	cannulated	during		ERCP	and	to	investigate	what	size	of	the	pancreatic	stent	that	has	the	best	results.	
Secondary	aims:	To	evaluate	the	risk	for	complications	(especially	PEP)	in	ERCP,	where	the	pancreatic	duct	has	been	inadvertently	cannulated	compared	to	where	it	was	not.				
2.3	Paper	3	(The	HOUSE	Classification:	A	novel	ERCP	complexity	grading	
scale)	
	
Primary	aims:	To	establish	a	new	ERCP	complexity	grading	scale	and	validate	it	in	relation	to	postoperative	complication	rates,	especially	PEP,	and	to	introduce	and	implement	a	novel	instrument	for	better	predicting	postoperative	complications	in	ERCP.	
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Secondary	aims:	To	validate	the	HOUSE	classification	in	relation	to	the	procedure	time	of	the	ERCP	per	HOUSE-class	and	thereby	to	introduce	an	instrument	for	time	scheduling	of	ERCP	procedures	for	a	better	opportunity	in	planning	endoscopic	clinical	activity.	
	
2.4	Paper	4	(Preoperative	biliary	drainage	by	plastic	stents	or	SEMS	)		
Primary	aims:	The	primary	outcome	measure	of	the	study	was	to	quantify	the	colony-forming	units/ml	(CFU/ml)	of	bacteria	 in	bile	harvested	during	surgical	exploration	of	resectable	periampullary	tumors.		
Secondary	 aims:	To	investigate	the	number	of	preoperative	stent	dysfunctions,	grade	the	 intraoperative	macroscopic	 inflammation	 in	the	hepatico-duodenal	 ligament,	study	the	 occurrence	 of	 adverse	 events	 after	 endoscopic	 stenting,	 investigate	 the	 surgical	difficulties	during	 the	pancreatic	 resection	and	 finally	 to	demonstrate	 the	 incidence	of	postoperative	complications.			
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3.	PATIENTS	AND	METHODS	
	
3.1	Paper	1	(The	role	of	antibiotic	prophylaxis	in	routine	ERCP)		
Patients	and	methods			
3.1.1	Study	design		A	nationwide	population-based	study	was	performed	to	study	all	patients	undergoing	ERCP	from	May	1,	2005	to	June	30,	2013	who	were	registered	in	the	national	GallRiks	Registry	and	to	investigate	the	complication	rates	in	relation	to	whether	or	not	prophylactic	antibiotics	were	given.		
3.1.2	The	GallRiks	Registry	database		The	register	was	established	in	2005	by	the	Swedish	Surgical	Society	and	supported	by	the	Swedish	Board	of	Health	and	Welfare	(Enochsson,	L.,	et	al.,	2013).	The	aim	of	the	registry	was	to	reach	a	complete	coverage	of	registration	of	all	gallstone	surgery	and	ERCPs	in	Sweden,	including	the	adverse	events	of	the	procedures	performed.	The	registry	is	web-based,	and	all	intraoperative	complications	of	the	ERCPs	are	registered	online	by	the	ERCP-performing	doctors.		The	30-day	overall	adverse	effects	are	registered	by	a	local	coordinator	who	is	a	non-physician.	Both	general	complications	and	more	ERCP	specific	complications	like	pancreatitis,	cholangitis,	hemorrhage	and	perforation	are	registered.	The	administration	of	antibiotics	adjacent	to	the	ERCP	is	registered	as	therapy,	prophylaxis	or	as	no	antibiotics	administered	at	all,	but	the	type	of	antibiotics	and	the	doses	are	not	available	to	register	in	GallRiks.	Other	compulsory	data	that	are	registered	in	the	GallRiks	database	include	patient	characteristics,	ERCP	
		
62	
indications,	mode	of	admission,	type	of	anesthesia,	cannulation	technique,	diagnostic	findings,	therapeutic	measures,	procedure	time	and	intraoperative	complications.	The	GallRiks	Registry	is	continuously	validated	through	independent	external	reviewers	who	compare	the	data	in	GallRiks	to	the	patients´	medical	record,	and	there	has	been	an	over	97	%	concordance	in	these	comparisons	(Enochsson,	L.,	et	al.,	2010).	Since	the	start	of	the	registry	in	2005,	there	has	been	an	increasing	proportion	of	ERCPs	included	in	the	register;	present	coverage	consists	of	about	90	%	of	all	ERCPs	performed	in	Sweden.		
	
3.1.3	The	Study	Base		We	studied	the	patients	registered	in	the	GallRiks	database	between	May	1,	2005	and	June	30,	2013	undergoing	ERCP,	but	the	procedures	that	were	not	index-ERCPs	(the	first	ERCP	procedure	during	that	treatment	episode)	were	excluded.	Furthermore,	patients	with	incomplete	registrations	in	GallRiks	or	with	ongoing	antibiotic	treatment	were	also	excluded	(Figure	2).	 	
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Figure	2.	The	profile	of	ERCP	procedures	included	in	the	analysis	in	Paper	1;	
Prophylactic	antibiotics	in	ERCP:	Olsson,	G.,	et	al.	The	Role	of	Prophylactic	Antibiotics	in	
Routine	ERCP	investigations.	Scand	Journ	Gastroenterology,	2015;	50:	924-31.	
		
3.1.4	The	variables	and	outcome	measures		A	postoperative	ERCP	complication	was	defined	as	any	adverse	event	that	caused	a	reoperation	or	any	other	reintervention,	antibiotic	treatment,	blood	transfusion	or	other	causes	that	prolonged	the	hospital	stay	or	the	recovery	of	the	patient.	PEP	was	defined	
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according	to	the	consensus	definition	of	Cotton	et	al.	(Cotton,	P.	B.,	et	al.,	1991).	A	hemorrhage	was	defined	as	bleeding	that	caused	a	significant	decline	in	the	patient´s	hemoglobin	level	with	a	need	for	blood	transfusions	or	requiring	any	reintervention.	A	postoperative	infection	was	defined	as	symptoms	requiring	postoperative	antibiotics.		The	variables	studied	were	the	use	of	antibiotics	adjacent	to	the	ERCP,	where	data	were	collected	from	the	GallRiks	Registry	where	antibiotics	were	registered	as	either	prophylactic	or	therapeutic	without	any	information	in	the	registry,	that	is,	on	neither	the	type	of	antibiotics	nor	on	the	doses.	The	patients	with	therapeutic	antibiotics	were	excluded	from	the	study,	since	the	aim	of	the	trial	was	to	investigate	prophylactic	antibiotics	only.				
3.1.5	Statistical	analysis		JMP	version	9.0.0	(SAS	Institute,	Cary,	NC,	USA)	was	used	for	the	statistical	analysis.	Descriptive	data	were	presented	as	mean	or	median	values	for	continuous	variables	and	as	percentages	for	categorical	variables.	In	the	latter	case,	the	Pearson´s	Chi2	was	used	for	calculation	unless	the	numbers	included	were	low,	in	which	case	Fisher´s	exact	test	was	used	instead.		To	identify	confounding	factors,	the	variables	influencing	the	postoperative	complication	risks	were	analyzed	with	multivariate	logistic	regression	analysis,	where	each	variable	was	introduced	one	by	one	and	tested	in	univariate	and	multivariate	models	according	to	the	purposeful	selection	of	Hosmer	et	al.	(Hosmer,	D.	W.,	et	al.,	
1978).	The	models	were	tested	for	multicollinearity	and	modification	effect	and	then	assessed	using	the	Homer-Lemeshow	goodness-of-fit	test.	The	effects	of	the	variables	are	presented	as	odds	ratios	(OR)	with	95	%	confidence	intervals	(CI).	The	level	of	statistical	significance	was	defined	as	p≤0.05.		
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Age	and	procedure	time	were	treated	as	continuous	variables	in	the	model,	although	they	were	then	dichotomized	(≤	or	>70	years,	≤30	or	>	30	minutes).	ASA	classification	was	also	dichotomized	(ASA	1-2/ASA	3-4)	as	well	as	cannulation,	use	of	antibiotics	and	sphincterotomy	(yes	or	no).	Finally,	hospital	volume	of	ERCP	was	dichotomized	into	high	and	low	volumes.		
3.2	Paper	2	(The	impact	of	prophylactic	pancreatic	stenting	on	PEP	rates)			
Patients	and	methods		
	
	3.2.1	Study	design		A	nationwide	population-based	study	was	performed	to	study	all	patients	undergoing	ERCP	from	January	1,	2006	to	December	31,	2014	who	were	registered	in	the	national	GallRiks	Registry.	This	study	was	carried	out	to	investigate	the	PEP	rates	in	relation	to	whether	or	not,	and	what	type	of,	prophylactic	pancreatic	stent	that	had	been	deployed.		
3.2.2	The	GallRiks	Registry	database		
The	Swedish	National	Registry	for	Gallstone	Surgery	and	ERCP	(GallRiks)	was	established	in	May	1,	2005	as	a	validated	registry	of	cholecystectomies	and	ERCP	procedures	(Enochsson,	L.,	et	al.,	2013,	Rystedt,	J.,	et	al.,	2014).	The	aim	of	the	registry	was	to	obtain	a	complete	database	including	demographics	and	patient	characteristics,	indication	and	treatment	methods	as	well	as	outcome	using	an	online	registration	platform.	For	patients	undergoing	an	ERCP,	procedure-related	information	includes	bile	and/or	pancreatic	duct	cannulation,	whether	sphincterotomy	was	performed	and	any	additional	diagnostic	or	therapeutic	procedures.	Intraprocedural	adverse	events	are	
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registered	by	the	endoscopists	performing	the	ERCPs.	At	the	30-day	follow-up,	all	medical	records	are	reviewed,	and	post-procedural	adverse	events	are	reported	online	in	the	registry	by	a	local	non-physician	coordinator	appointed	at	the	respective	units.	GallRiks	includes	data	from	almost	all	Swedish	hospitals	performing	ERCP.	Matching	GallRiks	data	with	the	Swedish	National	Patient	Registry	in	2014	showed	that	88	%	of	performed	ERCP	procedures	in	Sweden	at	that	stage	were	registered	in	GallRiks.	The	data	are	regularly	validated	by	an	independent	audit	group	that	compares	register	data	to	in-patient	records.	There	was	a	complete	match	between	registry	data	and	patient	medical	records	in	98	%	of	patients	with	a	100	%	concordance	for	bile	duct	injuries	
(Rystedt,	J.,	et	al.,	2014).	
3.2.3	The	Study-base		
All	patients	undergoing	ERCP	between	January	1,	2006	and	December	31,	2014	were	enrolled	for	the	study,	but	the	ERCP	procedures	that	were	not	index-ERCPs	(i.e.,	the	first	ERCP	during	the	treatment	episode,	within	30	days)	and	those	with	missing	data	or	incomplete	follow-ups	were	excluded	from	the	study.	Furthermore,	only	patients	for	whom	the	intention,	as	documented	by	the	indication	for	the	investigation,	was	a	selective	cannulation	of	the	bile	duct	(i.e.	no	intention	to	cannulate	the	pancreatic	duct)	were	included	(Figure	3).	 	
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Figure	3:	The	profile	of	endoscopic	retrograde	cholangiopancreatography	(ERCP)	
procedures	included	in	the	analysis	of	Paper	2:	Olsson,	G.,	et	al.,	The	impact	of	
prophylactic	pancreatic	stenting	on	post-ERCP	pancreatitis:	A	nationwide,	register-based	
study.	UEG-Journal	2017;	5(1):	111-18	
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3.2.4	The	variables	and	outcome	measures		The	outcomes	studied	were	general	intra-	and	post-procedural	adverse	events	and	specifically	ERCP-associated	adverse	events	like	cholangitis,	pancreatitis,	perforation	and	bleeding.	A	postoperative	ERCP	complication	was	defined	as	any	adverse	event	that	caused	a	reoperation	or	any	other	reintervention,	antibiotic	treatment,	blood	transfusion	or	other	causes	that	prolonged	the	hospital	stay	or	the	recovery	of	the	patient.	A	PEP	was	defined	according	to	the	consensus	definition	by	Cotton	et	al.	(Cotton,	
P.	B.,	et	al.,	1991),	and	a	hemorrhage	was	defined	as	bleeding	that	caused	a	significant	decline	in	the	patient´s	hemoglobin	level	with	a	need	for	a	transfusion	or	any	reintervention.	A	postoperative	infection	was	defined	as	the	patient	requiring	postoperative	antibiotics	due	to	symptoms	interpreted	as	infectious.	Intraprocedural	adverse	events	were	defined	as	bleeding,	extravasation	of	contrast,	perforation	or	any	other	reason	for	the	ERCP	being	prematurely	terminated.	Postprocedural	adverse	events	were	defined	as	any	of	the	abovementioned	complications	during	the	30-day	follow-up	period	that	required	some	form	of	medical	or	surgical	intervention.	The	variables	studied	were	firstly	the	insertion	of	a	pancreatic	stent	(PS)	and	secondly	pancreatic	cannulation,	which	was	defined	as	deep	or	superficial	cannulation	of	the	pancreatic	duct	with	subsequent	contrast	injection.	
3.2.5	Statistical	analysis		
Statistical	analysis	was	performed	using	JMP	9.0.0	(SAS,	Cary,	NC,	USA).	Comparisons	of	patient	and	procedure	characteristics	were	presented	in	contingency	tables	with	pairwise	differences	analyzed	with	Pearson's	Chi2	test	and	presented	as	p	values.	The	association	between	pancreatic	duct	cannulation	and	the	risk	of	adverse	events,	as	defined	above,	were	analyzed	using	multivariable	logistic	regression	modelling.	
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Variables	that	were	statistically	significant	in	univariate	analysis	were	included	in	the	multivariate	model	as	described	by	Hosmer	et	al	(Hosmer,	D.	W.,	et	al.,	1978).	In	the	multivariate	analysis,	the	outcome	was	adjusted	for	age	(dichotomized	into	more	or	less	than	70	years),	gender,	comorbidity	(dichotomized	into	ASA	score	of	1-2	and	ASA	≥3),	urgent	or	elective	procedures,	indication	and	previous	sphincterotomy.	Similar	regression	modeling	was	used	on	the	subgroup	of	patients	with	a	pancreatic	duct	cannulation,	analyzing	adverse	effects	depending	on	whether	or	not	the	placement	of	a	pancreatic	stent	was	made.	In	a	final	sub-analysis,	patients	receiving	PS	were	dichotomized	into	two	groups,	depending	on	whether	the	total	PS	diameter	was	>5	Fr	or	≤5	Fr	as	well	as	dichotomized	into	two	groups	depending	on	the	length	of	the	single	PS	(>5cm	or	≤5cm)	and	analyzed	for	adverse	events.	The	models	were	tested	for	multicollinearity	and	modification	effect	and	were	finally	assessed	for	goodness	of	fit.	The	effects	of	the	analyzed	variables	were	presented	as	odds	ratios	(OR)	for	adverse	events	with	95	%	confidence	intervals	(CI).	
	
3.3		Paper	3	(The	HOUSE	Classification:	A	novel	ERCP	complexity	grading	scale)		
Patients	and	methods	
	
3.3.1	Design	and	data	collection		Data	were	collected	retrospectively	from	reviews	of	the	medical	records	of	patients	being	subject	to	ERCPs	at	Karolinska	University	Hospital,	Huddinge,	between	2009	and	2011.	Data	from	these	cohorts	of	patients	representing	three	years	of	ERCP	procedures	at	Karolinska	University	Hospital,	Huddinge,	Stockholm,	Sweden,	regarding	the	
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complexity	of	the	ERCP	procedure,	were	gathered	and	divided	into	three	classes	called	HOUSE	classes	1-3.		Furthermore,	the	procedure	time,	the	general	postoperative	complications	and	the	PEP	rates	of	the	ERCP	procedures	were	noted.	The	GallRiks	Registry	of	the	patients	included		was	also	investigated	with	special	regard	to	the	postoperative	complication	rates	in	general	as	well	as	to	the	PEP	rates	specifically.	Details	of	the	GallRiks	Registry	are	described	above	in	Paper	1	(The	role	of	antibiotic	prophylaxis	in	routine	ERCP)	and	Paper	2	(The	impact	of	prophylactic	pancreatic	stenting	on	PEP)	 	
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Figure	4.	A	flow	chart	depicting	the	respective	ERCP	procedures	included	in	the	
analyses	(HOUSE	Classification):	Olsson	G.,	et	al.,	The	HOUSE-Classification;	a	novel	ERCP	
complexity	grading	scale.	BMC	Gastroenterology	2017;	17:38	
	
3.3.2	The	establishment	of	the	HOUSE	classification	and	the	division	of	ERCP	
procedures	into	three	different	classes	in	relation	to	their	complexity		Initially,	 the	HOUSE	classification	was	developed	and	 launched	 into	clinical	practice	 to	gain	financial	reimbursement	and	control	of	the	increasing	costs	for	endoscopic	devices	used	 as	 well	 as	 the	 prolonged	 procedure	 times	 required	 to	 complete	 the	 expanding	complexity	of	ERCP	examinations	done	at	the	Karolinska	University	Hospital,	Huddinge,	Stockholm,	Sweden,	which	over	time	has	evolved	into	a	national	tertiary-referral	center	for	advanced	endoscopy	in	Sweden.	Concomitantly,	there	was	a	continuous	demand	for	
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an	establishment	of	a	more	accurate	system	for	comparisons	between	different	centers,	both	regarding	results	as	well	as	post-procedural	complication	rates.	The	well-merited	opinion	 was	 that	 with	 more	 complex	 procedures,	 the	 risk	 became	 greater	 that	 the	results	were	marred	by	higher	 complication	 rates.	 The	higher	 complexity	 of	 the	 case-mix	of	the	procedures	performed	at	Karolinska	University	Hospital	was	also,	apart	from	the	risk	of	higher	complication	rates,	assumed	to	lead	to	higher	costs	per	procedure,	and	there	 was	 a	 desire	 from	 the	 research	 group	 to	 gain	 economical	 control	 over	 this	development.		The	original	database	was	scored	in	classes	based	on	the	perceived	complexity	of	each	procedure	 and	 classified	 into	 three	 groups,	 where	 group	 one	 represented	 the	 least	complex	 procedures	 and	 group	 three	 represented	 the	most	 complex	 ones.	 One	 of	 the	aims	 of	 the	 grading	 was	 that	 HOUSE	 class	 1	 procedures	 would	 represent	 the	 least	complex	routine	procedures	as	represented	by	those	being	performed	at	every	hospital	performing	 ERCP	 in	 Sweden	 (e.g.,	 extraction	 of	 common	 bile	 duct	 stones,	 relief	 of	obstructive	 jaundice	 due	 to	 periampullary	 tumors,	 intraoperative	 rendezvous	 ERCP	procedures).	The	HOUSE	class	2	represents	the	technically	more	advanced	procedures	mainly	performed	at	the	county	hospitals,	such	as	ERCP	for	intrahepatic	stones,	multiple	metal	 and	 plastic	 stenting	 and	 ERCP	 for	 primary	 sclerosing	 cholangitits.	 The	 HOUSE	class	 3	 represents	 ERCP	 procedures	 that	 demand	 extra	 resources	 like	 intraductal	cholangioscopy	 double-balloon	 ERCP	 for	 Roux-en-Y	 operated	 patients	 or	 confocal	endoscopy,	which	are	all	procedures	that	are	performed	at	the	tertiary	referral-centers.		The	database	of	 the	HOUSE	classification	was	then	compared	with	corresponding	data	from	the	GallRiks´	database	concerning	complications	in	general	and	pancreatitis	rates	in	particular	(Table	10).	
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The	classification	is	referred	to	as	the	HOUSE	classification,	which	is	an	abbreviation	of	the	first	letter	of	the	name	of	the	hospital	(Huddinge)	followed	by	the	first	letters	of	the	creators’	names	(Olsson,	Urban,	Swahn,	and	Enochsson).	The	outcomes	of	the	different	ERCP	procedures	were	also	classified	according	to	the	established	classification	systems	for	ERCP	procedures,	i.e.,	the	Cotton	complexity	grading	of	endoscopic	procedures	(see	Table	3)	(Cotton,	P.	B.,	et	al.,	2011).			
Table	10.	The	HOUSE	classification		
The	HOUSE	classification	 ERCP	procedures	HOUSE	1	 Diagnostic	ERCP,	EST,	CBDS,	Single	Stent, Brush	cytology,	Intraoperative	rendezvous	ERCP	HOUSE	2	 Intrahepatic	stone, Multiple	stents	Pancreatic	ERCP,	PSC	or	liver	TX,	Intrahepatic	interventions,	Prophylactic	pancreatic	stent,				”Caged”	papilla, ERCP	with	ESWL	HOUSE	3	 Pancreatic	sphincterotomy	and	lithotripsy,	Spy-Glass,	Mother-Baby	Scopy,	EHL, Multiple	pancreatic	stents,	Papillectomy,	Confocal	endoscopy,	PTC-	or	EUS-rendezvous. Billroth-2	op,	Roux-en	Y,	Whipple	op,	,	Gastric-Bypass-op,	ERCP	via	enteroscopy. 		
3.3.3	Variables	and	outcomes		The	outcomes	studied	were	general	intra-	and	post-procedural	adverse	events	and	specifically	PEP.	A	postoperative	ERCP	complication	was	defined	as	any	adverse	event	
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that	caused	a	reoperation	or	any	other	reintervention,	antibiotic	treatment,	blood	transfusion	or	other	causes	that	prolonged	the	hospital	stay	or	the	recovery	of	the	patient.	PEP	was	defined	according	to	the	consensus	definition	by	Cotton	(Cotton,	P.	B.,	
et	al.,	1991).	Another	outcome	that	was	studied	was	the	procedure	time	(minutes)	of	the	ERCP;	this	represented	a	measurement	of	the	resources	required	for	that	very	specific	investigation.	Furthermore,	a	final	outcome	that	was	studied	was	the	cannulation	success	rate	of	each	ERCP	procedure;	this	was	used	as	a	surrogate	marker	for	how	difficult	a	certain	investigation	would	be.		
3.3.4	Statistical	analysis:	Descriptive	data	for	cannulation	success	rates,	patients	suffering	complications	(or	not)	and	procedure	times	were	displayed	using	mean	for	continuous	variables	or	percentages	for	categorical	variables.	General	postoperative	complications	and	ERCP	specific	complications	(cholangitis,	perforation,	pancreatitis	and	postoperative	bleeding)	were	calculated	within	each	HOUSE	class	and	compared	using	Pearson´s	Chi2	test	with	HOUSE	class	1	used	as	a	reference	group.	Differences	in	mean	procedure	times	between	the	different	HOUSE	classes	were	analyzed	using	Student´s	t-test.	A	p-value	≤0.05	was	regarded	as	significant.	Statistical	analyses	were	carried	out	using	JMP®	version	12.1.0	(64-bit)	(SAS	Institute,	Cary,	NC,	USA).		
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3.4	Paper	4	(Preoperative	biliary	drainage	by	plastic	stents	or	SEMS)			
Patients	and	methods	
	
	3.4.1	Design	and	data	collection	A	prospective,	randomized	controlled	trial	was	performed	including	patients	with	extrahepatically	induced	jaundice	(bilirubin	≥49)	caused	by	periampullary	tumors,	which	were	presumed	to	be	resectable	at	the	time	of	the	ERCP-procedure.	Those	patients	were,	after	a	successful	cannulation	of	the	bile	duct,	randomized	to	either	receive	a	self-expandable	metal	stent	(SEMS)	or	a	plastic	stent.	An	unsuccessful	cannulation	or	a	previous	stenting	were	exclusion	criteria	as	well	as	an	inoperable	patient	or	an	unresectable	tumor	found	during	the	preoperative	investigational	work-up	before	the	ERCP.	Tumors	found	to	be	irresectable	after	the	ERCP	remained	in	the	study	(intention	to	treat	analysis,	ITT).	
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Figure	5.	Flow	chart	depicting	the	allocation	of	presumably	resectable	
periampullary	tumors	to	respective	study	group	(SEMS	vs	plastic	stents).	Olsson,	
G.,	et	al.,	Preoperative	biliary	drainage	by	plastic	or	self-expandable	metal	stents	in	
patients	with	periampullary	tumors:	results	of	a	randomized	clinical	study.	Endoscopy	
International	Open,	2017.	
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The	primary	outcome	of	the	study	was	the	amount	of	bacteria	(colony-forming	units/ml,	CFU/ml)	found	at	the	operation	in	bile	collected	from	the	bile	duct	and/or	the	gallbladder	during	the	pancreatico-duodenectomy.	Secondary	outcomes	were	preoperative	adverse	events,	such	as	stent	dysfunction	or	stent	exchange,	perioperative	technical	difficulties	as	judged	by	the	operating	surgeon	in	creating	the	anastomoses	or	the	grade	of	inflammation	in	the	hepato-duodenal	ligament	during	the	operation	and	also	measured	more	objectively	through	operational	time	and	perioperative	blood	loss.		Other	secondary	outcomes	were	the	histopathological	grade	of	inflammation	in	the	bile	duct	and	the	grade	of	sinus	histiocytosis	in	lymph	glandulae	in	the	hepato-duodenal	ligament	harvested	during	the	operation	as	a	marker	of	the	foreign	body	reaction	caused	by	the	preoperatively	inserted	stent.	Final	secondary	outcomes	studied	were	the	rates	of	postoperative	complications	after	the	pancreatico-duodenectomy	and	time	in	the	ICU	and	hospital.				
3.4.2	Logistic	protocol		After	informed	consent	was	given	before	the	ERCP	procedure,	the	patients	were	randomized	in	blocks	of	ten	patients	to	receive	a	SEMS	or	a	plastic	stent.	The	patients	were	then	discussed	in	multi-disciplinary	conferences	and	those	found	resectable	and	operable	were	offered	pancreatico-duodenectomy	within	six	weeks.	Patients	with	locally	advanced	borderline	tumors	were	offered	neo-adjuvant	oncological	therapy,	and	those	responding	were	subsequently	operated	later	than	six	weeks	after	the	inclusion	in	the	study.	Before	the	initial	endoscopy	and	before	the	pancreatico-duodenectomy,	blood	tests	(ASAT,	ALAT,	ALP,	bilirubin,	white	blood	cell	count,	CRP)	were	sampled	to	monitor	liver	function	and	grade	of	inflammation.	
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Cholangitis	and	cholecystitis	were	defined	according	to	the	Tokyo	guidelines	(Takada,	T.,	
et	al.,	2013)	and	pancreatitis	according	to	the	definition	by	Cotton	et	al.	(Cotton,	P.	B.,	et	
al.,	1991).		A	standardized	protocol	was	completed	adjacent	to	the	ERCP	with	clinical	and	laboratory	data	as	well	as	information	of	the	tumor	characteristics.	
	
3.4.3	Endoscopic	procedure	and	stent	insertion	
	After	cannulation	of	the	bile	duct,	the	patient	was	randomized	to	achieve	either	a	covered	SEMS	(Permalume	silicone	interior	covered	platinol	stent,	Boston	Scientific,	
Natick,	MA,	USA)	or	a	conventional	plastic	stent.	The	endoscopist	decided	what	size	of	SEMS	to	use	depending	on	the	clinical	findings	(e.g.,	length	of	stricture),	but	most	commonly	a	6-cm	SEMS	was	used	(n=37)	with	a	diameter	of	10	mm	when	fully	expanded,	whereas	the	plastic	stents	that	were	mostly	used	were	10	Fr	in	diameter	and	7	cm	in	length	(n=35).		
3.4.4	Surgical	procedure		The	patients	found	operable/resectable	were	offered	a	standard	pancreatico-	duodenectomy,	where	bile	was	sampled	at	the	beginning	of	the	operation	for	bacterial	cultures	from	the	bile	duct	and/or	the	gallbladder	and	was	transferred	to	a	culture	media	to	allow	for	bacteria	growth.	The	amount	of	bacteria	in	the	bile	was	measured	in	colony-forming	units/ml	(CFU/ml).	The	surgical	findings	were	classified	by	the	surgeon	in	a	three-level	scale	in	an	attempt	to	quantify	how	difficult	it	was	to	extract	the	stent	from	the	bile	duct,	to	dissect	the	hepato-duodenal	ligament	(grade	of	inflammation)	and	to	create	the	anastomoses	between	the	gut,	stomach,	pancreas	and	bile	duct.	Finally,	a	ring	of	the	bile	duct	from	the	transection	line	of	the	resection	was	sent	for	
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histopathological	examination	to	quantify	the	grade	of	cholangitis	(mild,	moderate	or	severe)	in	the	bile	duct	caused	by	the	stent;	a	lymph	node	was	also	harvested	from	the	hepato-duodenal	ligament	and	investigated	for	sinus	histiocytosis,	which	is	a	marker	of	foreign	body	reaction	that	represents	another	measurement	of	the	grade	of	inflammation	caused	by	the	stent.	The	patients	were	postoperatively	monitored	in	an	ICU	according	to	standard	protocols	until	they	were	ready	to	be	transferred	to	a	surgical	ward.	Postoperative	complications	were	registered	and	complications	like	pancreatic	fistula	were	defined	according	to	the	ISGPF	criteria	(Bassi,	C.,	et	al.,	2005)	and	delayed	gastric	emptying	according	to	ISGPS	(Wente,	M.	N.,	et	al.,	2007).	All	complications	were	recorded	and	defined	according	to	the	Clavien	Dindo	classification	(Dindo,	D.,	et	al.,	
2004).	The	patients	were	followed	up	4-6	weeks	after	the	operation	(after	discharge	from	the	hospital)	with	an	outpatient	appointment.		
3.4.5	Sample	size	estimation	
	The	required	number	of	enrolled	patients	was	estimated	to	be	able	to	detect	a	30	%	lower	CFU/ml	count	in	the	SEMS	group	with	a	probability	of	95	%	and	a	power	of	80	%.	In	order	to	achieve	this,	a	minimum	of	60	matched	patients	needed	to	be	surgically	explored	and	have	bile	samples	collected.	Thus,	given	the	expected	number	of	withdrawals	due	to	the	findings	meeting	the	exclusion	criteria	during	the	subsequent	preoperative	workup,	at	least	90	patients	had	to	be	randomized.	
	
	
3.4.6	Statistical	analysis		The	data	were	analyzed	using	the	statistical	software	JMP	9.0.0	(SAS	Institute,	Cary,	NC,	
USA).	The	demographics	and	clinical	characteristics,	endoscopic	adverse	events,	per-	
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and	postoperative	findings	and	complications	are	reported	as	means	or	medians	and	ranges	or	as	number	of	cases	and	percentage	of	the	total.		The	results	of	the	bacterial	cultures	are	reported	as	medians	and	interquartile	ranges	(IQR)	as	well	as	total	sum	of	CFU/ml	across	all	cases.	Categorical	data	were	tested	with	Pearson´s	Chi2	test	or	Fisher’s	exact	test	when	appropriate.	When	calculating	the	differences	between	means,	the	Student’s	t-test	was	used	for	data	with	a	normal	distribution.	For	numerical	values	not	normally	distributed,	the	Wilcoxon	Rank-Sum	Test	was	used.	P-values	<0.05	were	considered	significant.		 	
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4.	RESULTS	
	
4.1	Paper	1	(The	role	of	antibiotic	prophylaxis	in	routine	ERCP)		
Results	
	
4.1.1	Basic	characteristics	There	were	47,950	ERCP	procedures	performed	between	May	1,	2005	and	June	30,	2013	registered	in	the	GallRiks	Registry.	After	exclusion	of	those	procedures	with	incomplete	registrations	(n=5,995),	those	with	on-going	antibiotic	therapy	(n=8,208)	and	those	ERCPs	not	being	index	procedures	(n=2,559),	31,188	ERCP	procedures	remained	for	the	study	regarding	antibiotic	prophylaxis.	Of	these	ERCP	procedures,	13,623	(44	%)	received	prophylactic	antibiotics,	and	17,565	(56	%)	did	not.	These	two	groups	were	similar	concerning	sex	distribution,	ASA	classification	and	proportions	of	procedures	performed	urgently	or	electively.	However,	the	patients	receiving	prophylactic	antibiotics	were	1.5	years	younger	than	the	ones	not	given	prophylaxis	(65.9	vs	67.4	years,	p<0.0001).	For	details,	see	Table	1	in	Paper	1.	
	
4.1.2	Risk	factors	for	adverse	events	in	ERCP	There	were	no	differences	in	postoperative	adverse	events,	ASA	class,	hospital	volume	or	gender;	also,	the	complication	rates	were	not	affected	by	whether	or	not	the	bile	duct	was	cannulated	or	if	a	sphincterotomy	was	performed	during	the	ERCP.	The	only	indication	of	the	ERCP	that	demonstrated	an	increased	OR	for	adverse	events	in	the	multivariate	analysis	was	jaundice	(OR	1.11,	95	%	CI	1.02-1.21).	The	highest	elevation	of	the	OR	for	complications	was	seen	in	the	ERCP	procedures	lasting	for	more	than	30	minutes	(OR	1.54,	95	%	CI	1.43-1.65),	where	the	complication	rate	rose	from	
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10.7	%	to	15.8	%	after	30	minutes	and	those	where	the	pancreatic	duct	was	cannulated	(OR	1.34,	95	%	CI	1.24-1.44)	where	the	adverse	events	increased	from	12.0	%	to	16.4	%.	Patient	age	below	70	years	elevated	the	OR	for	adverse	advents	with	26	%	(OR	1.26,	95	%	CI	1.18-1.35),	and	the	OR	reduction	for	adverse	events	when	antibiotics	were	given	prophylactically	was	also	26	%	(OR	0.74,	CI	0.69-0.79)	when	the	confounding	factors	found	in	the	multivariate	analysis	had	been	compensated	for.	For	details,	see	Table	2	in	Paper	1.	
		
4.1.3	The	effect	of	prophylactic	antibiotics	in	ERCP	generally	The	overall	reduction	of	adverse	events	after	the	ERCP	procedure	was	2.6	%	(from	14.2	%	to	11.6	%,	p<0.0001)	if	prophylactic	antibiotics	were	administered,	which	corresponds	to	a	26	%	OR	reduction	of	complications	after	potential	confounders	have	been	compensated	for	in	the	multivariate	analysis.			
4.1.4	The	effect	of	prophylactic	antibiotics	in	ERCP	in	the	subgroup	of	the	three	
most	common	ERCP	indications	To	achieve	a	more	representative	picture	of	the	ERCP	procedures	performed	at	an	average	mid-volume	hospital,	we	performed	a	subgroup	analysis	of	the	three	most	common	indications	of	ERCP	(i.e.,	CBDS,	malignancy	and	jaundice),	which	contained	21,893	ERCP	procedures.		Here,	we	found	a	similar	reduction	in	overall	adverse	events	(OR	0.76,	95	%	CI	0.70-0.82)	if	antibiotics	were	given,	and	there	also	was	a	significant	reduction	in	septic	complications	(OR	0.85,	95	%	CI	0.73-1.00)	in	the	prophylaxis	group.	For	details,	see	Table	3	in	Paper	1.	
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However,	the	most	pronounced	reduction	of	complications	was	seen	in	the	group	when	the	indication	for	the	ERCP	was	jaundice,	where	the	overall	adverse	events	were	reduced	with	32	%	(OR	0.68,	95	%	CI	0.60-0.78)	in	the	multivariate	analysis,	corresponding	to	a	3.8	%	complication	reduction	(15.3	%	vs	11.5	%)	in	absolute	figures,	and	the	septic	complications	were	reduced	with	24	%	(OR	0.76,	95	%	CI	0.58-0.97)	from	3.6	%	to	2.9	%.		We	also	found	a	general	complication	reduction	when	prophylactic	antibiotics	were	given	in	the	group	where	CBDS	was	the	indication	of	the	ERCP.	This	was	not	as	enhanced	as	in	the	jaundiced	group	but	more	in	line	with	the	odds	reduction	seen	in	the	general	study	population	(OR	0.77,	95	%	CI	0.68-0.87).	For	details,	see	Table	4	in	Paper	1.		
4.1.5	Comments	The	main	finding	of	this	paper	was	that	we	found	a	significant	reduction	of	2.6	%	(14.2	%	 vs	 11.6	%)	 in	 overall	 adverse	 effects	 if	 prophylactic	 antibiotics	were	 administered	adjacent	 to	 the	 ERCP	 procedure.	 However,	 this	 figure	 must	 be	 put	 in	 relation	 to	 the	negative	side	effects	of	antibiotics	(e.g.,	the	development	of	antibiotic	resistance	or	side	effects	 for	 the	 patients).	 Although	 an	 OR	 reduction	 for	 adverse	 events	 of	 26	 %	 was	demonstrated,	 if	 antibiotic	 prophylaxis	 was	 given	 in	 conjunction	 with	 the	 ERCP,	 the	number	of	patients	 still	needed	 treat	 to	avoid	one	 complication	was	38,	which	 cannot	justify	a	policy	of	giving	every	routine	ERCP	antibiotics	prophylactically.	These	findings	are	 in	 line	with	a	previous	meta-analysis	by	Bai	 from	2009	(Bai,	Y.,	et	al.,	2009),	which	does	not	recommend	prophylactic	antibiotics	in	general.		Another	 finding	 of	 our	 study	 is	 that	 patients	 with	 jaundice	 seem	 to	 have	 a	 special	beneficial	 effect	 from	 prophylactic	 antibiotics	 with	 an	 OR	 reduction	 of	 32	 %	 when	
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antibiotics	are	given	in	this	group	with	a	24	%	OR	reduction	on	the	septic	complications.	This	corresponds	well	to	the	meta-analysis	by	Brand	from	2010	(Brand,	M.,	et	al.,	2010),	which	 states	 that	prophylactic	 antibiotics	 seem	 to	 reduce	cholangitis,	 especially	 in	 the	patients	where	 drainage	 of	 the	 bile	 duct	 cannot	 be	 completely	 achieved	 and	 suggests	that	prophylactic	 antibiotics	 could	be	 reserved	 for	 these	patients.	The	problem	 is	 that	this	situation	of	undrained	bile	ducts	cannot	be	anticipated	prior	to	the	ERCP	when	the	antibiotics	should	be	administrated,	and	perhaps	prophylactic	antibiotics	could	be	given	to	these	patients	with	a	higher	risk	of	unsuccessful	complete	drainage,	such	as	patients	with	hilar	strictures	or	primary	sclerosing	cholangitis.		A	 major	 problem	 of	 the	 findings	 of	 the	 previous	 meta-analyses	 on	 the	 subject	 of	prophylactic	 antibiotics	 in	 ERCP	 is	 that	 the	 number	 of	 randomized	 studies	 is	 limited		
(Brandes,	J.	W.,	et	al.	1981,	Byl,	B.,	et	al.,	1995,	Llach,	J.,	et	al.,	2006,	Lorenz,	R.,	et	al.,	1996,	
Niederau,	C.,	et	al.,	1994,	Raty,	S.,	et	al.,	2001,	Sauter,	G.,	et	al.,	1990,	Spicak,	J.,	et	al.,	2001,	
van	den	Hazel,	S.	 J.,	et	al.,	1996).	Most	of	 the	 studies	were	 small,	 the	 results	 conflicting	and	most	of	 the	studies	were	 from	the	1990s	with	 the	 latest	study	conducted	 in	2006	
(Llach,	 J.,	 et	 al.,	 2006).	 Therefore,	 in	 conclusion,	more	 randomized	 studies	 are	 needed	that	include	modern	antibiotics	and	modern	endoscopic	settings	to	resolve	the	issue	of	when	prophylactic	antibiotics	should	be	administered	in	ERCP.	One	strength	of	our	study	is	the	low	risk	of	selection	bias,	since	it	is	based	on	data	from	a	national	 registry,	 representing	 all	 types	 of	 endoscopic	 centers	 performing	 ERCP	with	different	volumes	of	patients	and	endoscopists	with	different	experiences.	Additionally,	the	 procedures	were	 undertaken	 on	 a	 great	 variety	 of	 patients	with	 various	 different	indications	 for	 the	 ERCP	 procedure	 –	 from	 common,	 less	 complicated	 ones	 to	 rare,	complex	ERCPs.	The	risk	of	random	error	 is	also	small	 in	a	study	of	 this	size,	as	 is	 the	
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risk	 of	 systematic	 errors	 since	 the	 register	 includes	 90	%	 of	 all	 ERCPs	 performed	 in	Sweden.	Another	strength	of	the	study	is	the	GallRiks	Registry´s	good	validity	with	a	match	with	the	patient	records	of	more	than	97	%	(Enochsson,	L.,	et	al.,	2013,	Rystedt,	J.,	et	al.,	2014),	minimizing	the	risk	for	misclassification.	There	also	seems	to	be	a	good	correlation	regarding	 the	basic	characteristics	between	the	 groups	 receiving	 prophylactic	 antibiotics	 compared	 to	 the	 groups	 that	 were	 not	given	prophylactic	antibiotics,	regarding	gender,	ASA	and	age,	although	the	age	differed	slightly	 between	 the	 groups	 (65.9	 vs	 67.4	 years,	 p<0.0001).	 Parameters	 are	 often	significantly	 different	 in	 large,	 national,	 register-based	 studies	 like	 this	 (mass	significance),	 but	 when	 looking	 at	 its	 clinical	 significance,	 the	 difference	 between	 66	years	and	67.5	years	probably	has	a	very	modest	effect	on	the	outcome	studied.	We	also	identified	other	risk	factors	for	ERCP	related	adverse	events	in	our	study.	Many	of	them	were	known	from	previous	studies	(Freeman,	M.	L.,	et	al.,	2001,	Freeman,	M.	L.,	et	
al.,	1996)	(e.g.,	the	time	of	the	ERCP	procedure	[>30	minutes],	which	increases	the	risk	for	complications).	Of	course,	it	is	not	the	time	itself	that	affects	the	complication	rates	but	the	things	being	performed	during	the	longer	procedure.	It	is	probable	that	these	30	minutes	 contain	 multiple	 cannulation	 attempts,	 guidewire	 passages	 to	 the	 pancreatic	duct	and	an	over-representation	of	more	precut	sphincterotomies	in	this	group,	where	time	represents	a	surrogate	marker	for	other	events	that	represent	the	real	risk	factors	for	postoperative	complications.	Lower	 age	 (<70	 years)	 is	 another	 factor	 that	 was	 found	 to	 increase	 the	 risk	 of	complications	 in	our	study,	which	 is	an	opposite	phenomena	compared	to	many	other	surgical	 interventions.	We	 interpret	 this	 by	 stating	 that	 younger	 people	 have	 a	more	
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viable	pancreas,	thereby	they	are	more	reactive	when	being	subject	to	an	ERCP	and	have	a	higher	risk	for	developing	a	PEP.	Another	 well-known	 risk	 factor	 in	 ERCP,	 which	 we	 also	 confirmed	 in	 this	 study,	 is	cannulation	 of	 the	 pancreatic	 duct	 (Freeman,	 M.	 L.,	 et	 al.,	 2001).	 We	 also	 noticed	 a	slightly	elevated	complication	risk	 in	patients	with	 jaundice	prior	 to	 the	ERCP,	but	we	did	 not	manage	 to	 demonstrate	 any	differences	 in	 adverse	 events	whether	 or	 not	 the	bile	 duct	was	 cannulated.	We	 also	 could	 not	 identify	 any	 differences	 in	 complications	depending	 on	 case	 volume	 of	 the	 center	 performing	 the	 ERCPs,	 which	 speculatively	could	be	explained	because	 larger	centers	have	more	endoscopists,	which	reduces	 the	number	of	investigations	per	endoscopist;	also,	larger	centers	have	more	trainees,	which	may	 increase	 the	 risk	 of	 complications,	 and	 larger	 centers	 also	 handle	more	 complex	cases,	which	may	result	in	more	adverse	events.	There	 are	 also	 weaknesses	 of	 register-based	 studies.	 Since	 they	 are	 not	 randomized,	there	 is	 always	 a	 risk	 for	 confounding	 factors,	 and	 there	 might	 be	 factors	 that	 are	unknown	and	thereby	cannot	have	been	compensated	for	in	the	multivariate	regression	analysis.	There	 is	also	a	risk	of	case-mixing	within	the	study	population—for	example,	the	 endoscopist	may	 be	more	 prone	 to	 give	 antibiotics	 if	 he	 suspects	 the	 ERCP	 to	 be	more	complicated.	A	final	consideration	is	the	long	inclusion	period	of	the	study	(2005-2013).	 This	 time	 period	 encompasses	 technical	 development	 and	 the	 introduction	 of	new	antibiotics,	and	these	factors	must	also	be	taken	into	account	when	interpreting	the	results	of	the	study.	In	conclusion,	our	study	shows	that	prophylactic	antibiotics	reduce	the	risk	of	adverse	events	by	2.6	%,	but	this	is	not	sufficient	to	make	a	general	recommendation	
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for	 their	 use	 in	 every	 ERCP,	 since	 the	 NNT	 (38	 patients)	 is	 too	 high	 to	 justify	 the	potential	 side	 effects	 induced	 by	 antibiotics	 and	 the	 risks	 of	 developing	 bacterial	resistance	to	avoid	one	single	complication	in	the	38	patients	who	need	to	be	treated.		More	 prospective,	 randomized,	 controlled	 trials	 with	 modern	 antibiotics	 in	 modern	endoscopic	 settings	 are	 needed,	 especially	 in	 the	 group	 of	 patients	 where	 complete	biliary	 drainage	 cannot	 be	 achieved	 to	 ultimately	 define	 the	 role	 of	 prophylactic	antibiotics	in	ERCP.		
4.2	Paper	2	(The	impact	of	prophylactic	pancreatic	stenting	on	PEP-rates)	
	
Results	
	
4.2.1	Basic	characteristics		Between	January	1,	2006	and	December	31,	2014,	a	total	of	60,954	ERCP	procedures	were	registered	in	the	GallRiks	Registry.	Those	procedures	that	were	not	index	procedures	(i.e.,	first	ERCP	during	that	treatment	episode	within	30	days)	or	that	had	an	incomplete	registration	were	excluded,	leaving	54,437	ERCPs	in	the	study	group.	Since	the	intention	of	the	study	was	to	evaluate	the	effect	of	prophylactically	deployed	pancreatic	stents,	we	further	excluded	those	procedures	where	the	indication	was	pancreatitis,	assuming	that	the	intention	of	these	procedures	was	to	purposefully	cannulate	the	pancreatic	duct.	The	remaining	procedures	(n=43,595)	formed	the	study	base,	in	which	the	effects	of	pancreatic	cannulation	and	pancreatic	stent	deployment	were	investigated.	The	most	common	indications	for	the	ERCP	procedures	were	the	following:	suspected	common	bile	duct	stone	(n=16,493,	38	%),	obstructive	jaundice	
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(n=11,802,	27	%),	malignancy	(n=5,534,	13	%),	cholangitis	(n=4,567,	10	%)	and	stent	dysfunction	(n=2,803,	6	%).	For	details	see	Table	1	in	Paper	2.	Pancreatic	cannulation	occurred	in	22.3	%	(n=9,718)	of	the	study	base,	which	was	interpreted	as	accidental,	as	the	indication	was	a	disease	in	the	biliary	tract,	as	mentioned	above.	70	%	of	the	procedures	were	performed	acutely	and	30	%	electively,	and	there	was	a	slight	female	dominance	among	those	patients	(53	%);	there	were	also	slightly	more	patients	over	70	years	than	under	(54	%).	For	details,	see	Table	1	in	Paper	2.	Of	the	patients	who	had	a	pancreatic	cannulation,	only	3.9	%	(n=376)	received	a	pancreatic	stent,	presumably	prophylactically,	whereas	96.1	%	did	not	(n=9,342)	receive	a	pancreatic	stent.		
4.2.2	The	effect	on	adverse	events	of	an	accidental	pancreatic	cannulation	If	the	pancreatic	duct	was	not	cannulated	during	the	ERCP	procedure,	the	risk	of	pancreatitis	was	2.6	%,	but	this	increased	to	7.9	%	(p<0.0001)	if	it	was	cannulated,	which	corresponds	to	a	three-fold	increased	OR	(OR	3.07,	95	%	CI	2.77-3.40)	in	the	multivariate	analysis,	where	the	confounding	factors	of	age,	gender,	comorbidity,	indication,	urgent	procedure	and	previous	sphincterotomy	were	compensated	for.	Both	the	intraoperative	(2.5	%	vs	4.1	%,	p<0.0001)	and	postoperative	(13.1	%	vs	16.9	%,	p<0.0001)	adverse	events	were	increased	when	the	pancreatic	duct	was	cannulated,	which	corresponds	to	a	52	%	(OR	1.52,	95	%	CI	1.35-1.73)	and	44	%	(OR	1.44,	95	%	CI	1.35-1.54)	increase	of	the	OR	in	the	multivariate	analysis,	respectively.	Finally,	a	pancreatic	cannulation	was	not	associated	with	an	increased	risk	of	perioperative	hemorrhage	during	the	ERCP	(1.4	%	vs	1.2	%,	p=0.16).	For	more	details,	see	Table	2	in	Paper	2.	
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4.2.3	The	effect	on	adverse	events	when	inserting	a	prophylactic	pancreatic	stent	There	were	no	differences	in	postoperative	complications	(16.5	%	vs	16.9	%,	p=0.82),	risk	of	pancreatitis	(8.0	%	vs	7.9	%,	p=0.93)	or	risk	of	bleeding	(1.6	%	vs	1.4	%,	p=0.71)	when	a	pancreas	stent	was	used	after	a	pancreatic	cannulation	had	occurred	during	the	ERCP	procedure.	However,	strangely	enough,	there	was	an	association	to	intraoperative	adverse	events;	that	is,	there	was	a	higher	risk	for	perioperative	complications	in	the	pancreatic	stent	group	(8.2	%	vs	4.0	%,	p<0.0001)	compared	to	the	group	not	receiving	a	pancreatic	stent,	corresponding	to	a	more	than	two-fold	increase	of	the	OR	(OR	2.28,	95	%	CI	1.52-3.31),	which	is	further	discussed	in	the	comments	in	the	next	chapter	in	this	thesis	and	in	Paper	2.		
4.2.4	The	effect	on	adverse	events	of	different	sizes	and	lengths	of	prophylactic	
pancreatic	stents	We	also	compared	different	sizes	of	pancreatic	stents	(≤5Fr	(n=241)	vs	>5	Fr	(n=135))	regarding	adverse	events	and	found	no	significant	differences	in	overall	intra-	and	postoperative	complications;	there	was	also	no	difference	in	the	risk	of	intraoperative	hemorrhage	when	a	pancreatic	stent	was	inserted.	However,	there	was	an	almost	four-fold	elevation	of	the	OR	for	PEP	when	a	pancreatic	stent	with	a	diameter	≤5Fr	was	used	compared	to	using	stents	with	a	diameter	of	>5Fr	(OR	3.58,	95	%	CI	1.40-11.07).	PEP	occurred	in	10.4	%	in	the	≤5Fr-stent	group	compared	to	only	3.7	%	in	the	>5Fr-stent	group	(p=0.02).	By	adding	the	parameter	length	of	the	pancreatic	stent	(≤5cm	vs	>5cm)	to	the	study,	the	risk	of	pancreatitis	was	decreased	further	in	favor	of	the	longer	and	thicker	stents,	where	the	PEP	risk	was	only	1.4	%	compared	to	9.4	%	(p=0.025)	if	the	
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stents	were	both	≤5cm	and	≤5Fr.	For	further	details	of	these	results,	please	see	Tables	4	and	5	in	Paper	2.	
	
4.2.5	Comments	One	 important	 finding	 in	 this	study	was	 that	we	demonstrated	a	more	 than	 three-fold	increase	 in	 the	 OR	 (OR	 3.07)	 for	 developing	 PEP	 if	 the	 pancreatic	 duct	 had	 been	cannulated	during	the	ERCP	procedure	(7.9	%	vs	2.6	%,	p<0.0001),	which	is	in	line	with	previous	 studies	 (Cotton,	P.	B.,	 et	 al.,	 2009,	Cotton,	P.	B.,	 et	 al.,	 1991).	 The	 other	major	finding	of	the	study	was	a	decreased	risk	of	developing	PEP	if	larger	diameter	pancreatic	stents	 were	 used	 (3.7	%,	 >5Fr-stent)	 compared	 to	 thinner	 ones	 (10.4	%,	 ≤5Fr-stent,	p=0.02).	Additionally,	the	PEP-risk	was	further	reduced	(to	1.4	%)	if	a	longer	stent	was	used	(>5	cm)	in	combination	with	the	 larger	diameter	(>5Fr).	However,	 these	findings	should	 be	 interpreted	with	 caution,	 since	 the	 number	 of	 patients	 actually	 receiving	 a	pancreatic	stent	was	very	low	(n=376)	compared	to	the	complete	study	base,	as	the	vast	majority	of	cases	were	excluded,	and	those	uncertainties	are	reflected	in	the	very	wide	confidence	 intervals	 received.	 However,	 it	 is	 important	 to	 generate	 hypotheses	 of	 the	type	of	prophylactic	pancreatic	stents	 that	should	be	preferred,	 since	previous	studies	have	come	to	opposite	suggestions	for	which	stents	to	use.	For	instance,	in	a	randomized	controlled	 trial,	 Chahal	 and	 co-workers	 (Chahal,	 P.,	 et	 al.,	 2009)	 preferred	 short,	 5-Fr	stents	to	long,	3-Fr	stents	because	the	former	had	fewer	adverse	effects	and	the	longer	3-Fr	stents	more	often	needed	a	repeat	ERCP	for	stent	extraction.	The	problem	with	this	study	 was	 that	 both	 the	 lengths	 and	 the	 diameters	 of	 the	 stents	 varied	 between	 the	groups,	making	it	difficult	to	interpret	the	actual	cause	of	the	differences	(i.e.,	the	length	or	the	diameter	of	the	stent).		
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On	 the	 other	 hand,	 Pakh	 and	 co-workers	 (Pahk,	 A.,	 et	 al.,	 2011)	 could	 not	 find	 any	differences	 in	 complication	 rates	 between	 4-Fr	 and	 5-Fr	 stents	 in	 a	 randomized	controlled	study,	whereas	the	opposite	was	found	by	Rashdan	(Rashdan,	A.,	et	al.,	2004),	who	claimed	that	thinner	stents	were	superior	to	thicker	ones.		All	studies	were	reviewed	in	a	meta-analysis	by	Afghani	(Afghani,	E.,	et	al.,	2014),	where	he	 concluded	 that	 prophylactic	 5-Fr	 stents	 were	 better	 than	 3-Fr	 stents,	 but	 the	protective	effect	of	the	stents	larger	than	5	Fr	still	needs	to	be	studied	prospectively,	as	there	is	certainly	a	risk	that	our	findings	of	the	lower	adverse	event	rates	in	the	group	of	stents	over	5	Fr	might	be	confounded	by	the	fact	that	the	endoscopists	were	more	prone	to	 deploy	 a	 thicker	 stent	 if	 he	 demonstrated	 a	wide	pancreatic	 duct	 during	 the	ERCP.	Also,	in	this	group	of	patients,	there	is	a	risk	that	there	might	be	an	over-representation	of	cases	of	chronic	pancreatitis,	which	has	a	protective	effect	on	PEP	(Iorgulescu,	A.,	et	
al.,	2013),	confounding	the	results	in	this	group	by	giving	a	false	low	rate	of	PEP	caused	by	the	over-representation	of	chronic	pancreatitis	rather	than	the	pancreatic	stent	itself.	On	the	other	hand,	there	are	major	strengths	associated	with	our	study.	These	strengths	include	a	large	sample	size,	which	minimizes	the	risk	for	selection	bias.	Also,	GallRiks	is	a	well-validated	registry	that	exhibits	a	97.3	%	match	with	the	patients´	medical	records	in	 previous	 studies	 (Enochsson,	 L.,	 et	 al.,	 2013).	 This	 minimizes	 the	 risk	 for	misclassification	of	the	ERCP	procedures	and	the	adverse	events.	However,	there	could	still	be	misclassification	harbored	 in	 the	study,	 since	what	we	have	 investigated	 is	 the	pancreatic	 cannulations	 actually	 recorded	 in	 the	 GallRiks	 Registry	 as	 opposed	 to	 the	ones	 actually	 taking	 place.	 Therefore,	 there	 could	 be	 inadvertent	 pancreatic	cannulations	missed	by	the	endoscopists	or	cannulations	not	recalled	by	the	endoscopist	at	the	time	of	the	registration	(recall	bias).	
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The	ERCP	procedures	 included	 in	 the	GallRiks	Registry	are	also	representative	 for	 the	wide	 clinical	 spectrum	 of	 ERCP	 investigations	 performed	 in	 Sweden,	 since	 it	 is	generated	 from	 all	 types	 of	 endoscopic	 centers	 and	 registered	 by	 endoscopists	 with	different	 experiences;	 this	 ensures	 that	 the	 ERCP	 procedures	 in	 GallRiks	 represent	 a	wide	variety	of	everyday	clinical	settings.	Currently,	about	90	%	of	all	ERCPs	performed	in	 Sweden	 are	 registered	 in	 GallRiks.	 These	 conditions	 nearly	 completely	 remove	 the	risk	of	systematic	errors.	Naturally,	 there	 are	 also	 weaknesses	 associated	 with	 the	 study.	 For	 example,	 the	assumptions	 we	 made	 that	 the	 pancreatic	 stents	 deployed	 in	 the	 study	 were	prophylactic	may	be	incorrect.	We	could	not	extract	the	exact	intention	of	the	pancreatic	stent	from	the	registry	but	only	assumed	this	from	the	indication	of	the	ERCP	procedure	(directed	 towards	 the	 bile	 duct).	 Therefore,	 any	 access	 to	 the	 pancreatic	 duct	 under	these	 circumstances	 would	 be	 accidental	 and	 thereby	 any	 stent	 deployed	 in	 the	pancreatic	duct	in	this	situation	would	have	a	prophylactic	purpose.		There	 also	 is	 a	methodological	 consideration	 that	must	 be	 taken	 into	 account,	 that	 is,	many	patients	were	excluded	from	the	original	study	base,	and	few	patients	were	left	to	study.	This	 is	reflected	 in	 the	broad	confidence	 intervals	generated	when	studying	 the	effects	of	the	pancreatic	stents.	The	risk	of	confounding	by	indication	must	also	be	mentioned	as	a	shortcoming	of	the	study	and	could	thus	be	an	explanation	of	the	findings	of	higher	intraoperative	adverse	events	rates	 in	 the	group	receiving	a	pancreatic	stent	compared	 to	 those	who	did	not.	We	do	not	have	any	explanation	other	than	that	 the	endoscopists	were	more	prone	to	deploy	a	pancreatic	stent	when	the	ERCP	procedure	was	difficult;	this	is	reflected	as	an	increase	 in	 the	 intraoperative	 adverse	 event	 rate,	 which	 is	 not	 caused	 by	 the	 stent	
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deployment	per	se	but	is	just	an	effect	of	confounding	that	is	not	compensated	for	in	the	multivariate	analysis.		Another	 potential	weakness	 of	 the	 study	 is	 the	 long	 inclusion	 time	 (2006-2014).	 This	time	 period	 includes	 changes	 in	 radiological	 and	 endoscopic	 techniques	 as	 well	 as	indications	for	an	ERCP	procedure.	The	introduction	of	the	MRI	technique	significantly	changed	 the	 indications	 for	diagnostic	ERCP	procedures,	which	have	 almost	 vanished.	Today,	 almost	 all	 ERCPs	 are	 therapeutic,	 and	 this	 has	 changed	 the	 complication	panorama.	On	the	other	hand,	 the	endoscopic	 instruments	and	devices	have	 improved	technically,	 which	 might	 have	 affected	 complication	 rates	 in	 a	 positive	 way.	 A	 final	feature	 that	 has	 been	 introduced	 in	 conjunction	 with	 ERCP	 is	 the	 use	 of	 rectally	administered	 prophylactic	 NSAIDs	 adjacent	 to	 the	 procedure,	which	 is	 also	 known	 to	reduce	PEP	rates	postoperatively.	This	use	was	only	sporadically	used	at	the	time	of	the	beginning	of	the	study	in	Sweden,	but	 it	has	gradually	increased	in	use	over	time.	This	parameter	was	not	included	in	the	GallRiks	Registry	previously	and	has	most	definitely	affected	 the	complication	rates.	Without	 it,	 it	would	be	 impossible	 for	us	 to	 study	 this	outcome	variable	previously.	However,	this	parameter	is	now	introduced	in	the	GallRiks	Registry,	and	it	is	available	to	investigate	or	compensate	for	in	future	studies.	So	ideally,	it	would	have	been	better	to	perform	the	study	over	a	shorter	time	span	to	include	this	parameter	 throughout	 the	entire	 time	period;	however,	 this	would,	on	the	other	hand,	have	minimized	the	number	patients	included	in	the	study.		A	further	limitation	of	the	study	is	that	neither	the	brand	nor	the	type	of	pancreatic	stent	(apart	 from	 length	 and	diameter)	were	 registered	 in	 the	GallRiks	Registry,	 and	 hence	factors	like	pigtail	flanges	on	the	stent	could	not	be	studied.		In	conclusion,	our	study	has	demonstrated	that	the	PEP	risk	was	increased	in	the	ERCP	procedure	 where	 the	 pancreatic	 duct	 was	 cannulated,	 which	 is	 in	 line	 with	 previous	
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knowledge	 (Cotton,	 P.	 B.,	 et	 al.,	 2009,	 Cotton,	 P.	 B.,	 et	 al.,	 1991).	 We	 have	 also	demonstrated	a	decreased	risk	of	PEP	if	longer	pancreatic	stents	with	larger	diameters	were	 used,	 which	 also	 correlates	 to	 previous	 findings.	 For	 example,	 the	 recent	meta-analysis	(Afghani,	E.,	et	al.,	2014)	advocates	5-Fr	to	3-Fr	stents	for	PEP	prophylaxis,	and	this	 is	also	 the	 recommendation	of	 the	ESGE	 (Dumonceau,	J.	M.,	et	al.,	2014).	What	our	study	adds	 to	previous	knowledge	 is	 that	even	 longer	or	 larger-diameter	 stents	might	reduce	 the	 PEP	 rates	 further,	 but	 these	 findings	 must	 be	 interpreted	 with	 caution	because	of	the	non-randomized	setting	of	our	study.	Still,	our	results	must	be	seen	as	an	interesting	 and	 hypothesis-generating	 work,	 which	 might	 spur	 future	 randomized	studies	 to	 compare	 different	 sizes	 of	 prophylactic	 pancreatic	 stents	 in	 a	 standardized	setting	to	finally	solve	the	issue	of	finding	the	ideal	prophylactic	pancreatic	stent.		
4.3	Paper	3	(The	HOUSE	Classification:	A	novel	ERCP	complexity	grading	
scale)	
	
Results	
4.3.1	Basic	characteristics	Between	2009	and	2011,	2,185	ERCP	procedures	were	registered	in	the	GallRiks	Registry	and	were	performed	at	the	Karolinska	University	Hospital,	Huddinge,	Stockholm,	Sweden.	After	exclusion	of	non-index	procedures	and	those	with	incomplete	registrations,	1,930	ERCPs	remained	in	the	study	population.	From	these	investigations,	information	was	gathered	from	the	patient	records	and	the	GallRiks	Registry.	The	ERCP	procedures	were	divided	into	three	groups	called	HOUSE	classes	1-3.	In	the	HOUSE	1	group	(the	least	complex	procedures),	there	were	924	procedures,	whereas	541	procedures	were	allocated	to	HOUSE	2	and	266	were	included	in	the	HOUSE	3	class	(the	
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most	complex	procedures).	There	were	more	women	in	the	class	HOUSE	1	(53.4	%)	and	more	men	in	the	class	HOUSE	2	(58.6	%).	In	HOUSE	3,	the	gender	distribution	was	more	even	(48	%	females).	The	patients	in	HOUSE	2	were	younger	(53	years)	than	in	the	HOUSE	1	and	3	(64	and	56	years,	respectively).	On	the	other	hand,	the	patients	in	HOUSE	2	were	healthier	(58	%	ASA	1-2)	compared	to	HOUSE	1	and	3	(65	%	and	67	%	ASA	1-2,	respectively).	The	most	common	indications	for	the	ERCP	procedure	in	the	HOUSE	1	group	were	common	bile	duct	stones	(36	%),	malignancy	(15	%),	obstructive	jaundice	(14	%)	and	scheduled	controls	(11	%).	In	the	class	HOUSE	2	scheduled	controls	and	“other	indication”	(16	%	each)	were	the	most	common	indications,	followed	by	primary	sclerosing	cholangitis	(14	%),	chronic	pancreatitis	and	jaundice	(10	%	each).	Finally,	in	HOUSE	3,	the	indications	“other”	(32	%),	primary	sclerosing	cholangitis	(17	%)	common	bile	duct	stones	(13	%),	chronic	pancreatitis	(11%)	and	malignancy	(9%)	were	the	most	common.	For	more	detailed	information,	please	see	Table	2	in	Paper	3.		
4.3.2	The	complication	rates,	cannulation	success	rates	and	procedure	times	of	
the	HOUSE	classification		There	was	a	lower	cannulation	success	rate	in	HOUSE	1	(91%)—which	is	a	parameter	used	in	the	GallRiks	Registry	as	a	quality	marker—compared	to	HOUSE	2	(96	%)	and	3	(95	%).	The	mean	procedure	time	for	an	ERCP	procedure	was	40	minutes	in	HOUSE	1,	which	was	significantly	shorter	than	in	HOUSE	2	(65	minutes)	and	3	(106	minutes)	(see	Table	3	in	Paper	3).	
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Postoperative	complications	occurred	in	12.6	%	of	the	total	study	population,	where	pancreatitis	represented	the	most	common	complication	(4.9	%)	followed	by	postoperative	bleeding	(2.5	%).	Infections	with	abscesses	were	less	common	(0.8	%).	Intraoperative	complications	were	seen	in	4.2	%	in	the	total	group	where	extravasation	of	contrast	(1.8	%)	and	intraoperative	hemorrhage	(1.2	%)	were	the	most	common.	When	comparing	the	complication	rates	between	the	HOUSE	classes,	we	demonstrated	a	significantly	higher	overall	postoperative	complication	rate	in	the	class	HOUSE	2	(16	%)	and	HOUSE	3	(13	%)	compared	to	class	HOUSE	1	(11	%,	p=0.03).	This	was	also	the	case	regarding	the	PEP	rate,	which	was	only	3.4	%	in	HOUSE	1	compared	to	7.0	%	and	6.8	%	in	HOUSE	2	and	3,	respectively	(p=0.0016).	We	found	no	significant	differences	between	the	HOUSE	classes	when	investigating	postoperative	bleeding	or	abscesses.		Regarding	the	intraoperative	overall	complications,	we	found	no	differences	in	the	rates,	whereas	the	complication	“extravasation	of	contrast”	was	higher	in	HOUSE	2	and	3	(3.0	%	each)	compared	to	0.9	%	in	HOUSE	1	(p=0.0027).	For	further	details	on	the	results,	see	Table	4	in	Paper	3.	
	
4.3.3	Comments	In	this	study,	we	created	and	validated	a	new	complexity	grading	scale	for	ERCP	procedures	intended	for	resource	planning	at	endoscopic	centers.	Additionally,	the	classification	could	work	as	an	aid	in	finding	ERCPs	with	an	increased	complication	risk,	making	it	possible	to	intensify	prophylactic	measures	in	these	procedures.	The	HOUSE	classification	could	also	be	used	for	educational	purposes	and	make	outcome-comparisons	between	different	endoscopic	centers	more	fair	and	reliable.		
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In	the	validation,	we	found	a	good	correlation	between	the	different	HOUSE	classes	and	the	overall	complication	rates	and	the	risk	of	PEP	(with	an	increasing	risk	for	both)	in	the	HOUSE	2	and	3	classes.	Additionally,	we	demonstrated	a	good	correlation	between	the	procedure	time	and	the	HOUSE	classes	with	a	shorter	procedure	time	in	HOUSE	1	(40	minutes)	compared	to	HOUSE	2	(65	minutes)	and	HOUSE	3	(106	minutes),	making	the	HOUSE	classification	a	good	instrument	for	planning	endoscopic	resources.		There	has	been	a	need	for	a	modern	and	validated	ERCP	complexity	grading	scale	since	the	previous	classifications	have	either	been	outdated	or	have	not	been	validated,	and	the	HOUSE	classifications	fulfills	both	these	requisites.		The	classification	presented	by	Cotton	et	al.	(Cotton,	P.	B.,	et	al.,	2011)	was	not	validated	but	was	solely	eminence	based,	where	experienced	endoscopists	decided	what	class	they	considered	a	certain	endoscopic	procedure	to	be	and	ranked	it	in	a	four-level	scale,	and	the	median	values	of	the	experts’	opinions	were	grouped	into	classes	1-4.	Another	ERCP	complexity	grading	scale	was	created	by	Schutz	in	2000	(Schutz,	S.	M.,	et	
al.,	2000),	but	this	scale	has	now	become	outdated	since	it	contained	classes	defined	by	whether	the	ERCP	was	diagnostic	or	therapeutic,	where	the	former	procedures	have	nearly	been	abandoned	after	the	introduction	of	the	MRI	technique;	this	makes	the	scale	difficult	to	implement	in	modern	practice.	This	scale	was	validated,	but	correlation	between	the	different	classes	was	found	only	in	the	success	rates	of	the	procedure	and	not	in	the	complications	rates;	therefore,	this	scale	could	not	be	used	for	anticipating	complications.		The	Morriston	Hospital	Grading	Scale,	which	was	launched	by	Ragunath	(Ragunath,	K.,	
et	al.,	2003),	was	mainly	introduced	for	educational	purposes,	but	this	scale	has	also	become	outdated	since	it	also	deals	with	diagnostic	ERCPs,	which,	as	mentioned,	have	
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been	subsequently	abandoned.	Additionally,	this	scale	could	not	demonstrate	any	differences	in	the	complication	rates	after	ERCP	but	only	in	the	success	rates	of	the	procedures	and	also	only	for	the	trainees	and	not	for	the	supervisors;	therefore,	this	hampers	the	grading	scale.		In	2016,	Torun	and	co-workers	(Torun,	S.,	et	al.,	2016)	presented	a	new	ERCP	complexity	grading	scale	completely	independently	of	the	introduction	of	the	HOUSE	classification,	which	was	also	validated	in	relation	to	success	and	complication	rates.	It	showed	linear	relationships	between	the	four	groups	into	which	the	ERCP	procedures	were	classified.	Although	the	classification	demonstrated	this	relationship	between	the	classes	compared	to	success	and	complication	rates,	it	lacked	the	relation	to	procedure	times	included	in	the	HOUSE	classification,	which	makes	Torun´s	classification	impossible	to	use	as	a	resource	planning	instrument	at	endoscopic	centers	in	contrast	to	the	HOUSE	classification.	In	light	of	the	previous	classifications,	the	HOUSE	classification	offers	a	modern	complexity	grading	scale	and	takes	into	account	all	types	of	current	ERCP	procedures.	It	is	also	well	validated	in	relation	to	both	complications	and	procedure	times.	The	GallRiks	Registry	was	validated	by	matching	data	with	the	patients´	medical	records	
(Enochsson,	L.,	et	al.,	2013,	Rystedt,	J.,	et	al.,	2014),	and	the	data	must	be	considered	valid	with	a	low	risk	of	misclassification.	However,	this	risk	cannot	be	fully	excluded	since	there	is	always	the	risk	that	some	of	the	data	introduced	into	the	register	could	involuntarily	have	been	missed	by	the	endoscopist	or	forgotten	if	the	registration	was	completed	after	the	investigation	(recall	bias),	especially	if	the	documentation	in	the	register	occurred	a	long	time	after	the	ERCP	procedure	took	place.	There	are	also	other	limitations	of	the	study,	including	that	the	scale	is	“constructed	by	man”	and	the	division	of	the	groups	were	made	almost	completely	arbitrary.	Therefore,	
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it	is	difficult	to	argue	why	certain	procedures	were	categorized	into	a	certain	group	and	how	the	borders	between	the	groups	were	chosen.	Originally,	the	division	was	made	from	an	economical	aspect	in	an	attempt	to	gain	control	over	the	costs	at	the	endoscopic	center	at	Karolinska	University	Hospital,	Huddinge,	Stockholm,	Sweden,	and	this	classification	was	then	extrapolated	to	the	complexity	grading	scale,	assuming	that	more	devices	and	time	spent	on	a	procedure	corresponded	to	more	complex	procedures.	A	major	weakness	of	the	HOUSE	classification,	when	used	for	resource	planning,	is	the	fact	that	some	of	the	obstacles	occurring	during	an	ERCP	procedure	cannot	be	anticipated.	An	altered	surgical	anatomy	such	as	a	previous	Billroth	2-operation	or		Roux-en-Y	reconstruction	could	be	easily	foreseen,	but	other	conditions	(e.g.,	a	difficult	cannulation	due	to	a	small	papilla)	are	difficult	to	identify	before	the	ERCP	procedure,	and	this	hampers	the	HOUSE	classification	in	its	applicability	for	resource	planning.	For	this	shortcoming,	we	have	found	no	solution.		Another	limitation	of	the	study	was	a	significant	risk	of	selection	bias	as	the	study	was	performed	at	an	endoscopic	tertiary	national	referral	center,	where	more	complex	procedures	were	over-represented,	and	this	might	skew	the	panorama	of	postoperative	complications.	Additionally,	a	tertiary	center	educates	many	ERCP	trainees,	which	also	might	increase	the	risk	for	complications	and	prolong	the	procedure	time.	These	aspects	must	be	considered	before	the	classification	can	be	implemented	in	a	non-referral	endoscopic	center	and	might	warrant	possible	additional	modifications	and	validations	of	the	HOUSE	classification.		In	conclusion,	this	study	presents	a	newly	constructed	validated	ERCP	complexity	grading	scale	that	can	be	implemented	in	clinical	praxis	as	an	instrument	for	resource	planning	at	endoscopic	centers,	in	educational	endoscopic	training	programs	or	used	as	
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an	aid	in	identifying	high-risk	ERCP	procedures	and	thereby	enabling	targeting	of	necessary	prophylactic	measures.	The	HOUSE	classification	might,	however,	warrant	further	evaluation	and	validation	before	it	is	introduced	in	clinical	praxis	at	non-referral	endoscopic	centers,	as	a	different	panorama	of	indications	and	ERCP	procedures	might	exist	there.		
4.4	Paper	4	(Preoperative	biliary	drainage	by	plastic	stents	or	SEMS	in	
patients	with	assumed	resectable	periampullary	carcinoma)	
	
Results	
4.4.1	Preoperative	patient,	tumor	and	stent	function	characteristics	92	patients	with	presumably	resectable	periampullary	tumors	were	randomized	to	either	achieve	a	SEMS	or	a	plastic	stent.	47	patients	were	allocated	to	the	SEMS	group,	and	45	patients	to	the	plastic	stent	group.	Eventually,	27	patients	in	the	SEMS	group	were	curatively	operated	upon,	13	were	not	operated	upon	and	7	underwent	palliative	surgery.	In	the	plastic	stent	group,	32	patients	had	a	curative	resection,	whereas	11	patients	were	not	operated	upon	and	11	patients	had	a	non-curative	operation,	like	an	explorative	laparotomy	or	a	surgical	bypass	without	a	resection.		When	comparing	patient	characteristics	in	all	of	the	operation	patients	(curatively	and	non-curatively,	n=34	in	each	group),	more	men	received	a	plastic	stent	(67	%),	but	this	difference	was	not	significant.	We	also	did	not	detect	any	differences	in	other	patient	characteristics,	including	weight,	age,	morbidity	or	bilirubin	level	when	the	stenting	occurred.	The	C-reactive	protein	level	(CRP)	was	significantly	higher	in	the	SEMS	group	(20	mg/ml	vs	9	mg/ml,	p=0.01),	but	the	clinical	importance	of	this	difference	should	be	small.	
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The	features	of	the	tumors	regarding	size,	stage,	grade	of	differentiation	and	type	of	origin	(pancreatic,	biliary,	papillary	or	duodenal)	did	not	differ	between	the	SEMS	and	plastic	stent	groups.	Also,	the	pancreatic	texture	of	the	glandula	did	not	differ	between	the	groups	(hard,	soft	or	intermediate)	when	the	anastomosis	was	created	according	to	the	surgeon´s	clinical	opinion	during	the	operation.	There	were	significantly	higher	rates	of	stent	dysfunction	(27	%	vs	11	%,	p=0.05)	and	stent	exchanges	(24	%	vs	8	%,	p=0.05)	in	the	plastic	stent	group	compared	to	the	SEMS	group	in	the	group	of	all	patients	randomized	(n=92),	but	there	was	no	difference	found	in	the	risk	of	cholecystitis,	cholangitis	or	pancreatitis	between	the	groups.	There	was	an	increased	risk	of	preoperative	stent	dysfunction	(21	%	vs	6	%,	p=0.15)	and	stent	exchange	(18	%	vs	3	%,	p=0.11)	in	the	plastic	stent	group,	in	those	patients	who	were	operated	on,	but	in	this	smaller	group,	the	difference	did	not	reach	statistical	significance.	On	the	contrary,	the	preoperative	stent	exchange	rate	in	the	curatively	operated	patients	was	significantly	lower	among	those	patients	who	had	received	a	SEMS	(19	%	vs	0	%,	p=0.03),	and	the	risk	of	stent	dysfunction	was	also	lower	among	the	patients	who	had	received	a	SEMS	(22	%	vs	4	%,	p=0.06);	however,	this	latter	finding,	was	not	statistically	significant.	In	the	patients	that	underwent	an	operation,	whether	curatively	or	not,	there	were	no	differences	in	the	risk	of	developing	cholangitis	or	in	the	bilirubin	or	CRP	levels	recorded	preoperatively.	There	were	also	no	differences	in	the	use	of	prophylactic	antibiotics,	the	frequency	of	failed	cannulations,	previous	sphincterotomized	patients	or	the	rate	of	precut	sphincterotomies	used	when	comparing	the	SEMS	and	plastic	stent	groups.	For	further	details,	see	Tables	1	and	2	in	Paper	4.	
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4.4.2	Perioperative	bacteriological,	histopathological	and	clinical	findings	The	amount	of	gut	bacteria	in	the	bile	collected	during	the	operation	was	identical	in	the	SEMS	and	plastic	stent	groups	(100.000	CFU/ml),	but	the	total	amount	of	all	bacteria	was	higher	in	the	SEMS	group	(131.000	vs	110.000	CFU/ml,	p=0.44);	this	difference	was	not	significant.	The	most	common	bacteria	found	in	the	bile	in	both	stent	groups	were	species	of	Klebsiella,	followed	by	Alpha	streptococcus	and	Enterococcus.	A	complete	list	of	the	bacteria	present	in	the	bile	cultures	is	presented	in	Table	3	in	Paper	4.	There	were	no	differences	in	the	operation	times	nor	in	the	perioperative	bleeding	between	the	plastic	stent	and	SEMS	groups.	There	were	also	no	differences	in	the	proportion	of	total	pancreatectomies	(compared	to	Whipple)	or	in	the	proportion	of	vascular	resections	performed	adjacent	to	the	pancreatico-duodenectomy	between	the	groups.		The	time	from	the	endoscopic	stenting	to	the	operation	was	similar	between	the	two	groups	as	well	as	the	procedure	times,	the	intraoperative	bleeding,	the	time	in	ICU	and	the	total	hospital	stay.		The	surgeons’	subjective	intraoperative	estimations	of	how	much	inflammation	was	present	in	the	hepato-duodenal	ligament	showed	no	differences	between	the	plastic	stent	and	the	SEMS	groups.	There	were	also	no	differences	in	the	difficulties	in	creating	the	anastomoses	or	in	extracting	the	stents	from	the	bile	duct	irrespective	of	stent	type	present.	When	a	ring-shaped	specimen	intraoperatively	harvested	from	the	bile	duct	was	investigated	histopathologically,	no	difference	could	be	detected	in	the	degree	of	cholangitis,	but	when	investigating	the	foreign	body	reaction	sinus	histiocytosis	specifically,	in	the	lymph	nodes	in	the	hepato-duodenal	ligament,	this	was	significantly	higher	in	the	plastic	stent	group	(26	%	vs	7	%,	p=0.05)	compared	to	the	SEMS	group.		
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4.4.3	Postoperative	complications	
	The	overall	complication	rates	in	the	patients	with	any	operation	(curative	or	non-curative)	were	higher	in	the	patients	receiving	a	plastic	stent	(68	%)	compared	to	the	SEMS	group	(50	%).	This	was	also	the	case	in	the	group	of	patients	operated	curatively	(72	%	vs	52	%),	but	none	of	these	differences	reached	statistical	significance	(p=0.14	and	p=0.11,	respectively).	The	risk	of	developing	a	specific	surgical	complication	among	those	patients	with	any	operation	(curative	or	non-curative)	was	higher	in	the	plastic	stent	group	(50	%)	than	in	the	SEMS	group	(35	%),	without	reaching	statistical	significance	(p=0.22),	and	the	difference	was	even	smaller	in	the	subgroups	of	patients	curatively	operated	(53	%	vs	44	%,	p=0.51).	In	the	group	of	all	patients	who	underwent	an	operation,	the	risk	for	anastomotic	leakage	was	higher	in	the	plastic	stent	group	(12	%)	than	in	the	SEMS	group	(2.9	%);	this	difference	also	was	non-significant.	Further	on,	nearly	similar	results	were	seen	in	the	curatively	operated	group	regarding	anastomotic	leakage	in	favor	of	the	SEMS	group	(12	%	vs	3.7	%,	p=0.36).	On	the	other	hand,	the	infectious	complications	in	patients	with	any	operation	(curative	or	non-curative)	were	more	common	in	the	SEMS	group	(29	%	vs	15	%,	p=0.14),	but	the	difference	was	less	enhanced	in	the	curatively	operated	patients	(SEMS	22	%	vs	16	%	plastic	stent,	p=0.51);	again,	none	of	the	differences	were	significant.	There	were	also	more	postoperative	bleedings	in	the	plastic	stent	group	(9	%	vs	3	%	in	all	operated	patients	and	9	%	vs	4	%	in	the	curatively	operated	patients),	but	once	more	these	results	were	statistically	non-significant.	To	summarize,	the	other	complications	(i.e.,	delayed	gastric	emptying,	reoperation,	wound	dehiscence,	postoperative	antibiotics	used	and	cardiopulmonary	complications)	were	too	rare	to	compare,	or	they	showed	no	mentionable	numerical	
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differences	(and	thus	no	statistically	significant	differences)	between	the	groups	(For	details,	see	Table	5	in	Paper	4).		
4.4.4	Comments	
	The	main	finding	in	this	prospective	randomized	study	comparing	SEMS	and	plastic	stents	in	patients	with	presumably	resectable	periampullary	tumors	was	that	the	risk	of	stent	dysfynction/exchange	prior	to	operation	was	reduced	if	a	SEMS	was	used	(27%/24%	vs	11%/8%,	p=0.05).	Intraoperatively,	we	found	no	technical	differences	for	the	surgeons	in	performing	the	pancreatico-duodenectomy	in	relation	to	the	stent	type	used	(no	difference	regarding	the	surgeon´s	subjective	findings,	operational	time	or	perioperative	blood	loss).	There	were	also	no	differences	in	the	amount	of	bacteria	in	intraoperatively	collected	bile	measured	in	colony-forming	units	of	bacteria	per	milliliter	(CFU/mL).	However,	there	was	a	more	histopathologically	enhanced	foreign	body	reaction	(sinus	histiocytosis)	in	the	lymph	nodes	harvested	intraoperatively	from	the	hepato-duodenal	ligament	in	the	patients	receiving	plastic	stents	compared	to	these	receiving	SEMS.	Finally,	we	found	numerical	differences	in	the	rates	of	overall	postoperative	complications	in	the	curatively	operated	patients	in	favor	of	the	SEMS	(72%	vs	52%,	p=0.11)	and	in	anastomotic	leakage	rates	(12%	vs	3.7%,	p=0.36),	however,	these	differences	did	not	reach	statistical	significance.	SEMS	have	been	previously	demonstrated	to	be	superior	to	plastic	stents	regarding	patency	in	palliative	patients	not	intended	for	a	curative	operation	(Zorron	Pu,	L.,	et	al.,	
2015)	and	also	in	the	neo-adjuvant	setting	with	locally	advanced	primary	irresectable	tumors,	as	these	patients	require	several	months	of	oncological	treatment	before	they	could	be	evaluated	for	surgery	again	(Aadam,	A.	A.,	et	al.,	2012).	Until	now,	there	has	
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been	no	prospective,	randomized	controlled	trial	comparing	SEMS	to	plastic	stents	in	patients	with	primary	resectable	periampullary	tumors;	instead,	there	are	only	retrospective	series.		A	meta-analysis	(Crippa,	S.,	et	al.,	2016)	of	these	retrospective	studies	(n=704),	which	of	course	methodologically	must	be	interpreted	with	caution,	did	however	demonstrate	a	higher	risk	for	a	reintervention	with	a	new	ERCP	procedure	due	to	stent	dysfunction	if	a	plastic	stent	was	used	preoperatively	compared	to	if	a	SEMS	was	used	(15	%	vs	3	%,	p<0.0001).	This	meta-analysis	also	showed	a	higher	risk	of	developing	a	pancreatic	fistula	postoperatively	in	the	plastic	stent	group	compared	to	the	SEMS	group	(12	%	vs	5	%,	p=0.04);	both	findings	are	in	line	with	our	results,	but	our	results	represent	the	first	data	gained	from	a	prospective	RCT.	It	is	important	to	note	that	in	Sweden,	almost	all	patients	while	awaiting	curative	pancreatic	surgery	during	the	preoperative	diagnostic	work-up	period	receive	some	kind	of	biliary	drainage,	although	several	previous	studies	have	shown	negative	effects	on	the	postoperative	results	with	an	increased	risk	of	postoperative	complications	if	a	preoperative	stenting	is	performed	(Chen,	V.	K.,	et	al.,	2005,	Fang,	Y.,	et	al.,	2013,	Sewnath,	
M.	E.,	et	al.,	2002,	van	der	Gaag,	N.,	et	al.,	2010).	The	most	often	cited	study	on	this	subject	is	the	one	by	van	der	Gaag	and	co-workers	from	2010,	which	was	published	in	New	England	Journal	of	Medicine	(van	der	Gaag,	N.,	et	al.,	2010)	and	showed	an	increased	risk	of	adverse	events	if	a	preoperative	decompression	of	the	bile	duct	was	used	compared	to	up-front	surgery	(74	%	vs	39	%,	p<0.01).	However,	this	study	was	not	performed	with	modern	SEMS	but	with	plastic	stents	or	sometimes	even	with	PTC	drains.	Therefore,	a	randomized	controlled	trial	is	needed	to	compare	SEMS	and	up-front	surgery.		
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In	Sweden,	preoperative	decompression	of	the	bile	duct	is	mostly	used	for	logistic	reasons,	while	the	patient	is	on	the	waiting	list	for	surgery	at	a	tertiary	center	and	while	the	diagnostic	work-up	is	in	progress,	minimizing	the	risk	for	cholangitis	or	coagulopathy.	This	is	why	some	of	the	patients	received	a	preoperative	bile	duct	decompression	with	a	lower	threshold	regarding	the	indication	of	the	stenting	than	is	usually	recommended.	The	strengths	of	our	study	are	that	the	data	are	collected	prospectively,	and	the	patients	are	randomized	to	either	receive	a	SEMS	or	a	plastic	stent.	This	reduces	the	risk	for	selection	bias,	and	this	study	is	the	first	study	where	this	was	performed	prospectively	in	this	clinical	situation	(preoperative	in	resectable	periampullary	tumors).		There	seem	to	be	no	major	differences	in	the	preoperative	demographics	of	the	patients,	neither	in	the	tumor	characteristics	(e.g.,	tumor	stage,	tumor	differentiation,	histological	types)	nor	in	the	laboratory	test	apart	from	C-reactive	protein	(CRP),	which	was	9	mg/ml	in	the	plastic	stent	group	compared	to	20	mg/ml	in	the	SEMS	group.	This	difference	is	clinically	modest	but	statistically	significant	in	our	study.		Another	strength	of	the	study	is	that	it	was	performed	at	a	large	national	tertiary	endoscopic	center	with	only	experienced	endoscopists;	this	minimizes	the	risk	of	variation	in	the	technical	quality	of	how	the	ERCP	procedures	were	performed.	On	the	other	hand,	many	of	the	ERCP	procedures	were	performed	at	a	teaching	hospital,	where	many	endoscopic	trainees	are	present	performing	the	ERCP	procedures,	which	might	have	affected	the	outcome.	But,	since	the	study	was	performed	as	an	RCT,	the	effects	should	be	equal	in	both	groups.	Also,	there	is	a	risk	that	the	ERCP	procedures	performed	at	a	national	tertiary	referral	endoscopic	center	may	not	be	representative	of	ordinary	ERCP	procedures,	as	more	technically	demanding	ERCPs	are	performed	here	compared	to	regular	endoscopic	centers.	This	might	also	skew	the	results,	but	again,	because	this	
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study	was	performed	in	a	prospective	randomized	manner,	no	differences	should	appear	between	the	groups.		A	final	strength	of	our	study	is	that	the	patients	remained	in	the	group	to	which	they	were	randomized.	This	intention-to-treat	design	gives	the	study	a	higher	validity.	Among	the	downsides	of	the	study	is	that	the	primary	outcome	was	chosen	to	be	the	amount	of	bacteria	in	intraoperatively	collected	bile;	when	the	study	was	set	up,	and	the	power	calculation	of	the	study	was	based	on	this.	This	led	to	the	negative	effect	that	the	study	probably	became	underpowered	regarding	the	secondary	outcomes,	such	as	clinical	symptoms	and	perioperative	complications.	Another	shortcoming	was	that	the	outcome,	especially	the	amount	of	bacteria	in	CFU/mL,	turned	out	to	be	equal	between	the	groups,	and	that	this	parameter	had	a	low	clinical	value,	not	corresponding	to	the	clinical	symptoms	and	outcome.	Retrospectively,	when	knowing	the	results	from	the	study	and	considering	the	study	design	critically,	instead	it	would	have	been	better	to	monitor	perioperative	complications	as	the	primary	outcome,	but	this	fact	could	of	course	not	be	anticipated	when	starting	the	study.	Perhaps	the	difference	in	overall	postoperative	complication	rates	then	would	have	reached	statistical	significance,	and	even	some	of	the	subgroups	of	complications	(e.g.,	anastomosis	leakage)	might	have	differed	statistically	significant	between	the	stent	type	groups.	However,	a	shortcoming	of	the	results	of	the	subgroup	of	anastomotic	leakage	was	that	the	type	of	leakage	could	not	be	clearly	distinguished	from	which	anastomosis	it	emanated.	Therefore,	this	group	might	represent	a	case-mix	of	different	complications	(e.g.,	pancreatic	fistulae,	bile	leakage).	Additionally,	there	was	probably	also	a	large	overlap	from	this	group	of	anastomotic	leakages	to	the	group	of	infectious	complications,	which	might	represent	the	effect	of	an	infected	fluid	collection	arising	from	a	previous	leakage.	
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A	further	weakness	of	the	study	was	that	it	was	not	completely	double	blind.	Although	the	study	was	blinded	to	the	patients	and	staff	at	the	surgical	wards,	the	endoscopist	was	aware	of	the	stent	type	used,	which	might	have	affected	the	patient´s	and	other	staff´s	opinion	and	thereby	the	outcome	of	the	study.	A	risk	for	pancreatitis	and	cholecystitis	has	been	described	when	using	SEMS,	while	these	were	thought	to	block	the	duct	orifices	(Cote,	G.	A.,	et	al.,	2010),	but	this	was	not	noted	in	our	study,	although	the	frequency	of	these	complications	was	slightly	higher	in	the	SEMS	group.	But,	again,	these	events	were	too	rare	to	gain	statistical	significance,	if	present	at	all.		The	stent	dysfunction	rate	was	higher	in	the	plastic	stent	group	as	well	as	the	stent	exchange	rate,	but	the	latter	may	not	be	a	good	measure	of	outcome,	as	the	endoscopist	may	be	more	prone	to	exchange	a	plastic	stent,	since	this	is	cheaper	and	easier	to	remove	than	the	more	costly	SEMS;	this	fact	may	also	have	biased	the	results.	Another	aspect	that	must	be	considered	is	the	surgeon´s	subjective	evaluation	of	the	operational	findings	regarding	difficulties	in	extracting	the	stent,	creating	the	anastomosis	and	estimating	the	grade	of	inflammation	in	the	hepato-duodenal	ligament.	These,	of	course,	were	highly	subjective	although	we	tried	to	classify	them	into	a	more	objective	three-leveled	scale.	Anyhow,	we	could	not	detect	any	differences.	Also,	there	were	no	differences	in	procedure	time	or	in	the	amount	of	perioperative	blood	loss,	both	representing	more	objective	measurements	of	technical	difficulties	during	the	operation.	On	the	contrary,	there	was	a	higher	grade	of	foreign	body	reaction	(sinus	histiocytosis)	in	the	lymph	nodes	in	the	hepato-duodenal	ligament	in	the	plastic	stent	group,	and	altogether,	this	strongly	suggests	that	SEMS	do	not	jeopardize	the	operation	technically.	Rather,	it	could	even	be	more	advantageous	to	use.			
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A	final	consideration	of	this	study	is	the	long	enrollment	period	(2007-2014)	during	which	endoscopic	instruments	and	devices	have	experienced	development,	which	may	have	also	affected	the	outcome	over	time.		In	conclusion,	this	study	gives	clear	evidence	that	SEMS	could	be	used	preoperatively	in	resectable	periampullary	tumors.	This	is	a	clear	advantage	for	patients,	since	the	resectability	is	not	always	known	at	the	time	of	the	biliary	decompression.	By	using	a	SEMS	directly,	this	might	avoid	the	morbidity	of	unnecessary	repeat	ERCP	for	stent	exchanges.		However,	there	was	no	difference	in	the	amount	of	bacteria	in	the	bile	collected	during	the	operation—this	was	the	primary	outcome	of	the	study—but	when	studying	the	secondary	outcomes	of	clinical	advantage	of	using	SEMS	in	resectable	periampullary	tumors,	these	were	threefold	and	present	in	both	the	pre-	and	intraoperative	phases	as	well	as	in	the	postoperative	period.	Preoperatively,	the	advantage	was	demonstrated	in	the	study	by	a	statistically	significant	lower	risk	for	stent	dysfunctions	and	need	for	stent	exchanges.	Intraoperatively,	the	SEMS	show	no	evidence	of	disadvantages	affecting	the	operation	technically	–	neither	through	the	subjective	findings	of	the	surgeon	nor	by	prolonging	the	operational	time	or	increasing	the	amount	of	blood	loss	during	the	pancretico-duodenectomy.	Finally,	postoperatively,	we	demonstrated	a	lower	risk	of	overall	complications	and	risk	of	anastomotic	leakages	if	SEMS	were	used;	the	lack	of	statistical	significance	regarding	the	postoperative	complications	is	likely	due	to	underpowering	of	the	study.				
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5.	GENERAL	DISCUSSION		When	the	interventional	ERCP	techniques	of	sphincterotomy	and	endoscopic	stenting	were	introduced	in	the	seventies,	this	new	development	reduced	the	complication	rates,	since	the	number	of	open	operations	could	be	reduced	and	be	replaced	by	this	new,	minimally	invasive	method.	Although	the	ERCP	instruments	and	devices	have	improved	over	time,	ERCP	is	still	marred	with	considerable	morbidity,	and	further	measures	must	be	undertaken	to	reduce	these	complication	rates	as	much	as	possible.		A	correct	indication	for	the	ERCP	(and	not	performing	unnecessary	procedures)	is	one	important	factor	that	can	reduce	complications.	The	introduction	of	the	MRI	technique	represented	a	great	breakthrough	in	reducing	the	number	of	diagnostic	ERCPs,	thereby	reducing	complications.	Another	important	factor	in	reducing	complications	is	a	good	educational	system	to	secure	the	skills	of	future	endoscopists	and	to	maintain	competence	among	active	ERCPists.	Guidewire	cannulation	represents	another	example	of	a	basic	ERCP	technique	that	reduces	the	complications	and	increases	the	chance	of	getting	access	to	the	bile	duct	and	is	recommended	by	the	ESGE	(Dumonceau,	J.	M.,	et	al.,	
2014).	Finally,	an	important	prophylactic	measurement	in	reducing	ERCP	complications	is	the	use	of	rectally	administered	NSAIDs	(indomethacin	or	diclofenac),	which	fortunately	has	increased	during	the	last	years.	It	significantly	reduces	the	risk	of	PEP,	and	is	recommended	in	ESGEs	guidelines	(Dumonceau,	J.	M.,	et	al.,	2014)	to	be	administered	to	all	patients	undergoing	ERCP	–	both	in	high-	and	low-risk	cases.			
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5.1	When	should	prophylactic	antibiotics	be	used	in	ERCP?		In	modern	society,	a	growing	problem	of	bacterial	resistance	to	antibiotics	is	seen,	which	should	be	considered	in	medicine	when	using	antibiotics,	especially	in	a	prophylactic	setting.	It	is	therefore	important	to	have	sharp	indications	for	prophylactic	antibiotics	in	ERCP,	but	defining	when	prophylactic	antibiotics	should	be	administrated	in	ERCP	is	difficult.	There	are	two	modern	meta-analyses	(Bai,	Y.,	et	al.,	2009,	Brand,	M.,	
et	al.,	2010)	on	the	subject,	and	they	reach	different	conclusions.	Bai	(Bai,	Y.,	et	al.,	2009)	suggested	that	antibiotic	prophylaxis	should	not	be	used	routinely,	as	it	did	not	reduce	the	risk	of	cholangitis,	but	they	also	warranted	more	studies	in	the	ERCPs	where	biliary	drainage	could	not	be	achieved.	On	the	contrary,	Brand	(Brand,	M.,	et	al.,	2010)	claimed	in	a	Cochrane	analysis	that	the	effect	of	prophylaxis	was	less	evident	in	routine	ERCPs,	and	they	also	suggested	to	reserve	the	prophylaxis	for	those	patients	where	decompression	of	the	bile	ducts	could	not	be	achieved;	they	also	speculated	whether	perhaps	the	antibiotics	could	be	administered	postoperatively	if	no	bile	duct	access	was	reached	during	the	ERCP	procedure.	Our	study	gave	similar	results	as	these	meta-analyses,	that	is,	a	modest	reduction	in	complications	if	antibiotics	were	used	prophylactically	(14.2%	vs	11.6%)	but	with	a	number	needed	to	treat	of	38	patients	to	avoid	one	postoperative	complication.	According	to	our	considerations,	these	results	do	not	justify	a	general	recommendation	to	use	prophylactic	antibiotics	in	all	ERCP	procedures.	We	later	found	a	greater	effect	on	the	reduction	of	complications	in	the	group	of	patients	with	jaundice	(15.3%	vs	11.5%),	which	is	also	in	line	with	the	findings	in	the	meta-analyses	mentioned	above,	with	a	number	needed	to	treat	of	26	patients	to	avoid	one	adverse	effect	in	this	subgroup,	which	might	justify	a	more	generous	recommendation	of	antibiotic	prophylaxis	in	these	particular	ERCP	procedures.		
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One	way	could	be	to	administer	the	antibiotics	postoperatively	in	these	ERCP	procedures	where	no	biliary	access	is	gained	to	reduce	the	administration	of	antibiotics,	but	more	studies	are	warranted.	Until	this	problem	is	solved,	we	will	be	directed	to	use	a	strategy	where	we	estimate	the	risk	in	a	certain	indication	of	the	ERCP	procedure	for	not	achieving	biliary	drainage;	if	this	risk	is	sufficiently	high,	this	will	guide	us,	when	to	use	prophylactic	antibiotics.		
5.2	When	and	which	type	of	prophylactic	pancreatic	stents	should	be	used	
in	ERCP?		Prophylactic	pancreatic	stents	reduce	the	risk	of	developing	PEP,	but	they	have	historically	not	been	frequently	used	in	ERCP	in	Sweden.	Not	only	do	the	stents	reduce	the	PEP	rates,	but	they	also	seem	to	almost	eliminate	the	risk	of	severe	PEP,	and	they	are	recommended	in	ESGE	guidelines	(Dumonceau,	J.	M.,	et	al.,	2014)	in	high-risk	ERCP	procedures.	One	problem	is	finding	the	appropriate	definition	for	a	high-risk	ERCP	procedure;	currently,	Halttunen	and	co-workers	(Halttunen,	J.,	et	al.,	2014)	suggested	the	rule	of	“5-5-2”,	where	the	different	separate	figures	represent	an	ERCP	procedure	with	either	five	attempts	to	cannulate	the	bile	duct,	more	than	five	minutes	of	cannulation	attempts	or	two	passages	of	the	guidewire	into	the	pancreatic	duct	through	which	all	the	risk	of	complications	increase.	This	may	be	a	suitable	way	to	decide	when	a	pancreatic	stent	should	be	deployed.	This	definition	of	a	difficult	cannulation	was	currently	also	adapted	by	the	ESGE	(Testoni,	P.	A.,	et	al.,	2016).	Another	issue,	apart	from	the	indication	of	a	prophylactic	stent,	is	which	type	of	stents	that	should	be	preferred	as	the	golden	standard.	In	a	recent	meta-analysis	(Afghani,	E.,	et	
al.,	2014),	it	was	demonstrated	that	5-Fr	stents	performed	better	than	3-Fr	stents	in	reducing	complications	and	were	also	easier	to	deploy	in	the	pancreatic	duct.	This	meta-
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analysis	also	speculated	about	whether	flanged	or	unflanged	stents	were	better,	but	this	was	less	obvious,	and	they	only	concluded	that	there	was	no	difference	between	those	two	types.	They	interpreted	this	finding	as	suggesting	that	the	diameter	is	the	important	issue	and	not	the	flanges.	However,	there	is	an	increased	risk	for	a	repeat	ERCP	to	remove	the	flanged	stents,	which	is	also	the	case	for	the	longer	stents.	So,	all	together,	the	recommendation	must	be	to	use	a	short,	unflanged	5-Fr	stent	for	prophylaxis,	which	is	in	line	with	the	ESGE	recommendation	(Dumonceau,	J.	M.,	et	al,	2014).	Another	aspect	of	prophylactic	pancreatic	stents	is	the	time	that	the	stents	should	be	in	place	in	the	pancreatic	duct	and	how	the	dislodgement	of	the	stent	should	be	controlled.	Here,	the	ESGE	recommend	five	to	ten	days	stenting	(Dumonceau,	J.	M.,	et	al,	2014)	and	a	control	so	that	retained	stents	can	be	removed.		Our	contribution	in	the	field	of	prophylactic	pancreatic	stenting	is	that	we	have	investigated	the	effect	on	PEP	of	even	larger	stents	(>5Fr,	>5	cm)	in	a	national	population-based	registry.	We	found	that	these	may	reduce	the	PEP	rates	further,	but	these	findings	must	be	confirmed	through	future	RCTs.	Therefore,	presently	the	recommendation	of	prophylactic	pancreatic	stenting	is	to	use	short	5-Fr	stents	in	high-risk	procedures,	preferably	defined	through	the	“5-5-2-rule”	described	above.			
5.3	Why	should	an	ERCP	complexity	grading	scale	(The	HOUSE	
Classification)	be	implemented	in	clinical	praxis?		ERCP	is	one	of	the	most	advanced	endoscopic	procedures	that	is	performed	today,	but	the	complexity	between	different	procedures	varies	considerably;	therefore,	it	is	desirable	to	introduce	a	new	ERCP	complexity	grading	scale.	Firstly,	this	scale	can	function	as	a	resource-scheduling	system	at	endoscopic	centers,	when	planning	for	the	right	amount	of	time	for	an	ERCP	procedure,	the	right	endoscopic	competence	and	that	
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the	correct	devices	are	present.	Secondly,	the	scale	can	be	used	for	targeting	prophylactic	measures	towards	more	complex	procedures—for	example,	a	higher	level	of	postoperative	control	or	a	more	liberal	indication	for	perioperative	prophylactic	measures	during	the	procedure.	This	new	HOUSE	classification	can	also	be	used	for	educational	purposes	in	finding	the	right	level	of	difficulty	of	the	ERCP	procedure	in	relation	to	a	certain	level	for	the	trainee	in	an	endoscopic	training	fellowship.	Finally,	the	HOUSE	classification	can	be	used	for	economical	billing	when	transferring	money	between	different	healthcare	systems	or	as	an	instrument	to	make	comparisons	of	complications	and	research	results	more	reliable	and	fair	between	different	endscopic	centers.		An	endoscopic	complexity	classification	system	introduced	by	Cotton	(Cotton,	P.	B.,	et	al.,	
2011)	is	hampered	by	a	lack	of	validation	and	is	solely	eminence	based,	whereas	the	HOUSE	classification	is	validated	in	relation	to	procedure	time,	for	resource	planning	possibilities	and	to	complication	rates	and	is	able	to	direct	prophylactic	measures	towards	the	ERCP	procedures	with	higher	complication	rates.		Another	classification	presented	recently	in	2016	(Torun,	S.,	et	al.,	2016),	launched	completely	independently	to	the	HOUSE	classification,	seems	promising	since	it	demonstrates	a	good	correlation	to	success-	and	complication	rates,	but	lacks	the	HOUSE	classification´s	correlation	to	procedure	time	and	could	thereby	not	be	used	for	resource	planning.	Former	ERCP	classifications	(Madhotra,	R.,	et	al.,	2000,	Ragunath,	K.,	et	al.,	2003,	Schutz,	
S.	M.,	et	al.,	2000),	although	validated,	have	been	outdated,	since	both	radiological	(MRI)	and	endoscopic	techniques	have	developed,	making	those	classifications	difficult	to	apply	to	modern	ERCP	procedures.	
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The	HOUSE	classification	presented	in	our	study	represents	a	modern	ERCP	complexity	classification	that	is	applicable	in	modern	endoscopic	praxis.	It	is	validated	in	relation	to	both	procedure	time	for	resource	planning,	to	complications	in	general	and	to	PEP	rates	in	particular	and	could	be	used	as	an	aid	to	anticipate	postoperative	problems,	which	provides	the	possibility	to	act	against	them	at	an	early	stage.			
5.4	What	are	the	benefits	of	using	a	SEMS	preoperatively	in	resectable	
periampullary	tumors?		Several	previous	studies	and	meta-analyses	(Chen,	V.	K.,	et	al.,	2005,	Fang,	Y.,	et	al.,	2013,	
Sewnath,	M.	E.,	et	al.,	2002)	have	shown	that	routine	preoperative	biliary	endoscopic	stenting	increases	morbidity	by	adding	preoperative	complications	(e.g.,	PEP)	but	also	by	increasing	postoperative	complications	presumably	mediated	through	the	infected	bile	and	contaminating	the	inserted	stent	through	ascending	bacteria	along	the	stents.	However,	many	of	these	studies	were	performed	with	older	endoscopic	devices	like	plastic	stents	or	sometimes	even	with	PTC	drainages	of	the	bile	duct;	this	may	add	more	complications	than	associated	with	modern	SEMS.	For	instance,	this	was	the	case	in	the	often	quoted	study	by	van	der	Gaag	and	co-workers	(van	der	Gaag,	N.,	et	al.,	2010),	which	showed	a	significantly	lower	risk	of	postoperative	complications	in	the	group	where	the	pancreatic	surgery	was	performed	up-front	without	any	previous	bile	duct	decompression.	Despite	this	knowledge,	most	patients	in	Sweden	diagnosed	with	jaundice	due	to	periampullary	tumors	receive	a	stent	preoperatively	due	to	logistical	reasons	while	the	diagnostic	work-up	is	in	progress	and	while	the	patients	wait	for	their	operations,	which	are	performed	at	a	tertiary	referral	center	often	4-6	weeks	after	the	initial	diagnosis.		
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Some	pancreatic	surgeons	believe	that	the	SEMS	might	induce	a	more	severe	inflammation	in	the	hepato-duodenal	ligament,	jeopardizing	the	operation	and	making	it	more	difficult	to	dissect	the	tumor	and	to	create	the	anastomoses	during	the	pancreatico-duodenectomy.	This	has	led	to	a	skepticism	in	using	SEMS	in	potentially	resectable	periampullary	tumors	among	pancreatic	surgeons.		There	has	been	a	lack	of	prospective,	randomized	controlled	studies	comparing	SEMS	to	plastic	stents	in	resectable	periampullary	tumors	until	our	study,	but	a	recent	meta-analysis	based	only	on	retrospective	studies	(Crippa,	S.,	et	al.,	2016)	showed	less	adverse	events	if	SEMS	were	used	preoperatively	compared	to	plastic	stents.		Our	study,	which	is	to	our	knowledge	the	first	RCT	to	compare	SEMS	to	plastic	stents	in	the	preoperative	setting	in	periampullary	tumors,	clearly	showed	that	the	risk	of	preoperative	stent	dysfunction	was	lower	in	the	SEMS	group,	thereby	reducing	the	risk	and	morbidity	of	a	repeat	ERCP	preoperatively	for	a	stent	exchange.	Additionally,	the	apprehension	for	technical	difficulties	during	the	pancreatic	operation	could	be	dispatched	in	our	study,	since	no	differences	were	seen	in	operation	time	or	blood	loss	during	the	pancreatico-duodenectomy;	also,	surgeons	could	not	detect	any	subjective	difference	in	technical	difficulties	as	judged	by	their	personal	opinion	of	how	they	experienced	the	operation.	On	the	contrary,	the	histopathological	foreign	body	reaction	(sinus	histiocytosis)	in	the	lymph	nodes	in	the	hepato-duodenal	ligament	was	lower	in	the	SEMS	group	compared	to	the	plastic	stent	group,	indicating	a	lower	grade	of	inflammation	in	the	SEMS	group	in	the	hepato-duodenal	ligament	compared	to	the	plastic	stent	group.		Finally,	the	postoperative	overall	complications	were	lower	in	the	group	where	a	SEMS	was	used	compared	to	a	plastic	stent;	however,	these	results	were	not	significant.	
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In	conclusion,	SEMS	can	always	be	used	when	the	bile	duct	is	decompressed	due	to	a	periampullary	tumor,	independently	of	the	stage	of	the	tumor,	which	is	not	always	known	at	the	time	of	the	ERCP	stenting.	Resectable	tumors,	especially	those	requiring	neo-adjuvant	treatment	before	operation,	will	benefit	through	a	lower	risk	of	needing	a	repeat	ERCP	for	stent	exchange	prior	to	the	operation.	This	strategy	must	be	recommended,	since	no	perioperative	technical	problems	during	the	pancreatic	surgery	were	seen	in	our	study	and	additionally	since	the	postoperative	complications	might	be	lower	when	using	the	SEMS,	although	these	results	were	not	statistically	significant.	If	the	tumor	after	the	diagnostic	work-up	turns	out	to	be	irresectable,	the	patient	still	benefits	from	the	SEMS,	as	the	patient	in	this	palliative	situation	might	avoid	an	unnecessary	stent	exchange	because	the	SEMS	has	a	longer	patency	that	is	longer	than	the	life	expectancy	of	the	patient.	
	
6.	CONCLUSIONS		The	following	conclusions	can	be	drawn	from	the	data	provided	from	our	studies:		6.1	Prophylactically	administered	antibiotics	in	conjunction	with	ERCP	were	associated	with	a	lower	rate	of	infections	and	overall	complications.	The	association	was	strongest	in	the	group	of	patients	where	the	indication	for	the	ERCP	was	jaundice,	where	both	infections	and	overall	complications	were	further	reduced	when	prophylactic	antibiotics	were	given.	However,	the	reduction	in	complications	was	not	that	high	that	prophylactic	antibiotics	could	be	recommended	on	a	general	basis	for	all	ERCP	procedures.		
		
118	
6.2	When	the	pancreatic	duct	was	accidentally	cannulated	during	an	ERCP	that	intended	for	a	bile	duct	cannulation,	there	was	an	increase	in	the	overall	intra-	and	postoperative	complication	rates,	especially	for	PEP	where	the	OR	for	complications	was	increased	more	than	three	times.	If	a	≤5-Fr	pancreatic	stent	was	deployed	in	the	pancreatic	duct	after	an	inadvertent	pancreatic	cannulation,	there	was	an	increased	risk	for	PEP	compared	to	if	a	>5-Fr	pancreatic	stent	was	used,	corresponding	to	an	almost	fourfold	OR	increase	in	the	multivariate	analysis	(OR	3.6).	Furthermore,	a	pancreatic	stent	>5	cm	in	length	further	significantly	reduced	pancreatitis	frequency	compared	to	shorter	stents.	
6.3	If	the	three-level	ERCP	complexity	grading	scale	called	the	HOUSE	classification	is	implemented	in	clinical	praxis,	this	could	be	used	for	resource	planning	in	endoscopic	centers	or	as	a	guide	for	a	greater	alertness	in	detecting	postoperative	complications	in	more	complex	procedures.	Note	that	the	HOUSE	classification	was	validated	in	relation	to	procedure	time	and	to	the	postoperative	complication	rates;	shorter	procedure	times	and	lower	complication	rates,	like	PEP,	were	found	in	HOUSE	1	compared	to	the	higher	HOUSE	classes.	
6.4	In	resectable	periampullary	tumors	requiring	preoperative	biliary	drainage,	there	were	no	differences	in	the	amount	of	bacteria	growing	in	bile	collected	intraoperatively	during	the	pancreatico-duodenectomy	between	plastic	stents	and	SEMS	–	this	was	the	primary	outcome	of	the	study.	Clinically,	SEMS	were	superior	to	plastic	stents,	since	they	reduced	the	risk	for	preoperative	stent	dysfunction	and	decreased	the	stent	exchanges	before	the	operations.	Also,	there	were	no	intraoperative	technical	downsides	in	those	patients	who	had	received	a	SEMS,	since	this	did	not	jeopardize	the	operation,	as	subjectively	judged	by	the	surgeons	during	the	pancreatico-duodenectomy	(grade	of	
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inflammation	in	the	hepato-duodenal	ligament,	difficulties	in	stent	extraction	or	in	creating	anastomoses)	neither	did	the	stent	type	affect	the	operational	time	nor	the	peroperative	blood	loss.		
There	were	also	no	differences	between	the	plastic	stent-	and	SEMS	groups	in	the	grade	of	cholangitis	in	the	bile	duct	harvested	during	the	pancreatico-duodenectomy	when	this	was	histopathologically	investigated.	On	the	contrary,	there	was	a	more	enhanced	histopathological	foreign	body	reaction	(sinus	histiocytosis)	in	the	lymph	nodes	harvested	intraoperatively	from	the	hepato-duodenal	ligament	if	a	plastic	stent	had	been	used.		
The	postoperative	complication	rates	after	the	pancreatico-duodenectomy	was	lower	in	advantage	of	the	SEMS	group,	but	these	differences	were	not	statistically	significant.	
	
7.	PROPOSAL	FOR	FUTURE	CLINICAL	RESEARCH	
	Since	ERCP	is	a	minimally	invasive	method	that	clearly	has	advantages	compared	to	open	surgery,	it	is	still	plagued	with	significant	morbidity	(e.g.,	pancreatitis,	bleeding,	perforation	and	cholangitis),	and	every	effort	must	be	made	to	undertake	measures	to	reduce	these	complications.	Future	research	must	focus	on	defining	the	procedures	where	prophylactic	measures	should	be	intensified	to	reduce	adverse	events	using	cost-benefit	analyses.	Desirable	future	studies	and	designs	are	presented	below.		7.1	A	multi-center,	prospective,	randomized	study	focusing	on	the	effects	of	modern	
prophylactic	antibiotics	in	ERCP	with	special	focus	on	the	subgroup	of	patients	where	
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no	complete	bile	duct	drainage	can	be	achieved	should	be	considered.	This	subgroup	of	ERCP	procedures	may	benefit	the	most	from	prophylactic	antibiotics.		7.2	A	multi-center,	prospective,	randomized	study	comparing	prophylactic	pancreatic	
stent	to	no	stent	in	a	national	population	of	unselected	ERCP	procedures	should	be	considered	to	evaluate	the	effects	on	adverse	events	of	ERCP	in	this	population	and	to	define	the	high-risk	procedure	of	ERCPs	where	prophylactic	pancreatic	stents	are	justified	from	a	cost-benefit	and	morbidity	perspective.		7.3	The	HOUSE	classification	of	ERCP	complexity	grading	should	be	implemented	in	a	non-educational	endoscopic	center.	In	this	clinical	setting,	the	scale	should	be	validated	in	a	prospective	manner	in	relation	to	procedure	time	and	complication	rates	for	the	different	HOUSE	classes.		7.4	The	RCT	on	preoperative	stenting	(SEMS	vs	plastic	stents)	in	resectable	
periampullary	tumors	should	be	repeated	with	a	primary	endpoint	of	clinically	relevant	parameters	like	preoperative	adverse	events	and	postoperative	complications;	a	power	calculation	should	be	used	to	identify	differences	in	complication	subgroups	(e.g.,	infections,	anastomotic	leakage).	Finally,	a	prospective,	randomized	study	comparing	preoperative	biliary	drainage	with	modern	SEMS	to	up-front	surgery	without	any	preoperative	bile	duct	decompression	in	resectable	periampullary	tumors	should	be	completed	 	
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8.	POPULÄRVETENSKAPLIG	SAMMANFATTNING				I	denna	avhandling	presenteras	kunskapsläget	om	komplikationer	till	ERCP	och	vad	som	är	känt	som	effektiva	åtgärder	för	att	minimera	risken	för	negativa	effekter	av	undersökningen.	Dessutom	redovisas	resultaten	av	fyra	vetenskapliga	studier.		
	
ERCP,	dess	komplikationer	och	åtgärder	mot	dessa.		Endoskopisk	retrograd	cholangio-pancreatografi	(ERCP)	är	en	undersöknings-	och	operationsmetod	för	att	behandla	sjukdomar	i	gallgången	och	bukspottskörteln.	Metoden	infördes	i	slutet	av	sextiotalet,	först	som	en	möjlighet	att	röntga	gall-	och	bukspottskörtelgång	via	en	undersökningsslang	som	fördes	ner	via	magsäcken	till	tolvfingertarmen.	Där	kunde	sedan	en	tunn	kateter,	under	endoskopisk	uppsikt	föras	in	i	den	gemensamma	gall-	och	bukspottskörtelmynningen,	något	som	var	revolutionerande	på	den	tiden.	Sedermera	förfinades	ERCP-tekniken,	då	man	under	sjuttiotalet,	kunde	genomföra	de	första	små	operationerna	via	ERCP-instrumentet	genom	att	med	en	strömförande	böjd	tråd	kunna	skära	upp	slutmuskeln	av	gallgången	och	därigenom	skapa	en	större	öppning	till	gallgången	genom	vilken	man	kunde	utföra	sina	ingrepp.	Denna	operation	kom	att	kallas	sfinkterotomi	och	de	vanligaste	ingreppen	som	nu	kunde	genomföras	var	att	rensa	gallgången	från	gallstenar	och	att	behandla	gulsot	orsakad	av	hinder	i	gallgången,	genom	att	ett	plaströr	kunde	stoppas	in	i	gallgången	för	att	leda	gallvätskan	förbi	hindret	och	därmed	upphäva	gulsoten	(s.k.	stentning).	Införandet	av	ERCP-tekniken	ledde	till	att	man	nu	kunde	undvika	de	öppna	operationer	som	tidigare	krävts	för	att	behandla	t	ex	stenar	i	gallgången	och	gulsot	orsakad	av	tumörer	i	bukspottskörteln.	Man	hade	nu	lyckats	sänka	komplikationerna	vid	dessa	
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sjukdomstillstånd	men	upptäckte	snart	att	även	den	nya	ERCP-tekniken	var	behäftad	med	komplikationer,	men	som	var	av	en	ny	natur.	Den	vanligaste	komplikationen	till	ERCP	är	bukspottskörtelinflammation	(pankreatit),	som	uppstår	ungefär	efter	var	tjugonde	ERCP-undersökning.	Orsaken	till	denna	är	inte	fullständigt	känd,	men	på	något	sätt	retas	bukspottskörteln	av	ERCP-undersökningen	och	reagerar	med	en	inflammation.	Oftast	blir	denna	lindrig	och	snabbt	övergående	men	i	ovanliga	fall	kan	den	leda	till	svåra	buksmärtor	och	påverkan	på	övriga	organsystem	i	kroppen,	med	långvarig	sjukhusvistelse	som	följd,	ibland	krävande	intensivvård.	I	sällsynta	fall	krävs	till	och	med	operationer	för	att	rensa	ut	död	vävnad	från	buken	när	bukspottskörteln	bryter	ned	sig	själv	och	omkringliggande	vävnader.		Man	vet	att	det	finns	vissa	faktorer	vid	ERCP,	som	medför	att	risken	för	bukspottskörtelinflammation	ökar	i	anslutning	till	undersökningen,	där	en	del	är	patientberoende	och	andra	är	beroende	av	själva	ingreppet.	Till	de	patientrelaterade	faktorerna	hör	kön	och	ålder,	där	risken	är	förhöjd	hos	kvinnor	och	hos	yngre	patienter.	Till	de	riskfaktorer	som	är	relaterade	till	själva	ERCP-undersökningen	hör	om	undersökningen	varit	tekniskt	svår	och	tagit	lång	tid	eller	om	kontrastvätska	eller	något	instrument	förts	in	i	bukspottskörtelgången.	Förutom	att	genomföra	en	så	skonsam	och	tekniskt	lyckad	ERCP-undersökning	som	möjligt	av	en	välutbildad	ERCPist,	kan	vissa	förebyggande	åtgärder	vidtas	för	att	minska	risken	för	att	bukspottskörtelinflammation	skall	uppstå.	Den	vanligaste	och	mest	förebyggande	åtgärden	är	att	patienten	får	ett	stolpiller	med	ett	inflammationshämmande	preparat	innan	undersökningen.	En	annan	viktig	åtgärd	som	kan	genomföras	under	ERCP-undersökningar	där	risken	för	bukspottskörtelinflammation	bedöms	som	förhöjd,	är	att	via	ERCP-instrumentet	införa	ett	tunt	rör	(stent)	i	den	yttersta	delen	av	bukspottskörtelgången	som	får	sitta	kvar	där	under	några	dagar	efter	undersökningen,	för	att	sedan	plockas	bort.	Man	tror	att	detta	
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lilla	rör,	gör	det	lättare	för	bukspottet	att	tömma	sig	till	tarmen	och	på	det	sättet	minskas	risken	för	bukspottkörtelinflammation.		Andra	komplikationer	som	kan	uppstå	vid	en	ERCP-undersökning	är	infektion	i	gallgången,	levern	eller	i	andra	närliggande	organ.	Infektion	i	gallgången	kan	dels	uppstå	innan	ERCP-undersökningen	om	det	blir	stopp	i	gallgången,	som	då	snabbt	infekteras	när	gallflödet	hämmas,	dels	kan	den	uppstå	som	en	följd	av	själva	ERCPn,	då	tarmbakterier	kan	föras	upp	under	undersökningen	och	sedan	orsaka	en	inflammation	om	inte	undersökningen	leder	till	att	gallvägen	kan	dräneras	ordentligt.	De	typiska	symptomen	för	gallgångsfeber	är	hög	feber,	ofta	över	fyrtio	grader,	med	frossbrytningar.	Tillståndet	är	tacksamt	att	behandla	då	symptomen	ofta	snabbt	viker	på	intravenös	antibiotika,	om	bara	gallvägarna	blivit	avlastade	under	ERCP-undersökningen.	Slutligen	kan	två	andra	tillstånd	nämnas,	som	kan	uppstå	efter	en	ERCP-undersökning.	Det	ena	är	blödning	från	sfinkterotomin,	som	uppstår	då	slutmuskeln	av	gallgången	skärs	upp.	Denna	blödningstyp	kan	oftast	behandlas	med	metoder	som	är	tillgängliga	via	ERCP	instrumentet,	t	ex	som	injektion	av	adrenalin	med	en	nål	runt	blödningskällan.	I	sällsynta	fall	krävs	dock	operation	för	blodstillning	eller	en	åtgärd	där	man	går	in	med	en	kateter	via	ljumsken	i	lårpulsådern	och	upp	till	det	aktuella	kärlet	vid	gallgången	och	stoppar	in	blodstillande	material	i	denna	pulsåder	för	att	stoppa	blödningen,	s	k	“coiling”.	Den	andra	komplikationen,	slutligen,	är	att	det	kan	gå	hål	på	tolvfingertarmen	i	anslutning	till	ERCP-undersökningen,	oftast	som	en	effekt	av	sfinkterotomin	och	mat	och	tarmvätska	kan	då	läcka	ut,	utanför	tolvfingertarmen.	Är	inte	hålet	för	stort,	kan	tillståndet	behandlas	med	antibiotika,	men	ibland	krävs	en	operation	för	att	täta	hålet.				
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Vetenskapliga	studier:		Det	första	delarbetet	beskriver	effekterna	av	att	ge	förebyggande	antibiotika	innan	varje	ERCP-undersökning.	Bakgrunden	till	ett	sådant	förfarande	skulle	vara	att	när	man	för	upp	en	kateter	i	gallgångsmynningen	också	för	upp	tarmbakterier,	som	antibiotikan	därmed	teoretiskt	skulle	slå	ut	och	på	så	vis	undvika	en	gallgångsinflammation.	Dock	är	kunskapsläget	för	en	sådan	generell	hållning	svagt	och	kan	möjligen	försvaras	vid	de	ERCP-undersökningar	där	man	inte	lyckas	avlasta	gallvägarna.	Det	som	studien	visar	är	att	man	förvisso	sänker	risken	för	komplikationer	med	ett	par	procent	om	man	ger	antibiotika	innan	ERCP-undersökningen	men	för	att	undvika	en	enskild	komplikation,	måste	man	behandla	38	patienter	för	att	undvika	en	komplikation.	Detta	medför	att	man	utsätter	37	patienter	i	onödan	för	biverkningar	till	antibiotikan	för	att	undvika	EN	komplikation	hos	EN	patient	samtidigt	som	man	ökar	antibiotika-trycket	i	samhället	med	alla	risker	det	innebär	för	utvecklande	av	antibiotika-resistens	mot	bakterier.	Detta	medför	i	sin	tur	att	man	inte	kan	rekommendera	antibiotika	till	alla	patienter	generellt	innan	varje	ERCP,	utan	bara	i	utvalda	fall	och	den	framtida	frågan	är	att	ta	reda	på	till	vilka.		Det	andra	delarbetet	som	vi	presenterar	handlar	om	effekterna	att	vid	ERCP-undersökningen,	införa	ett	tunt	plaströr	(s	k	“pancreas	stent”)	i	den	yttersta	delen	av	bukspottskörtelgången.	Detta	låter	man	sedan	ligga	kvar	under	några	dagar	och	kan	på	så	vis	minska	risken	för	bukspottskörtelinflammation	efter	ERCP-undersökningen.	Det	studien	först	visar	är	att	risken	för	bukspottskörtelinflammation	ökar	trefaldigt	om	man	under	undersökningen	av	misstag	råkar	komma	in	i	bukspottkörtel	gången	med	ett	instrument	eller	med	röntgenkontrast.	Det	andra	som	studien	visar	är	att	risken	för	
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bukspottskörtelinflammation	kan	minskas	genom	att	ett	plaströr	lämnas	kvar	i	bukspottskörtelgången	efter	undersökningen	och	ju	tjockare	och	längre	röret	är	desto	mer	minskar	det	risken	för	bukspottskörtelinflammation	efter	undersökningen.			I	vårt	tredje	delarbete	i	avhandlingen	redovisar	vi	resultaten	av	en	utvärdering	av	en	ny	klassifikation	(HOUSE-klassifikationen)	som	använts	för	att	indela	ERCP	i	tre	grupper,	utifrån	deras	tekniska	svårighetsgrad.	Klassifikationen	är	värderad,	dels	i	förhållande	till	hur	lång	tid	varje	ERCP-undersökning	tar,	dels	i	förhållande	till	hur	vanliga	komplikationerna	är	i	relation	till	dess	klass	i	HOUSE-skalan.		HOUSE	skalan	introduceras	för	att	kunna	hjälpa	sjukhus	och	ERCP-center	att	bättre	kunna	planera	sin	verksamhet	och	styra	resurserna	till	de	undersökningar	som	kräver	mest	tid	och	kompetens.	Ett	annat	användningsområde	för	HOUSE-skalan	är	att	den	kan	användas	efter	undersökningen	för	att	kunna	identifiera	de	ERCPer	som	kräver	extra	övervakning,	där	man	genom	dessa	åtgärder	förhoppningsvis,	skall	kunna	upptäcka	komplikationer	tidigare,	som	kan	ha	uppstått	under	ERCP-undersökningen,	och	på	så	vis	tidigare	kunna	åtgärda	dem.		I	avhandlingens	sista	och	fjärde	delarbete	har	vi	jämfört	effekten	av	olika	stent-typer	
som	använts	hos	patienter	med	tumörer	i	bukspottskörteln,	som	senare	blev	
föremål	för	kirurgi.	Traditionellt	har	man	använt	plaströr	för	att	avlasta	gulsoten	som	ofta	uppstår	då	patienter	drabbas	av	bukspottkörtelcancer,	i	de	fall	där	man	tror	att	patienten	kan	bli	föremål	för	senare	kirurgi,	dels	för	att	det	är	billigare	och	dels	för	att	man	haft	en	farhåga	att	de	moderna	metallstentarna	skulle	försämra	möjligheterna	till	en	lyckad	operation.	Å	andra	sidan,	medför	en	användning	av	metallstent	en	längre	funktion	av	stentet,	vilket	leder	till	att	patienten	kan	undvika	en	onödig	ERCP,	och	
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används	alltid	i	de	fall	där	tumören	inte	kan	avlägsnas	genom	en	operation.	I	denna	studie	har	vi	lottat	patienter	som	skall	bli	opererade	för	bukspottkörtelcancer	till	att	antingen	erhålla	ett	plast-	eller	metallstent,	och	det	vi	fann	var	att	metallstentet	fungerade	bättre.	Den	främsta	orsaken	var	att	stentet	fungerade	bättre	fram	till	operationen	och	patienten	därigenom	kunde	undvika	att	behöva	genomgå	ytterligare	en	onödig	ERCP	undersökning.	Vi	fann	dock	även	för	att	ett	metallstent	heller	inte	alls	påverkade	själva	operationen	negativt,	utan	att	de	patienter	som	genomgick	operation	som	tidigare	fått	ett	metallstent	fick	samma	goda	operation	som	de	som	fått	ett	plaststent.	Den	sista	fördelen	med	att	använda	ett	metall	stent	var	efter	operationen,	då	det	visade	sig	att	även	komplikationerna	efter	ingreppet	var	lägre	om	man	fått	ett	metallstent	innan	operationen,	men	denna	sistnämnda	skillnad	var	inte	statistiskt	säkerställd.	Sammanfattningsvis	visar	våra	studier	att	profylaktisk	antibiotika	inte	bör	användas	generellt	vid	alla	ERCP-undersökningar	eftersom	det	inte	sänker	risken	för	komplikationer	tillräckligt,	men	att	pankreas-stent	bör	användas	oftare	vid	ERCP	då	undersökningen	varit	besvärlig,	eftersom	det	då	sänker	risken	för	bukspottkörtelinflammation	väsentligt.	Vi	har	vidare	introducerat	en	ny	ERCP-svårighetsgrads-skala	(HOUSE-skalan)	och	värderat	denna	i	förhållande	till	undersökningarnas	längd	och	komplikationsfrekvens,	och	den	kan	användas	för	planering	och	komplikationshantering	vid	sjukhus	som	genomför	ERCP.	Slutligen	har	vi	visat	att	metallstent	är	överlägset	vid	behandling	av	gulsot	hos	patienter	som	skall	opereras	för	bukspottkörtelcancer	eftersom	de	fungerar	bättre	innan	operationen,	inte	påverkar	operationen	negativt	och	till	och	med	kanske	minskar	risken	för	komplikationer	efter	operationen.	 	
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